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Abstract
Hepatitis B virus (HBV)-specific CD8+ T cells are critical for a successful immune 
response to HBV infection. These cells are markedly diminished in patients that are 
unable to contain the virus and the mechanisms contributing to their depletion are not 
well-understood. The aim of this work was to further dissect this response in 
individuals with chronic infection.
Studies of the HBV-specific CD8+ T cell immunodominance hierarchy demonstrated 
that persistent infection was associated with a hyporesponsiveness that was 
exacerbated with increasing antigenic load. The immunodominant core 18-27-specific 
response appeared to be particularly prone to deletion whereas a population of 
envelope 183-191-specific CD8+ T cells managed to persist despite excessively high 
viral loads but with an inability to exert effective antiviral function.
cDNA microarrays were used to compare these responses in resolved and chronic 
infection and helped identify a group of functionally-related genes that were 
selectively up-regulated in HBV-peptide stimulated CD8+ T cells from individuals 
with chronic infection. The most striking of these was the pro-apoptotic mediator of 
cross-tolerance induction, Bim, whose expression was confirmed to be upregulated at 
the protein level. Inhibition of Bim-mediated apoptosis resulted in enhanced detection 
of HBV-specific CD8+ T cells both in culture and directly ex vivo. In accordance to 
Bim-mediated deletion of CD 127^°  ^ CD8+ T cells, the HBV-specific CD8+ T cells 
surviving in chronic HBV infection were found to be CD 127 '^^ .^ These populations 
had elevated levels of the anti-apoptotic protein M cl-l, suggesting they had been 
subject to IL-7 mediated rescue from apoptosis.
This study indicates that Bim-mediated attrition of HBV-specific CD8+ T cells 
contributes to the inability of these populations to persist and control viral replication.
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Overview of the thesis layout
The main introduction begins with a brief description of persistent viral infection, 
followed by a focus on host immune evasion strategies, and continues with a detailed 
description of the pathogen focused on in this study; the hepatitis B virus. This is 
followed by a description of the main compartments of the overall immune response 
with a particular focus on antiviral immunity towards HBV. The chapter concludes 
with a detailed description of microarray gene expression analysis.
The material and methods contain details of all the protocols and reagents (except 
standard laboratory consumables) that were used to execute this study.
Chapter three is a study of the immunodominance hierarchies associated with 
resolved and chronic HBV infection that also served to identify the antiviral 
responses that were further examined in chapters four and five.
Chapter four covers the initial testing, validation and subsequent use of cDNA 
microarrays for the study of HBV-specific CD8+ T cells derived from individuals 
with resolved and persistent HBV infection.
Chapter five is a detailed investigation of the involvement of one candidate gene 
(identified in chapter 4) in HBV-specific CD8+ T cell attrition in individuals with 
persistent HBV infection.
Future directions are also provided indicating potential studies that can be pursued to 
build upon the work in this thesis.
During the course of this investigation, work in addition to the studies in HBV 
infected individuals, led to the publication of a paper comparing the CD8+ T cell 
response associated with HIV-1 and HIV-2 infection; a copy is provided at the end of 
the thesis.
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1 Chapter 1 -  Introduction
Humans are continuously exposed to viral microbes that attempt to invade and 
colonise the host. Primary resistance is based on physical barriers but when these are 
breached the pathogen encounters a secondary highly organised system of defence. 
This immunity is exerted through multiple specialized cell types that differ 
principally in the way that they recognise and respond to the pathogen. Among these 
subtypes, CD8+ T cells have the unique capability of directly recognizing virally 
infected cells and subsequently exerting appropriate antiviral functions to contain the 
pathogen. Several studies have demonstrated that chronic infection is associated with 
defects in both the quantity and quality of this CD8+ T cell response. Understanding 
these defects is critical to the development of immunotherapeutic strategies aimed at 
overcoming persistent viral infections.
1,1 Viral pathogens
Viruses exhibit tremendous diversity but can be broadly categorized according to 
their genetic make-up. According to the Baltimore classification system that groups 
viruses into families according to their genome type and method of replication, the 
three main groups consist of DNA viruses (including double and single stranded 
DNA viruses), RNA viruses (including positive-sense single stranded RNA viruses, 
negative-sense single stranded RNA viruses and double stranded RNA viruses) and 
reverse transcribing viruses (double-stranded reverse-transcribing DNA viruses and 
single-stranded reverse-transcribing RNA viruses including retroviruses). Viral 
persistence refers to perseverance of these pathogens in either the host or the 
environment. This thesis focuses on the former: virus-host interactions.
Viral microbes utilize either acute or persistent patterns of infection and these are 
reflective of two different survival strategies associated with distinct evolutionary 
ecologies (Villarreal et al., 2000).
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1.2 Acute and persistent viral strategies
The acute viral life strategy involves a transient form of host infection that is limited 
by the host immune system. Due to the limited window of opportunity, the pathogens 
must be able to rapidly transmit to a new host to ensure the preservation of the 
species. Several human viruses that cause epidemic disease (influenza, measles, 
polio, smallpox) use this strategy. They are usually associated with high mutation 
rates, diverse quasi-species, and the ability to replicate in multiple host species, 
particularly those that exhibit congregational populations (Villarreal et al., 2000). The 
majority of DNA viruses (herpesvirus and papilloma viruses) utilise a persistent life 
strategy that is highly species-specific (Bernard, 1994; Umene and Sakaoka, 1999). 
These viruses are not as dependent on the host population structure; natural 
transmission occurs either vertically from parent to offspring or horizontally by 
sexual contact or bites.
1.3 Viral evasion of the host immune system
Successful viral persistence relies on the ability of the pathogen to effectively counter
the immune response. Several mechanisms, that that target both innate and adaptive 
immunity, have been extensively reviewed (Barber, 2001; Farrell and Davis-Poynter, 
1998; Finlay and McFadden, 2006; Hilleman, 2004; lannello et al., 2006; Klenerman 
and Hill, 2005; Lieberman et al., 2002; Oldstone, 2006; Peterhans et al., 1999; 
Villarreal et al., 2000; Vossen et al., 2002); these can be grouped according to the 
survival strategy they employ (Xu et al., 2001).
1.3.1 Escape
Effective viral control relies on the ability of antiviral CD8+ T cells to recognize
pathogen-derived peptides that are displayed on MHC class I complexes (MHCI) on 
the surface of target cells; some viruses have evolved mechanisms that interfere with 
this process. For example, herpes simplex virus utilises infected cell protein 47
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(ICP47) to inhibit peptide transport from the cytosol to the endoplasmic reticulum 
(ER) (Ahn et a l, 1996b; York et al., 1994). Human cytomegalovirus uses the US6 
gene product to block TAP-mediated peptide translocation (Ahn et al., 1997; Lehner 
et al., 1997), US2 and US 11 gene products to dislocate the MHCI heavy chain, and 
the US3 gene product to retain MHCI within the ER (Tortorella et al., 2000).
Alternatively, HCMV and HIV-1 have evolved ways to direct the MHCI complex to 
endosomal compartments for degradation (Le Gall et al., 1998; Wiertz et al., 1996a). 
Additionally, in order to avoid susceptibility to natural killer (NK) cell-mediated 
killing, viruses such as HIV-1 selectively downregulate MHCI complexes critical to 
antiviral function (HLA-A and HLA-B) but maintain expression of the immune 
inhibitory receptors (HLA-C and HLA-E) (Cohen et al., 1999).
Instead of interfering with the presenting complex, certain pathogens, particularly 
RNA viruses that utilize error prone reverse transcriptases, escape detection by 
mutating critical antigenic determinants (Bertoletti et al., 1994; Klenerman et al., 
1994; Koup, 1994).
Lastly, viral latency, an effective form of viral escape, enables pathogens such as 
EBV, HSV-1 and HIV-1, to remain invisible by minimising viral protein expression. 
These viruses become active when the cell is activated, during which time they 
replicate, infect other cells and transit to other hosts (Khanna et al., 2004; Tsurumi et 
ah, 2005).
1.3.2 Resistance
In order to survive, viruses must ensure that the cells they infect do not undergo 
programmed cell death before they can generate a sufficient quantity of infectious 
progeny. Cellular apoptosis can be mediated through several pathways; these involve 
multiple death mediators that present a variety of targets for viral interference. KSHV 
disrupts recruitment of caspase 8 to the Fas-associated death domain (FADD) via a
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product of the 0RP71 gene (Thome et ah, 1997). The HIV nef protein inhibits Fas 
and TNF receptor mediated apoptosis of infected cells by blocking the apoptosis- 
signal-regulating kinase 1 (ASKl) (Geleziunas et al., 2001). Adenovirus, papilloma 
virus and HBV all target and inhibit the proapoptotic protein p53 (Benedict et al., 
2002).
1.3.3 Counterattack
Rather than passive evasion of the host response, some viruses directly engage 
immune cells. The envelope glycoprotein (gpl20) of HIV is involved in killing 
uninfected bystander T lymphocytes (Gougeon, 2005; Petrovas et al., 2005). HIV nef 
on the other hand induces the expression of Fas ligand (Fas L); this engages Fas on 
the non-infected CD8+ T cell compartment (that includes cells specific for the virus) 
and triggers them to apoptose (Xu et al., 1997). Additionally, immunosuppressive 
cytokines and chemokines or decoy receptors are used to counteract the immune 
response (Alcami, 2003). EBV encodes an interleukin 10 (IL-10) homologue that can 
inhibit the production of IFN-y and TNF-a and decrease the expression of 
costimulatory molecules (ICAM-1, CD80 and CD86) (Jones et al., 2002; Kotenko et 
al., 2000; Spencer et al., 2002). Vaccina virus encodes vIFNa/bBP, a protein that 
binds to the cell surface and prevents type I IFNs from binding to its cognate 
receptors (Colamonici et al., 1995). Finally, some viruses decorate their external 
surface with immunomodulatory viral or host-derived proteins such as CD-family 
receptors, complement inhibitors, signalling ligands or adhesion molecules to achieve 
immunosuppressive activity (Cantin et al., 2005).
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1.4 Hepatitis B virus epidemiology
The hepatitis B virus (HBV) belongs to the family hepadnaviridae that infects liver 
hepatocytes of birds, rodents, certain non-human primates and humans (Gould et ah, 
2001). First discovered in 1966, it is now one of the most important global pathogens. 
Two billion people (one third of the worlds population) have evidence of exposure to 
the virus and approximately 400 million have persistent infection (Mast et ah, 1998); 
the latter group have a high risk of developing chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma.
Global distribution can be divided into three areas: low, intermediate and high 
prevalence with <2%, 2-5% and >8% of individuals with chronic infection 
respectively. Within the latter, transmission occurs mainly at parturition with the risk 
of developing chronic infection estimated at 90%. This can be reduced to 10% if 
hepatitis B vaccination is administered at birth and the risk drops to below 5% if 
immunoglobulin to hepatitis B is also given (Beasley et ah, 1983). From the age of 0 
to 5 years horizontal infection, possibly via open wounds or contaminated injections, 
results in a 25-30% chronicity rate. This is partly due to prolonged viability of the 
virus outside the host (approximately one week) (Bond et ah, 1981). Other horizontal 
routes of infection including sexual contact and drug use result in a 5-7% rate of 
chronicity in individuals from the age of 5 years upwards (McMahon, 2005).
1.5 HE V virology -  genome
8 major genotypes, displaying >8% sequence diversity, have been defined (Locamini, 
2004). The viral genome is partially double stranded DNA and approximately 3181 to 
3221 nucleotide pairs depending on the genotype. The circular configuration is 
maintained by a 226 base pair sequence overlap in between the 5’ ends of the DNA 
strands that contain 11-nucleotide direct repeats referred to as DRl and DR2. Once 
encapsidated, the minus strand of the genome maintains a fixed 5’ and 3’ end 
containing a terminal redundance of 8 to 9 nucleotides and the viral polymerase is 
covalently bound to the 5’ end of the minus strand. This strand is not closed circular
26
but contains a nick near the 5’ end of the plus strand. The 5’ end of the plus strand is 
composed of an 18 base oligoribonucleotide which is capped in the same way as 
messenger RNA (Will et ah, 1987). The 3’ end of the plus strand varies in its position 
of termination; a gap is present that varies from between 20 to 80% of the viral 
genome and can be filled in by the endogenous viral polymerase. The viral genome 
minus strand contains four open reading frames (ORFs) that overlap by a frame shift. 
HBV is capable of producing multiple proteins from a single ORF by employing 
multiple initiation codons (AUG). The viral polymerase is encoded by the longest 
ORF. The envelope protein (PreS and S) ORF is contained within the ORF for 
Polymerase, and the ORF for the core (PreC/C) and X gene partially overlap with the 
Polymerase ORF (Locamini et al., 2003) (figure 1.).
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Figure 1.1: The genomic structure of the hepatitis B virus.
The inner black circles represent the full-length minus (-) strand (with the terminal protein 
attached to its 5' end; green spot) and the incomplete plus (+) strand of the HBV genome.
The red lines represent the 3.5, 2.4,2.1 and 0.7 kilobase mRNA transcripts, which are all termi­
nated near the poly(A) (polyadenylation) signal. The outermost coloured lines indicate the 
translated HBV proteins: large, middle and small HBV surface proteins, polymerase protein, X 
protein, and core and pre-core proteins.
Adapted by permission from Macmillian Publishers ltd. Nature Reviews Immunology; 
Rehermann, B; 2005; 5(3).
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1.6 HBV virology - proteins
1.6.1 Polymerase
The polymerase protein spans approximately 80% of the viral genome and is 
translated from a pregenomic RNA molecule. The 90Kda protein product of the 
polymerase ORF contains at least 4 domains. The sequence in codons 834 to 845 is 
homologous to a reverse transcriptase. Domain 1, at the N terminal, forms a covalent 
linkage to the 5’ end of the minus strand and is necessary for the priming of minus- 
strand synthesis. This is followed by a second spacer domain and then a third domain 
that performs the RNA- and DNA-dependent polymerase function. This region 
contains a YMDD motif that is essential for the RT activity. The final domain at the 
C terminal has ribonuclease H activity needed for cleavage of the RNA in the RNA- 
DNA hybrids during reverse transcription and is also involved in viral RNA 
packaging, optimization of the priming of minus-strand DNA synthesis, and 
elongation of the minus-strand viral DNA. Protein priming of reverse transcription 
relies on the pro vison of a tyrosine substrate at amino acid 63; this forms a covalent 
bond with the primary nucleotide (guanine) at the minus stand (Zoulim and Seeger, 
1994).
1.6.2 Precore/Core
The Pre-C/C ORF encodes two proteins. The core protein is 183, 185 or 195 amino 
acids in length depending on the viral genotype and forms a coat that packages the 
viral genome. The ORF for core is preceded by a short upstream region that when 
transcribed in conjunction with core encodes for a protein referred to as HBe antigen 
(HBeAg).
HBcore (p21) is composed of two distinct domains: amino acids 1 to 144 are required 
for the assembly of the 32nm nucleocapsid and the second arginine rich domain
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mediates nucleic acid binding, encapsidation and DNA replication. The arginine rich 
region further divides into four parts and contains a nuclear localization sequence.
HBe (p25) is a protein transcribed from precore/core mRNA and translates to a 
protein composed of the entire core but with an additional 29 amino acids at the N 
terminus. The first 19 amino acids form a signal responsible for its secretion into the 
lumen of the endoplasmic reticulum. Once there, these 19 amino acids are cleaved-off 
by a signal peptidase thereby producing a shorter protein, p22. p22 is modified by C - 
terminal cleavage of ~34 amino acids, resulting in a heterogenous array of protein 
products of 15 to 18 KDa long, defined as HBeAg. These can be secreted from the 
cell but not exclusively; a certain quantity remains within the cell. Contained within 
the p25 protein is a nuclear transport signal, thus HBeAg products are found in both 
nuclear and cytosolic compartments of the cell.
Although the primary sequences of HBeAg and HBcAg are similar, the final products 
differ significantly. HBeAg is essential to establishment of persistence. A woodchuck 
HBeAg-negative mutant was unable to establish persistence despite being infectious 
to newborn pups (Chen et ah, 1992). Similar observations were made in human HBV 
infection (Milich et a l, 1987). Additionally, HBeAg has been shown to function as a 
tolerogen in vivo (Milich et al., 1990). High levels of this protein are found in the 
serum during the tolerant phase of chronic infection alongside high levels of viral 
load.
There are a growing number of HBeAg seronegative individuals that contain a 
replication-competent viral mutant (commonly termed the precore mutant) that is 
assoeiated with more severe disease outcome (Omata et ah, 1991). The most common 
mutation is a nucleotide substitution A to T at position 1762 together with a G to A 
substitution at position 1764 resulting in a stop codon (TOG to TAG) at the end of the 
precore sequence (Kramvis and Kew, 1999).
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1.6.3 PreS/S
Three sizes of HBsAg (small, medium and large) are utilized by the virus and occur 
in two forms that differ according to the extent of glycosylation. The secretion of 
infectious virions requires N-linked glycosylation as well as glucosidase processing. 
Subviral particles of 23nm diameter, as well as filamentous rods, (figure 1.3) lack 
viral genomes and do not require glycosylation for secretion.
The small HBsAg (SHBs), 226 amino acids in length, is the most abundant protein 
found in all three forms of secreted particles (subviral, rods and virions). This protein 
contains a high number of cysteine residues that cross-link with each other forming a 
loop that is a major antigenic determinant previously referred to as the “a” 
determinant but now renamed the major hydrophilic region (MHR) located between 
amino acids 99 to 160 (Carman et ah, 1990). The subdeterminants d, y, w and r 
contain a lysine, arginine, lysine or arginine at position 122, 122, 160 and 160 
respectively.
The medium HBsAg (MHBs; PreS2) is made of the SHBs coupled to a 55 amino acid 
N-terminal region and is a minor component of the seereted particles. The protein can 
be single or double glycosylated but neither form is required for viral assembly and 
secretion. The central region contains the MHR and a region between amino acids 3 
and 16 has the ability to bind to polymerised serum albumin however, a role for this 
interaction has not as yet been demonstrated. MHBs has greater immunogenic 
properties than SHBs with respect to B cell responses (Milich et ah, 1985).
The large HBsAg (LHBs; PreSl) is composed of 108 or 119 amino acids coupled to 
the N-terminal of the MHBs protein. It occurs in a great excess compared to MHBs in 
both virons and filaments, but less so in subviral particles. In a mature viral particle, 
the PreS domains are exposed at the surface but shielded by the PreS 1 portion of the 
LHBs. This protein is essential for infection of target cells via a myristylated N 
terminal region.
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1.6.4 X  protein
The X protein (HBxAg) is 154 amino acids in length and 17Kda in size and although 
it is not required for viral production {in vitro) it is critical for infectivity in vivo. 
HBxAg protein functions as a transcriptional transactivator of various viral and 
cellular gene promoters by direct interaction with transcription factors and also 
participates in the activation of signal transduction pathways (Zoulim and Seeger, 
1994). HBxAg also acts as a co-factor in the development of hcpataccllular 
carcinoma possibly through alterations in cellular gene expression (Rossner, 1992). 
Additionally, interaction with and inactivation of the tumour suppressor p53 has been 
demonstrated (Truant et al., 1995); p53-dependent apoptosis can be interrupted by 
HBxAg (Wang et al., 1994). Finally, HBxAg has been shown to target the 26S 
proteosome complex thus interfering with the efficiency of protein processing and 
presentation that could in turn affect the recognition by the hosts T lymphocyte 
compartment (Hu et al., 1999).
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Figure 1.2: The three forms of hepatitis B surface antigen.
Electron Micrograph of HBV by Linda Stannard, Department of Medical 
Microbiology, University of Cape Town. The virus is 42nm in diameter and 
possesses an isometric nucleocapsid or "core", surrounded by an outer coat. The 
protein of the virus coat is termed "surface antigen" or HBsAg. It is sometimes 
extended as a tubular tail on one side of the virus particle. The surface antigen is 
generally produced in vast excess, and is found in the blood of infected individuals in 
the form of filamentous and spherical particles. Filamentous particles are identical to 
the virion "tails"; they vary in length and have a mean diameter of about 22nm. 
http://web.uct.ac.za/depts/mmi/stannard/hepb.html.
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1.7 Hepatitis B virus replication
The initial event of the life cycle involves attachment of the virus to the target cell. 
Amino acids 21-47 of the PreSl domain are required for hepatocyte binding as 
demonstrated in vitro with the HepG2 cell line (Neurath et ah, 1986); binding was 
blocked by antibodies to preSl (amino acids 21-47). The PreS2 domain is not 
required for entry however it may enhance viral uptake and uncoating. Its ability to 
bind human serum albumin suggests that it may act as a bridging moiety; hepatocytes 
express a receptor for human serum albumin. SHBs can also bind primary 
hepatocytes, however the significance of this is not well understood. Ultimately, virus 
binding to the appropriate receptor (which has not been identified although several 
have been proposed (Neurath et al., 1986) allows delivery of the nucleocapsid to the 
cytoplasm. This is transported to the nucleus where the viral genome is converted into 
cccDNA.
cccDNA formation involves filling in of the gap region, removal of the 5’-terminal 
structures and covalent ligation of the two strands. The cccDNA is organized into 
nucleosomes which forms the viral minichromosome that is the major template for 
the transcription of the two classes of viral mRNA; subgenomic and genomic. All 
species are capped and polyadenylated. The former are translated into envelope and X 
protein, while the latter produce precore, core and polymerase. Pregenomic mRNA 
has two functions: it serves as a template for the translation of core and polymerase 
proteins and it is used for the production of the DNA negative strand by reverse 
transcription. The latter occurs primarily within core particles, the formation of which 
is initiated by the binding of polymerase to a pregenomic mRNA transcript. Capsids 
containing the relaxed circular DNA are enveloped only after reverse transcription 
has been initiated to a point at which a signal is transmitted to the surface of a capsid. 
Enveloped particles are deposited into the lumen of the endoplasmic reticulum, move 
to the golgi apparatus and are finally secreted from the cell (figure 1.3). Subviral 
particles are formed from the aggregation of approximately 100 HBsAg monomers in 
the endoplasmic reticulum.
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Figure 1.3: Putative life cycle of HBV.
After entry to the cell, hepatitis B virus (HBV) nucleocapsids transport their cargo, 
the genomic HBV DNA, to the nucleus, where the relaxed circular DNA is converted 
into covalently closed circular (ccc) DNA. The cccDNA functions as the template for 
the transcription of four viral RNAs (of 0.7 kilobases (kb), 2.1 kb, 2.4 kb and 3.5 kb), 
which are exported to the cytoplasm and used as mRNAs for the translation of the 
HBV proteins. The longest (pre-genomic) RNA also functions as the template for 
replication, which occurs within nucleocapsids in the cytoplasm. Nucleocapsids are 
enveloped during their passage through the endoplasmic reticulum (ER) and/or Golgi 
complex and are then secreted from the cell.
Adapted by permission from Macmillian Publishers ltd. Nature Reviews 
Immunology; Rehermann, B; 2005; 5(3).
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1.8 Natural history of HBV infection
1.8.1 Acute resolving infection
Primary infection of susceptible hosts is either symptomatic or asymptomatic, with 
the latter being more common, particularly in children. Although one percent develop 
fulminant hepatitis associated with coagulopathy, encephalopathy and cerebral 
oedema, probably due to an excessive immune response, the majority of healthy 
adults demonstrate self-limited infection that is associated with long-lasting immunity 
to reinfection and their history of infection can be divided into three main stages 
(figure 1.4).
Stage one corresponds to a period of active viral replication associated with immune 
tolerance lasting up to four weeks. HBeAg, HBsAg and infectious virions can 
normally be detected in the serum. In the majority, active viral replication ensues 
without a significant elevation in serum aspartate and alanine aminotransferase 
(ALT). Amino-L-transferase, a protein normally found within hepatocytes, is released 
into the circulation when these cells are damaged and is used as a measure of liver 
integrity; approximately 35 and 45 lU/ml are considered normal for females and 
males respectively.
Stage two is associated with the generation of a significant immune response that 
results in a dramatic reduction in the serum viral load; maximal viral suppression 
occurs before significant liver damage most likely though noncy to lytic antiviral 
mechanisms (Guidotti et ah, 1999; Webster et al., 2000). The subsequent rise in 
serum ALT indicates the initiation of liver damage; symptomatic hepatitis lasts for 
approximately three to four weeks manifesting as fever, jaundice and weight loss. 
Viral replication in infected hepatocytes is subsequently controlled, resulting in the 
loss of serum HBeAg and the appearance of anti-HBeAg antibodies. HBsAg can still 
be detected possibly due to integration of the HBsAg gene into the hepatocyte 
genome. Individuals remain sero-negative for antibody to HBsAg. Serum HBV DNA
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is greatly reduced to very low levels that can be detected by PCR but not 
hybridization techniques and serum ALT levels returns to normal.
In the last stage individuals become HBsAg negative and anti-HBsAg antibody 
positive; HBV DNA is undetectable by PCR indicating successful viral containment.
1.8.2 Chronic infection
Although, the majority of healthy adults manage to contain the virus, -5%  do not 
resolve but instead maintain chronic infection. This manifests as an extremely 
heterogenous disease (see figure 1.4b).
Primary infection of neonates and children is subclinical and anicteric; approximately 
90% of infants of HBsAg and HBeAg-positive mothers become carriers (McMahon 
et al., 1985) compared to 30% of children infected between 1 to 5 years (Chang, 
2000). A high maternal HBV DNA and HBeAg level is associated with increased risk 
of developing chronic infection (Burk et al., 1994) that is characterized by a 
prolonged immunotolerant phase and a low rate of HBeAg clearance (Chang, 2000). 
However, less than 10% of infants born to mothers that are HBeAg negative and anti- 
HBeAg antibody positive develop chronicity (Chang, 2000). Perinatal infection is 
characterized by a prolonged immunotolerant phase with a low rate of spontaneous 
HBeAg clearance; entry into the immunoactive phase, 10 to 30 years later, is 
associated with the development of chronic hepatitis with elevated ALT (Lok et al., 
1987). Those that were infected during childhood present in the immunoactive phase 
earlier in life; the majority have raised ALT and seroconvert to an anti-HBeAg 
antibody positive status sooner than those infected perinatally, usually during 
adolescence (Fattovich, 2003).
30 to 50% of adults that experience primary infection develop icteric hepatitis 
(McMahon et al., 1985) of which 1 to 5% maintain chronic infection (Tassopoulos et 
ah, 1987). Some of these exhibit high viral loads, typically 10  ^ to 10  ^ virions/ml
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(Weinberger et al., 2000) associated with HBeAg seropositivity - apart from those 
that have precore mutations. Each year 5-10% of individuals with high viral load 
suppress viral replication by up to five orders of magnitude, clear HBeAg from their 
circulation and develop anti-HBeAg antibody; this is often preceded by a transient 
rise in salt, also termed a flare (Ribeiro et al., 2002).
The other group of chronically infected adults maintain a long-term inactive carrier 
state; anti-HBeAg antibody positive, HBeAg seronegative, with relatively low levels 
of viral replication compared to the acute phase. The majority sustain biochemical 
remission and very low risk of cirrhosis and hepatocellular carcinoma (de Franchis et 
al., 1993; Hsu et al., 2002). 20 to 30% undergo spontaneous reactivation of high-level 
HBV replication and multiple episodes can lead to progressive liver damage and 
hepatic decompensation (Perrillo, 2001). 1 to 2% of inactive carriers resolve infection 
(develop antibody to HBsAg and loose HBsAg) (Alward et al., 1985; Fattovich et al., 
1998).
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Figure 1.4; Clinical and virological course of acute and chronic hepatitis B virus 
(HBV) infection.
(a) A schematic depiction of the immune response in acute infection with hepatitis B 
virus (HBV) through horizontal transmission, followed by clinical recovery, is
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shown. After recovery, neutralizing HBV surface antigen (HBsAg)-specific 
antibodies and HBV-specific T cells confer lifelong, protective immunity (for further 
details, see main text), (b) Chronically evolving hepatitis B results from vertical 
transmission. Chronic hepatitis B is most commonly seen after vertical transmission 
from mother to neonate. The course of disease is characterized by several phases of 
variable length. The immunotolerant phase is characterized by high levels of 
circulating HBV DNA and HBV e antigen (HBeAg) and normal alanine
aminotransferase (ALT) levels, and this phase can last for decades. For unknown 
reasons, it can transition into an immunoactive phase, in which HBV DNA titres are 
lower but liver disease is markedly more severe and can progress to liver cirrhosis. 
Alternatively, the immunoactive phase might transition into a low replicative phase, 
with clearance of free HBeAg from the serum and development of HBeAg-specific 
antibodies. In the low replicative phase, serum HBV DNA is typically below the 
detection limit of hybridization assays; ALT levels also normalize, and
necroinflammatory liver disease improves. The low replicative phase might last for 
life, but a subgroup of patients, especially those who have undergone
immunosuppressive therapy, might experience recurrent high-level HBV replication 
and marked necroinflammatory liver disease. Mutations in the promoter region of the 
gene that encodes HBV core antigen (HBcAg), which are associated with increased 
replication, and pre-core mutations, which result in an HBeAg-negative phenotype, 
have been described.
Adapted by permission from Macmillian Publishers ltd. Nature Reviews
Immunology; Rehermann, B; 2005; 5(3).
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1.9 Host immunity to viral infection
The specialized cells of the immune system derive from common pluripotent self- 
renewing haematopoetic stem cells (CD34+) located in the bone marrow (Lessard et 
al., 2004) that differentiate into myeloid or lymphoid progenitors. Myeloid 
progenitors further differentiate into the various cells of the innate immune 
compartment and the lymphoid progenitors differentiate into natural killer cells, 
dendritic cells and the two categories of cells of the adaptive immune compartment, 
the B and T lymphocytes (Galy et al., 1995).
1.10 Innate host immunity to viral infection
The innate immune compartment is composed of non-clonal cells whose main 
function is to stop the progressive infection of susceptible cells and to raise a state of 
alert. It is particularly critical at the early stage of infection. The response is 
immediate and does not result in selective memory. Effector cells include neutrophils, 
basophils, eosinophils, granulocytes, monocytes, dendritic cells, and natural killer and 
natural killer T cells. While some of these denature the pathogen following 
endocytosis, others engage with and subsequently secrete a variety of antimicrobial 
inflammatory cytokines and chemokines. In addition to these specialized cell types, 
epithelial cells and endothelial cells are also able to participate in the innate response 
through the immediate production of cytokines, chemokines and antimicrobial 
peptides following the recognition of pathogens (Andonegui et al., 2003; Eckmann et 
al., 1997; Hertz et al., 2003; Kagnoff and Eckmann, 1997).
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1.10.1 DC subsets
Dendritic cells are the professional antigen presenting cells of the body; they capture 
antigen, migrate to local draining lymph nodes, and present antigen-derived peptides 
to naïve or quiescent memory T lymphocytes. They are eapable of activating cells 
with the cognate TCR, thereby driving their proliferation into effector cells (Jung et 
ah, 2002; Norbury et ah, 2002; Smith et ah, 2003); these expanded T lymphocyte 
populations exit the lymph node and guided by ehemokines, migrate to the inflamed 
site where they exert cytolytic/noncytolytic funetion. Dendritic cells themselves are a 
heterogenous population that have been broadly divided into six subsets. The first 
main division is between plasmacytoid DCs and the other five DCs subsets (Grouard 
et ah, 1997); the latter can be grouped according to the site from where they are 
derived, either blood or tissue.
1.10.1.1 Plasmacytoid DCs
Plasmacytoid DCs are found throughout the body but are not thought to be important 
for antigen presentation. Their main role during the induction phase of the immune 
response appears to be the production of type I IFNs (Celia et ah, 1999; Diebold et 
ah, 2003) following TLR-mediated recognition of pathogens (Asselin-Paturel et ah, 
2001; Kadowaki et ah, 2001; Nakano et ah, 2001). This leads to the inhibition of viral 
replication as well as the activation of other DCs, particularly those specializing in 
cross-presentation (Le Bon et ah, 2003). This subset can express CD8a particularly 
following activation (Henri et ah, 2001).
1.10.1.2 Tissue derived conventional DCs
Lymph nodes that drain the skin contain two tissue-derived DCs: langerhans cells 
(Romani et ah, 2003) and dermal interstitial DCs. Langerhans cells are found in the 
epithelia of the skin and act as sentinels. Pathogen encounter induces migration via
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draining lymphatics to lymph nodes. Recent evidence indicates that these cells may 
not actually prime CD8+ T cells (Allan et ah, 2003; Zhao et ah, 2003) but may 
instead cater more to the transportation of antigens (Allan et ah, 2006; Carbone et ah, 
2004; Randolph, 2006; Villadangos and Heath, 2005; Yoneyama et ah, 2005). Organs 
other than the skin do not contain langerhans cells but have DCs that are similar to 
dermal interstitial DCs. This indicates that each organ contains its own specific 
interstitial DC subset and potentially raises the total number of subsets to over six. A 
distinguishing feature of tissue-derived DCs is the expression of the mannose 
receptor CD205 (Henri et ah, 2001). This marker is also present on CD8+ DCs but 
the subsets can be easily differentiated from each other because the latter express the 
CD8+ coreceptor at a high level.
1.10.1,3 Blood-derived conventional DCs
Blood-derived conventional DCs can be separated according to their expression of 
CD4 and CD8 coreceptors (Vremec et ah, 2000; Vremec et ah, 1992); they are either 
double negative (CD4-CD8- DCs), CD4+ (CD4 DCs) or CD8+ (CD8+ DCs). Double 
negative DCs preferentially produce IFN-y (Hochrein et al., 2001); no dominant 
cytokine production has been associated with CD4 DCs. CD8+ DCs are thought to be 
the main immunoactive subtype in the blood: they are the predominant IL-12 
producers (Steinman et al., 1997) and have a central role in cross-presentation (den 
Haan et ah, 2000).
1.10.2 Role of DCs in HBV
Although it is known that infection with persistent viruses such as HIV and HCV can 
be associated with impaired DC function (Auffermann-Gretzinger et ah, 2001; 
Donaghy et ah, 2003; Kanto et al., 1999; Steinman et al., 2003a), the role of DCs in 
HBV infection has only recently been studied and is under debate. Tavakoli et al have 
reported that HBV infection of (monocyte-derived) DCs lead to phenotypic and
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functional alterations but the antiviral T cell stimulatory capacity of these cells was 
maintained (Tavakoli et al., 2004). On the other hand, Van der Molen et al have 
demonstrated that chronic HBV infection is associated with the functional 
impairment of both myeloid and plasmacytoid DCs (van der Molen et ah, 2004). 
Additionally, Untergasser et al have recently shown that although DCs were capable 
of taking up viral particles, the microbe did not replicate within these cells 
(Untergasser et al., 2006) suggesting that contact with circulating viral antigen 
particularly subviral particles, rather than infection by virus, could be contributing to 
altered DC functionality.
1.10.3 Innate recognition of pathogens
There are two main categories of pathogen recognition: extra and intra-cytoplasmic 
(Meylan and Tschopp, 2006).
1.10.3.1 Extracytoplasmic sensing of pathogens
The extracytoplasmic pathway for pathogen sensing relies on several pattern- 
recognition receptors (PRRs) such as C-type lectins, scavenger receptors, pentraxins, 
lipid transferases, integrins, and leucine-rich proteins that include the Toll-like 
receptor family; these sample the extracellular environment for pathogen-associated 
molecular patterns (PAMPs) (Medzhitov and Janeway, 1997). The TLR family 
(particularly TLR3, 7, 8 and 9) has received considerable attention because of their 
relevance to infection with viruses; upon engagement with cognate ligand, these 
molecules transmit signals through cytoplasmic Toll/Interleukin-1 receptor (TIR) 
domains resulting in the transcriptional induction of multiple genes, particularly those 
for type I IFNs (figure 1.5).
Toll like receptor 3 (TLR3) is expressed on the cell surface and recognizes 
extracellular double stranded RNA (dsRNA) released following lysis of infected
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cells. Engagement triggers a series of cellular events that culminate in the activation 
of the transcription factors IFN regulatory factor 3, neural factor kB (NF-KB), and 
activating protein 1 (API) that coordinate the transcriptional regulation of the IFN-(3 
gene (Kawai and Akira, 2006; Sasai et ah, 2006; Wathelet et ah, 1998). TLR3 
signalling has been shown to be particularly important for the cross-presentation of 
soluble antigen by CD8+ DC to CD8+ T cells (Fujimoto et ah, 2004).
TLR 7, 8 and 9 are located in the endosomes of plasmacytoid DCs (Rato et ah, 2005). 
Viral particles or infected apoptosing cells are endocytosed thereby facilitating the 
recognition of PAMPs by N-terminal endosomal leucine-rich repeats. Fc receptor 
mediated endocytosis of virus-antibody complexes can also lead to TLR triggering 
(Wang et ah, 2007). Subsequent intracellular signalling through the MyD88- 
IRAK1/4-IRF1/3/7 pathway culminates in the expression and release of IFN a  & |3 
(Kawai and Akira, 2006; Marie et ah, 1998).
TLR7 and TLR8 recognize ribonucleic acid homologs and ssRNA rich in guanosine 
or uridine (Heil et ah, 2004; Lund et ah, 2004) (Diebold et ah, 2004) typical of HIV-1 
and influenza genomes. TLR9 on the other hand recognizes unmethylated 2’- 
deoxyribo cytidine-phosphate-guanosine (CpG) DNA motifs present in viral DNA. 
Synthetic CpG oligonucleotides are potent promoters of T helper type I responses and 
have recently been shown to improve responses to HBV vaccines particularly in low- 
responders (Cooper et ah, 2005; Cooper et ah, 2004; Verthelyi et ah, 2004).
1.10.3.2 Cytoplasmic sensing of path ogens
The intracellular (cytoplasmic) recognition of viruses occurs through retinoic acid- 
inducible gene I (RIG-1) and melanoma differentiation-associated gene 5 (Mda5) 
(figure 1.9). These proteins belong to a DLxD/H box RNA helicase family that have, 
in addition to a helicase domain, an N-terminal caspase recruitment domain (CARD). 
They function by sensing viral RNA through the helicase and then transmit a signal 
through the CARD domain (Meylan et ah, 2005) that leads to the activation of
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transcription factors IRF3, NK-kB and AP-1 that in turn induces IFN-b. Apart from 
recognizing dsRNA (Kato et ah, 2006; Yoneyama et ah, 2004) Rig-1 is also activated 
by ssRNA that contain 5'-phosphates (Pichlmair et ah, 2006). Studies have also 
shown that the HCV protein NS3/4A protease abrogates RIG-1 mediated antiviral 
function by cleaving a cofactor (mitochondria-associated Cardiff protein) that is 
required to initiate IFN production (Breiman et ah, 2005; Vilasco et ah, 2006).
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Figure 1.5: The pathways to and from type I interferons.
Families of sensors are available to detect viral products and induce expression of 
cytokines. One set senses components in the cytoplasm. Another set is localized in 
cell membranes. There is also flexibility in the signaling pathways used by type 1 
IFNs, with the potential to induce the activation of multiple ST AT molecules and 
their downstream targets of transcription.
Adapted by permission from the American Association for the advancement of 
Science. Garcia-Sastre, A; 2006: 312
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1.10.4 Type 1 Interferons
Type 1 Interferons (IFNI) are composed of multiple genes clustered within one locus 
on chromosome 9 (Theofilopoulos et ah, 2005); humans have 13 subfamiles of IFN-a 
and only one 1FN-|3 gene (Weissmann and Weber, 1986). They can be divided into an 
immediate early response group (lFN-a4 and lFN-j3) and a late group (lFN-a2, 5, 
6&S); the former can induce the latter (Marie et ah, 1998). All of these proteins 
regulate the immune response through the type 1 IFN receptor that is composed of 
two subunits, IFNARl and 1FNAR2 (Platanias, 2005) (Brierley and Fish, 2002). 
Binding triggers a cascade of events that culminate in the transcription of multiple 
IFN-stimulated genes (ISGs), the products of which contribute to the antiviral and 
immunoregulatory response (Katze et ah, 2002).
The best characterised of these include the myxovirus resistance gene (Mx) that acts 
by sequestering viral ribonucleoproteins to specific subcellular compartments; the 2’- 
5’ oligoadenylate synthetase (OAS) that generates 2’-5’ oligoadenylates which 
activate ribonuclease L (RNase L) leading to the degradation of cellular and viral 
RNA; and the dsRNA-stimulated serine-threonine protein kinase (PKR) that, 
following recognition of dsRNA, phosphorylates downstream substrates such as the 
elongation initiation factor 2A (elF2A) leading to an inhibition of translation. The 
latter of these has been implicated in the 10-fold reduction of nucleocapsids 
containing pregenomic RNA and reduction in viral replication in HBV-transgenic 
mice (Guidotti et ah, 2002; Wieland et ah, 2000).
Recently, APOBEC3G, a member of the apolipoprotein B mRNA-editing catalytic 
polypeptide-like editing complex (ABOBEC) superfamily of cytidine deaminases that 
have antiviral activity against a variety of viruses (Harris et ah, 2003; Mangeat et ah, 
2003), has also been shown to be upregulated by IFN-a resulting in a decrease in 
HBV replicative intermediates (Rosier et ah, 2005).
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1.10.5 Natural Killer (NK) cells
NK cells are a distinct subset of lymphoid cells that have innate immune functions 
(Cerwenka and Lanier, 2001) and exert antiviral activity in a non-MHC dependent 
manner. They are activated by cytokines or following encounter with target cells that 
express ligands for NK receptors (Lanier, 2005); the outcome of NK activity is 
determined by a balance of signals from activating and inhibitory receptors. Particular 
inhibitory receptors recognize MHC class I molecules that are normally present on all 
healthy cell types. In addition to host-derived or pathogen-induced activation signals, 
down-regulation of MHCI following infection is the additional danger signal that 
triggers NK activity (Ljunggren and Karre, 1985).
NK cells are capable of both cell-to-cell contact-dependent cytolysis and the 
production of high levels of cytokines. Type I and II IFNs, IL-12 and IL-15 are 
thought to be required for optimal NK activity against viral infections (Lee et al., 
2000; Nguyen et al., 2002a). NK cells have been shown to be critical for the 
inhibition of HBV replication in vivo (transgenic mouse model) (Kakimi et al., 2000); 
the robust activation of IFN-y and TNF-a that immediately follows the exponential 
phase of HBV infection (Guidotti et al., 1999) is likely to derive from these 
populations that normally account for one third of total intrahepatic lymphocytes 
(Sprengers et al., 2005).
Recent work in acutely infected chimpanzees has demonstrated that that the rapid 
decrease in viral replication in resolving chimps occurs in conjunction with 
intrahepatic production of IFN-y prior to the recruitment of T lymphocytes (Guidotti 
et al., 1999). Similarly, in a human study during the incubation phase of HBV 
infection, suppression of viral replication was also associated with an increased 
circulating frequency of NK cells that preceeded the appearance of HBV-specific 
CD8+ T cells (Webster 2000). Our own studies indicate that the cytokine-enhanced 
antiviral activity of NK cells could be contributing to the immunopathology that is 
observed in chronic HBV infection (Dunn et al., 2007).
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lA l  Adaptive immunity to viral infection
The adaptive immune compartment exerts specific resistance to infection that is 
clonal and exhibits memory upon repeated exposure to the original antigen. It is 
composed of two main compartments: B and T cells.
1.11.1 B Lymphocytes
B cells develop from a lymphoid progenitor that differentiates within the bone 
marrow. These cells recognize conformational epitopes; antigens that are either 
present on the surface of infected cells or secreted into the extracellular environment. 
Each naïve B cell expresses a unique immunoglobulin receptor on its cell surface. 
Following recognition of antigen these cells undergo three main events. They begin 
to secrete large quantities of soluble immunoglobulin into the circulation; this is 
aimed at neutralizing free circulating antigen. These cells also undergo somatic 
hypermutation to modify the reactive immunoglobulin in order to recognize the 
antigen better. Third, following internalization and processing of the antigen, they 
migrate to secondary lymphoid organs where they function as professional antigen 
presenting cells that prime T cells. Type I and type II interferons bridge the gap 
between innate and adaptive immunity by regulating the development, proliferative 
potential, immunoglobulin secretion and Ig heavy chain switching capacity of B cells 
(Schroder et al., 2004; Stark et al., 1998).
The B cell response to HBV envelope antigens (HBsAg) is T cell-dependent (Milich 
and McLachlan, 1986); these antibodies are readily detectable in resolved individuals 
but not present in chronic infection. Viral containment occurs by the formation of 
antibody-virus complexes preventing attachment and entry into hepatocytes. The 
antibody response to HBcAg and HBeAg is not fully understood; it does not 
neutralize viral infectivity because it can be present alongside high titres of virus, 
however, chimpanzees that have passively been administered HBeAg antibodies were 
protected from HBV infection (Stephan et al., 1984). It also appears that the anti-
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HBe/cAg antibody response can function in a T cell-independent manner because this 
antibody response can be strong in chronic infection when the T cell response is 
known to be weak (Milich and McLachlan, 1986). The antibody response to HBV 
polymerase and X protein has not been well studied.
1.11.2 T lymphocytes
T lymphocytes develop from lymphoid progenitors that leave the bone marrow as 
double negative thymocytes and migrate via the blood to the thymus where they 
differentiate into T helper (CD4+) or T cytotoxic (CD8+) cells.
1.11.2.1 Central Tolerance
In each day of the postnatal period of life, approximately 10 to 100 hematopoiteic 
progenitors enter the thymus from the bone marrow via the bloodstream. Over the 
course of two weeks, double negative thymocytes undergo approximately 20 
divisions (Porritt et al., 2003; Shortman et al., 1990) resulting in the production of 
about 50 million T cells/day of which only 1 to 2 million exit the thymus (Kyewski 
and Klein, 2006). More than 95% of the cells are lost. The initial process, |3 selection, 
relies on pre TCR signalling and allows only double negative (DN; CD4-CD8-) with 
successfully rearranged TCRp genes to proceed to the double positive status 
(CD4+CD8+) (von Boehmer et al., 2003) upon which TCR rearrangement occurs. 
Once the a p  receptor is expressed the T cell it is subject to series of 
TCR/peptide/MHC interactions that determine its survival. A large proportion of T 
cells cannot bind MHC alleles of the host. The process of positive selection in the 
cortex of the thymus selects for those that can recognise self-peptide-MHC 
complexes, permitting only these to further differentiate. This step, also termed death 
by neglect, accounts for the majority (90-95%) of cell death. It also indicates that the 
preference for selection of self-specificity exceeds the selection against autoreactive 
cells.
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About 50-70% of these cells are subsequently subjected to negative selection that 
occurs in the medulla region of the thymus and is exerted principally by thymic 
dendritic and thymic epithelial cells (Derbinski et ah, 2001; Hanahan, 1998). This 
latter population are able to express peripheral antigens and pass them to thymic 
dendritic cells (DCs) to increase exposure -  reports estimate the DCs scan ~ 
5000T/hour (Miller et ah, 2004). The promiscuous expression of peripheral antigens, 
as well as late self-antigens, extends the scope of central tolerance. In this way T cells 
with high avidity to self-peptide/MHC, and thus capable of inducing autoimmunity, 
are neutralized. Low avidity T cells proceed unhindered towards maturation and are 
allowed to exit the thymus and populate secondary lymphoid tissues.
1.11.2.2 Peripheral Tolerance
Not all self-specificities are eradicated within the thymus; although most self-proteins 
are expressed at this site (Su and Anderson, 2004), some specificities do manage to 
escape. In order to avoid the induction of autoimmune responses to the latter, T cells 
subsequently encounter peripheral tolerance mechanisms. Under specific conditions, 
peripheral TCR/self-peptide/MHC interactions result in the induction of 
unresponsiveness (anergy) or activation induced cell death (peripheral deletion).
Apart from a TCR-dependent stimulus, T cells require the provision of costimulatory 
signals. Costimulatory proteins are upregulated on professional antigen presenting 
cells (pAPCs) during inflammation or infection thereby allowing T cells to 
distinguish between noninfectious-self and infectious-self (Medzhitov and Janeway, 
2000). Thus, T cells stimulated by pAPCs that do not have appropriate (raised) levels 
of costimulatory proteins are anergised (Macian et ah, 2004; Schwartz, 2003); the 
hallmarks of which are the inability to proliferate, secrete cytokines and differentiate 
into functional effectors (DeSilva et al., 1991).
A large number of co-stimulatory receptors have been described (Bertram et al., 
2004b; Croft, 2003; Kroczek et al., 2004) (figure 1.6). The first subgroup, the
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immunoglobulin superfamily, includes CD28 and the inducible co stimulator (ICOS), 
of which the former is better characterized (Sharpe and Freeman, 2002); the 
respective ligands include B7.1 & B7.2 and ICOS ligand (that is related to the B7 
family) (Sharpe and Freeman, 2002). CD28 signalling is required and in fact 
sufficient for the induction of optimal activation, maintaining viability and preventing 
anergy in naïve and resting cells (Harding et ah, 1992; Jenkins et al., 1991); ICOS 
signalling on the other hand is more relevant to the co stimulation of previously 
activated and effector cells. The immunoglobulin family also includes co-inhibitory 
receptors (PD-1 and CTLA-4); these are normally upregulated following successful 
activation of the cell and are designed to maintain overall T cell homeostasis by 
silencing the specific response (Greenwald et al., 2005). The second group, the 
tumour necrosis factor receptor (TNFR) superfamily includes 0X40, 4-IBB, CD27, 
CD30 and HVEM, the ligands for which are OX40L, 4-lBBL, CD70, CD30L and 
LIGHT (Croft, 2003).
In addition to DCs, the liver contains other antigen presenting cells. Liver sinusoidal 
endothelial cells (LSECs) and Kupffer cells are able to present antigen to CD4+T 
cells but fail to induce differentiation to a Thl phenotype (Knolle et al., 1999); 
instead, these cells produce IL-10 and TGF-|3 that downregulate T cell activation 
thereby promoting anergy (Knolle et al., 1998) or apoptosis of T cells (Knolle and 
Gerken, 2000).
The precise mechanism of anergy induction is thought to involve the cell cycle 
inhibitor p27Kipl that interferes with the cyclin-dependent kinase 2 (CDK2) and the 
maintenance of the activity of the transcription factor Smad3 (Li et al., 2006) (figure 
1.7). Suboptimal activation due to substandard costimulation fails to downregulate 
p27Kipl resulting in an impaired proliferation; p27Kipl -deficient cells are resistant 
to anergy (Rowell et al., 2005), whereas the upregulation of this protein induces 
anergy and tolerance despite the provision of costimulation (Boussiotis et al., 2000a; 
Powell et al., 1999).
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Figure 1.6: Costimulatory and inhibitory interactions on activated T cells.
The CD28 superfamily includes the stimulatory members CD28 and ICOS and the 
inhibitory members, CTLA-4 and PD-1. CD40L a member of the TNF ligand family 
is expressed on activated T cells, and its binding to CD40 on dendritic cells induces 
expression of 4-lBBL, OX40L and CD70, the ligands, respectively, for 4-IBB, 
0X40 and CD27. Although these interactions are illustrated as taking place on the 
same cell, in vivo, they may involve different subsets of AFC and T cells, different 
locations in the lymphoid organ and may also be temporally segregated. Based on 
expression of TNF/TNFR ligands other TNF/TNFR interactions could involve T-T, 
T-B, T-NK, NK-B, NK-DC interactions and could involve TNFR receptor 
expression on AFC as well as T cells.
Adapted by permission from Elsevier Ltd. Seminars in Immunology; Bertram, EM; 
2004: 16(3).
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Figure 1.7: The tolerogenie pathway involves inhibition of Cdk2 activity by 
p27Kipl and an increase in Smad3 function.
(a) Regulation of the cell cycle. Cells progress from GO or G 1 to S (DNA synthesis), 
G2 and mitosis. Cyclin E-Cdk2 complexes drive the transition from G1 to S, whereas 
cyclin A-Cdk2 and cyclin A-cyclin B-Cdk2 complexes are involved in S and G2, 
respectively. The anaphase-promoting complex (APC) is required for anaphase and 
exit from mitosis. The inhibitor p27kipl binds and inhibits cyclin E-Cdk2 kinase, 
whereas Cdk2 can phosphorylate the serine at position 212 of Smad3 (pS-212) and 
inhibit its transcription activity. Smad3 increases p i5 (Cdk inhibitor 2B) and inhibits 
IL-2 production. The proteins p i5, pl6CdkN2a (p i6; also called INK4a) and 
p21Wafl/Cipl (p21) can inhibit Cdk4 needed for G1-phase progression, (b) In this 
model, anergy and in vivo tolerance is induced by p27Kipl binding and the inhibition 
of cyclin E-Cdk2 complexes, which leads to less inhibitory phosphorylation of 
Smad3. That results in increased Smad3 activity, increased p i5 expression and 
inhibition of IL-2 production. Conversely, proliferation and clonal expansion results 
from a loss of p27Kipl expression and/or binding to cyclin E-Cdk2, leading to an 
increase in inhibitory phosphorylation of the serine at position 212 of Smad3 and a 
reduction in pi 5 and upregulation of IL-2 production.
Adapted by permission from Nature Publishing Group. Rudd, CE; 2006: 7(11)
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1.11.3 CD4+ T lymphocytes
CD4+ T helper cells (Th) recognise peptides presented by MHC class II molecules 
that are expressed on antigen presenting cells including dendritic cells, B cells and 
macrophages. The CD4 molecule is a co-receptor that participates in the formation of 
the immune synapse by associating with a domain of the MHCII complex (Kuhns et 
ah, 2006). CD4+ T cells are robust producers of cytokines and influence the 
development of CD8+ effector T cells and antibody-producing B lymphocytes.
Quiescent naïve CD4+ T cells circulate between secondary organs via the blood and 
lymphatics (Girard and Springer, 1995) surveying the body for appropriate triggers. 
Priming follows TCR/peptide/MHCII engagement, costimulation, and signals from 
the surrounding cytokine/chemokine milieu (Molon et ah, 2005). This results in a 
series of rapid divisions that are associated with the acquisition of the capacity to 
secrete effector cytokines (Murphy and Reiner, 2002). Fully differentiated daughter 
cells then migrate to appropriate sites where they secrete specific cytokines to 
functionally organize the immune response.
Several subsets of CD4+ T cells have been defined according to their cytokine 
secreting profile (figure 1.8). T helper (Th) 1 and Th2 cells (produce IFN-g and IL-4 
respectively; however, Th 0 cells produce both of these cytokines) (Lund et ah, 2005; 
Mosmann and Coffman, 1989), Th3 cells (transforming growth factor |3) (Carrier et 
ah, 2007a, b), Th follicular helper cells (ThFH) (Chtanova et ah, 2004; Rasheed et ah,
2006), T h l7 (IL-17-A) (Acosta-Rodriguez et ah, 2007; Harrington et ah, 2005), T 
regulatory (Tr) I cells (IL-IO) (den Haan et ah, 2007) and peripherally-induced T 
regulatory (Treg) cells (FoxP3+) (Maloy and Powrie, 2001) (Reinhardt et ah, 2006; 
Ruprecht et ah, 2005).
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Figure 1.8: T helper subsets.
Although the precise lineage of the subsets in blue has not been defined by cell fate- 
mapping experiments, Thl, Thl? and Th2 cells represent alternative effector cell 
fates individually derived from naïve precursor T cells (Thp). The degree to which 
these cells fates are conditioned by different classes of dendritic cells (DC) is 
unknown. The differentiation, maintenance and effector functions of these subsets 
share certain symmetries. Thl cells express T-bet and IL-12 receptors (IL-12R) 
downstream of IFNy signals, and are further- maintained by IL-12 and IL-18, 
members of the greater IL-6-like and IL-l-like superfamilies, respectively. Thl? cells 
develop in the presence of TGFp and IL-6, and are further maintained by IL-23 and 
IL-ip, members of the same superfamilies. Th2 cells are maintained by IL-4 itself, as 
well as by the IL-1 superfamily member IL-33. Downstream, Th subsets recruit 
distinct innate cell types to mediate effector functions in the periphery.
Adapted by permission from Elsevier Limited. Current Opinion in Immunology; 
Reinhardt RL; 2006:18(3).
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Self-limited HBV infection is associated with Thl CD4+ T that recognise multiple 
determinants in the core protein and respond by producing IL-12 & IFN-y (Ferrari et 
ah, 1990; Jung et ah, 1991; Penna et ah, 1997); these responses persist for decades 
following resolution of infection (Penna et ah, 1996).
Nucleocapsid-specific CD4+ T cells have been suggested to be critical to viral control 
given that HBeAg seroconversion is associated with an increased frequency of these 
populations (Rossol et ah, 1997; Tsai et ah, 1992), however, it is not known whether 
the activity of CD4+ T lead to seroconversion, or whether seroconversion is followed 
by the appearance of CD4+ T cells. CD4+ T cells specific for HBV polymerase and 
X antigen have not been studied sufficiently, but preliminary studies indicate that 
polymerase determinants are capable of inducing strong helper T responses 
(Mizukoshi et ah, 2004). In contrast, HBV envelope antigen does not naturally appear 
to elicit a relatively strong response (Bocher et ah, 1999; Ferrari et ah, 1990). This 
does not mean that envelope is a weak CD4 immunogen since it promotes strong 
responses in vaccinated individuals (Bocher et ah, 1999; Cells et ah, 1988; Ferrari et 
ah, 1989); this however, could be attributed to differences in antigen presentation that 
are related to the use of synthetic adjuvants.
The influence CD4 T regulatory cells during HBV infection is not well understood. 
Some studies have demonstrated an increased frequency of Tregs in the peripheral 
circulation of individuals with chronic HBV infection (Barboza et ah, 2007; Fu et ah, 
2007; Stoop et ah, 2005; Xu et ah, 2006). These data are in conflict with other work 
(Franzese et ah, 2005); although depletion of Tregs increased the function of the 
HBV-specific T cells, this was observed in chronic as well as resolved infection 
indicating that the mechanism was not specific to infection with HBV.
IL-10 appears to be a critical factor in influencing the protective immune response to 
viral infections (Klenerman and Ludewig, 2006) and can determine progression to 
either chronicity or effective control (Brooks et ah, 2006b). Blockade of the IL-10 
receptor has been shown to contribute to resolution of chronic infection (Ejmaes et 
ah, 2006). HIV-1 and HCV-speciflc T cells have been shown to exhibit IL-10
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mediated immunosuppressive activity (Accapezzato et al., 2004; Elrefaei et al.,
2007). IL-10 secreting HBV-specific T cells have also been described recently 
(Hyodo et al., 2004) and allude to Trl mediated immunosuppressive mechanism. In 
line with these findings, our own studies have revealed a significant elevation of IL- 
10 in the serum of patients with chronic infection, compared to resolvers 
(unpublished observations; Maini, MK et al., UK.).
1.11.4 CD 8+ T lymphocytes
CD8+ T lymphocytes recognise peptides in the context of MHC class I molecules 
that are ubiquitously expressed by all nucleated cells and are critical to the control of 
intracellular pathogens. Infected cells are recognised via the TCR. The majority of T 
cells (both CD4+ and CD8+) bear receptors that are composed of an a  and a p chain, 
yô TCR receptors predominate earlier on in ontogeny but occur at relatively smaller 
frequencies from birth onwards apart from localised sites such as the gut where they 
exhibit tolerogenic activity (Chien and Konigshofer, 2007; Kapp et ah, 2004).
1.11.4.1 TCR a  chain
The a  chain consists of a variable (V) amino-terminal region, joining (J) segments 
and a constant (C) region whereas. The C region encodes a transmembrane 
polypeptide and is involved in anchoring the TCR to the cell surface. It also 
participates in intracellular signal transduction pathways. The V, J and C gene 
segments are rearranged by somatic recombination during T cell development in the 
thymus with additional diversity introduced by the protein TdT that catalyses the 
addition of nucleotides at the gene segment junctions. Heptamer and nonamer 
recombination signal sequences flank the gene segments and are recognized by a 
complex of enzymes called VDJ recombinase. Lymphoid-speciflcity is conferred 
from products of RAG-1 and Rag-2 (recombination-activation genes) genes. Gene
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arrangement results in the excision of gene segments that take the form of T cell 
receptor excision circles (TRECs) (Ye and Kirschner, 2002).
1.11.4.2 TCR p  chain
The p chain consists of variable (v), diversity (d), joining (j) and constant (c) gene 
segments and undergoes rearrangement before the alpha chain. Dp segments 
rearrange to jp  segments, followed by vp to DJp. Survival of the thymocyte depends 
on the expression of a pre-T cell receptor. Thus, if the rearranged construct does not 
produce a functional p chain, the VDJ arrangement has the potential of being rescued 
by subsequent rearrangements from two additional clusters of Dp and Jp gene 
segments that occur upstream of the two Cp genes. When a productive p chain 
arrangement is finally achieved it is expressed in conjunction with an invariant 
partner chain (pTa) and CD3 molecules and transported to the surface of the cell. This 
expression signals the phosphorylation and subsequent degradation of Rag-1 and 
Rag-2, thereby terminating further p chain gene rearrangement. Cell proliferation 
ensues, followed by the expression of CD4 and CD8+ allowing the production of 
multiple double positive thymocytes with identical p chains but still lacking the a  
chain.
Once proliferation is terminated, the Rag genes are expressed once again and the a  
chain segments begin to undergo specific rearrangement and expression culminating 
in an a p  TCR thymocyte. Rearrangement of the a  chain can however continue 
despite production of a TCR at the cell surface. Several a  chains are produced 
successively and simultaneously within each developing T cell and are tested, in 
conjunction with a consensus p chain, for recognition of self-antigen. This phase of 
gene rearrangement is terminated upon positive selection.
The D and J segments of the a  and p chains contribute to the formation of a hyper 
variable loop termed the complementarity determining region 3 (CDR3) which forms 
the center of the peptide binding site of TCR. Diversity is concentrated in this region
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that is surrounded by the CDRl and CDR2 loops that are encoded by the less variable 
(v) segments that make contact with the (relatively less variable) MHC molecule. The 
TCR variable loops fits diagonally across the peptide-MHCI binding site and buries 
most of the peptide as well as a large part of the MHC (Garboczi et al., 1996).
1.11.4.3 The CDS complex
The TCR a  and p chains do not possess enzymatic activity nor do they undergo 
covalent modifications by intracellular enzymes. The TCR is used to transmit signals 
though nonpolymorphic polypeptides that make-up the CD3 complex; these include 
Y, Ô, s and disulphide linked Ç chain dimers (Samelson et al., 1985; Weissman et al.,
1986). Following TCR ligaton, conformational changes induce the phosphorylation 
of tyrosine residues in the CD3 polypeptides; one site on y, 6, avô e and three on each 
^ chain (Samelson et al., 1986). Phosphorylation, catalysed by two cytosolic Src 
family kinases (Lck and Fyn), occurs on 16 amino acid long consensus sequences 
termed immunoreceptor-based tyrosine activation motifs (ITAMs) that bind to the 
SyK-family tyrosine kinase, ZAP-70 (Chan et al., 1992; Wange et al., 1992). 
Differences in ^ chain phosphorylation are though to differentially activate the Lck 
and Fyn kinases that in turn recruit particular adapter proteins to transmit a the signal 
that either leads to productive T cell activation or anergy. Lck kinase activity has 
been associated with productive activation whereas Fyn has been associated with 
anergy (Boussiotis et al., 1996; Gajewski et al., 1995; Gajewski et al., 1994).
1.11.4.4 The CDS coreceptor
CD8 is a disulphide-linked heterodimer that consists of an a  and a p chain each of 
which contains an immunoglobulin-like domain that is linked to the membrane by an 
extensively glycosylated segment - this segment serves to maintain the polypeptide in 
an extended conformation and it also protects the molecule from protease cleavage. 
When the CD8 a  chain is expressed without the p chain it is able to form
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homodimers that are involved in alternative specific functions -  non-classical MHCI 
interactions. CDS (a|3) on the other hand interacts with the invariant region of the a3 
domain of the MHCI molecule and the strength of this interaction is related to the 
extent of glyscolyation - an increase in the proportion of sialic acid residues decreases 
the strength of the interaction. The variation of sialic acid composition varies with 
maturation and activation state. The cytoplasmic tail of the CDS a chain on the other 
hand binds lck, a src- family tyrosine kinase, and brings it into closer proximity with 
the TCR.
1.11.4.5 The Major Histocompatibility Complex Class I
Almost all nucleated cells have MHCI, and these complexes present peptide 
fragments of endogenously expressed proteins. This is critical to protection of the 
host because it allows the immune system to detect cells that are infected by 
pathogens. In the case of viral infections, viral proteins that are synthesized as part of 
the viral replication cycle are processed and fragments of these polypeptides are 
displayed on the surface of the cell.
The human MHC Class I [termed the human leukocyte antigen (HLA)] was first 
defined serologically with alloantibodies in the 1950s. The structure consists of two 
polypetide chains. The larger of the two, the a  chain, is encoded by a genetic locus 
located on chromosome 6 and contains a carboxy terminal transmembrane spanning 
region. Three classes exist, denoted A, B and C. Their highly polymorphic nature 
contribute to their broad peptide binding specificity. A smaller non-polymorphic 
second chain, p microglobulin, encoded on a separate chromosome (15 in humans) is 
non-covalently attached and completes the dimer.
The completed molecule is composed of 4 domains, three of which are produced by 
the a  chain and the fourth is produced by p microglobulin. The A3 domain and B2- 
microglobulin fold together to form an immunoglobulin structure. The a l  and a2 
domains form a cleft on the surface of the molecule that is able to bind short peptides
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usually 8 to 10 amino acids in length. Longer peptides are also able to settle into the 
cleft particularly if the carboxy terminus suits binding, but the extended bits are 
normally subsequently digested off by exopeptidases in the endoplasmic reticulum.
Peptide binding in the MHC molecule cleft is stabilized by contacts at both ends 
between atoms in the amino and carboxy termini of the peptide and the invariant sites 
at the end of the cleft with the peptide lying in an elongated conformation along the 
cleft. These contact points are the main stabilizing contacts. Peptides that bind to a 
specific MHC variant also contain the same (or similar) aminio acid residues at two 
or three specific positions. The residues at these locations insert into pockets in the 
MHC and are known as anchor residues. Not all peptides that conform to anchor 
residue requirements are able to bind a given MHC variant; binding is reflective of 
the precise composition and electrostatic nature of the individual amino acids (Falk et 
al., 1991); certain amino acids may be preferred at secondary sites (Barouch et al.,
1995).
HLA-A2, the first human type I major histocompatability complex to be defined, is 
present at a high frequency in most populations (Browning and Krausa, 1996). The 
structure of HLA-A2 was obtained through X-ray crystallography in 1985 (Bjorkman 
et al., 1987a, b) and a consensus HLA-A2-binding peptide motif was subsequently 
identified by sequencing peptides eluted molecules; 9mer peptides with anchor 
residue leucine and valine/leucine are required at position 2 and 9 respectively (Falk 
et al., 1991).
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1.11.5 The CD8+ T cell response
A successful CD8+ T cell response to a pathogen can be divided into four phases 
(figure 1.9);
Phase 1 begins with the priming of naïve CD8+ T cell by mature antigen presenting 
cells such as dendritic cells, macrophages or B cells (Lanzavecchia and Sallusto,
2001). An optimal response requires the provision of three signals. Signal 1 is 
delivered through the TCR following engagement with the peptide/MHCI complex 
on the pAPC, signal 2 is provided by costimulatory molecules also on the pAPCs, and 
signal 3 is provided by the inflammatory cytokines IL-12, Type I and Type II IFNs 
(Haring et al., 2006). Additionally, the formation of a stable interaction has been 
shown to greatly influence the outcome; a 4-hour stimulus resulted in abortive clonal 
expansion, whereas a longer (20-hour) engagement leads to an effective response 
(Schoenberger, 2003).
Phase 2 covers the expansion of successfully activated CD8+ T cells and lasts for 
approximately 5 to 8 days; in this time the frequency of antigen-specific cells 
increases greater than 10,000-fold (Badovinac and Harty, 2002; Kaech et al., 2002). 
Cells undergo up to 3 divisions a day and can divide between a minimum of 8 and up 
to 15 times before they arrive at their peak (Kaech and Ahmed, 2001; Selin et al., 
1996). This phase also involves subsequent differentiation into a population of cells 
with poor proliferative capacity but strong functionality and migratory capacity that 
are able to travel throughout the body and home to infected cells (Weninger et al.,
2002).
Phase 3 involves the elimination of 90-95% of the expanded cells and occurs over 
approximately one week (Sprent and Tough, 2001). The kinetics of the contraction 
phase is independent of the dose, duration of infection or amount of antigen that is 
presented, rather, it appears that the early programming events during and 
immediately subsequent to CD8+ T cell priming govern the fate of the cell
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(Badovinac et al., 2002; Mercado et a l, 2000; van Stipdonk et al., 2001; Wong and 
Pâmer, 2001).
The final phase of the response involves the maintenance of a memory pool 
composed of the cells that have survived phase 3 (Kaech et al., 2002). These 
populations are able to respond faster to antigen re-encounter thereby providing more 
effective immunity (Bachmann et al., 1999a; Bertram et al., 2004a; Kersh et al., 2003; 
Slifka and Whitton, 2001). Additionally, the ability to express CD25 has been shown 
to be critical for the development of secondary responses emphasizing the importance 
of help during the early priming events (Kalams and Walker, 1998; Williams et al., 
2006).
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Figure 1.9: Naive-to-memory CD8+ T cell progression after acute infection or 
vaccination.
Antigenic peptides presented by mature dendritic cells (DCs) to naive CD8++ T cells 
trigger expansion and differentiation into effector CD8++ T cells. Five to ten percent 
of CD8+ T cells detected at the peak of expansion survive the contraction phase to 
initiate the memory pool, which can remain stable in number for life. LOD represents 
limit of detection
Printed with permission from Elsevier Limited. Immunity; Haring, JS.; 2006: 25(1)
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1.11,6 CD8+ T cell differentiation
The differentiation of CD8+ T cells has been well described and subsets have been 
delineated according to their homing capacity and effector function (Masopust et al., 
2001; Reinhardt et al., 2001; Sallusto et al., 2004; Sallusto et al., 1999).
According to the linear differentiation model, naïve cells are thought to initially 
differentiate into an effector population ( T e ) .  These cells then develop into effector 
memory T ( T e m ; CD45RO+CD27-CCR7-CD62-) with poor proliferative but potent 
functional capacity. T e m  subsequently develop into central memory population ( T c m ; 
CD45RO+CD27+CCR7+CD62+) with limited effector function but capable of 
proliferation into potent effectors following secondary antigen encounter. IL-7 is 
required for the survival of memory cells (Prlic et al., 2002) and its receptor (CD 127) 
has recently been suggested to be the most reliable marker for the identification of 
memory cells in humans (Fuller et al., 2005; Paiardini et al., 2005; van Leeuwen et 
al., 2005) (figure 1.10).
The progressive differentiation model on the other hand favours the involvement of 
an intermediate T subset (Tim) that develops from naïve cells that can then directly 
give rise to either Tem or Tcm (Bachmann et al., 2005a; Bachmann et al., 2005b; 
Huster et al., 2006) (figure 1.11).
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Figure 1.10: Correlation between phenotype and function of antigen-specific 
CD8+ T ceils.
Adapted by permission from Elsevier Limited. Current Opinion in Immunology; 
Huster, KM; 2006: 18(4).
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Figure 1.11: Progressive differentiation model.
Proposed lineage relationship of CD8+ T cell subsets. Dashed lines indicate potential 
differentiation pathways, which have so far not been elucidated.
Adapted by permission from Elsevier Limited. Current Opinion in Immunology; 
Huster, KM; 2006: 18(4).
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1.11.7 CD8+ T cell antiviral function
Although commonly referred to as cytotoxic T lymphocytes (CTL), CD8+ T cells are 
able to exert antiviral function through both cytotoxic and non-cytotoxic mechanisms.
Cytotoxicity can be achieved either through the granule exocytosis pathway or 
through FasL (CD95L) signalling (Berke, 1995), both of which initiate the caspase 
cascade in target cells leading to programmed cell death (Shresta et al., 1998). 
Efficient function by the former requires the coordinate delivery of perforin and 
granule enzymes into the target cell (Heusel et al., 1994). Effector cells themselves 
are protected from the lytic mediators by cathepsin B and protease inhibitor 9 (PI-9) 
that are released at the immunological synapse (Catalfamo and Henkart, 2003). Fas 
ligand induced death is triggered following the engagement of the death receptor Fas 
on the surface of target cells (Ashkenazi and Dixit, 1998; Varadhachary and Salgame, 
1998).
Non-cytotoxic mechanisms on the other hand involve the release of antiviral 
cytokines and chemokines. IFNs and TNF-a are involved in the downregulation of 
gene expression and clearance of hepatitis B virus (Guidotti et al., 1994; Guidotti et 
al., 1996; Guidotti et al., 1999b), IFN-y and TNF-a mediate the clearance of 
persistent lymphocytic choriomeningitis virus (LCMV) infection of the liver 
(Guidotti et al., 1999a); RANTES, M IP-la and M IP-lp have been implicated in the 
control of HIV-1 infection (Cocchi et al., 1995). The downstream pathways remain to 
be properly defined, however two IFN-induced pathways have been recently been 
proposed and are thought to act by shutting-off viral protein synthesis (Schneider and 
Mohr, 2003; Tian and Mathews, 2001).
Persistent stimulation of CD8+ T cells can result in a sequential loss of effector 
function ultimately leading to deletion (Wherry and Ahmed, 2004).
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1.11.8 CD8+ T cell response to HBV
CD8+ T cells are the principal effector cells that contribute to viral containment 
(Guidotti et al., 1996); this has been clearly demonstrated in CD8+ T cell depletion 
studies in a chimpanzee model (Thimme et al., 2003). Studies have shown that an 
effective HBV-specific CD8+ T cell response is robust and multispecific (Bertoletti 
et al., 1991; Jung et al., 1999; Maini and Bertoletti, 2000; Maini et al., 2000a; Maini 
et al., 1999; Penna et al., 1991). Both cytolytic and noncytolytic mechanims are 
involved (Guidotti et al., 1999; Murray et al., 2005). The main CD8+ T cell effector 
cytokines, IFN-y and TNF-a, mediate viral clearance by destablizing the 
nucleocapsid an degrading viral proteins and HBV RNA (Biermer et al., 2003). The 
role of this arm of the adaptive immune response is covered in more detail in chapter 
five.
1.11.9 CD8+ T cell homeostasis
The principal function of activated T cells is to exert effector function that contributes 
to the control of pathogens. This mechanism must be tightly controlled; a careful 
balance that is neither autoimmune pathology at one extreme nor immunodeficiency 
at the other must be achieved (Arnold et al., 2006). Two separate pathways govern 
the fate of activated cells: an active activation induced cell death (AICD) and a 
passive activated T cell autonomous death (ACAD) (Lenardo et al., 1999) (figure 
1. 12).
T cell undergo AICD as a consequence of signalling through cell surface death 
receptors receptors (figure 1.13) whereas ACAD is the result of an intrinsic 
mechanism that involves the balance of pro- and anti-apoptotic factors that are 
influenced by TCR signalling and/or cytokine deprivation (figure 1.14). Both 
pathways converge into caspase activation.
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Figure 1.12: The propriocidal or feedback-response paradigm of mature T 
lymphocyte apoptosis.
The T cell response to antigen occurs in two molecularly distinct phases: activation, 
which leads to the production of IL-2; and proliferation, which is due to cell cycle 
progression caused by IL-2. Cycling T cells become highly susceptible to apoptosis 
and whether death ensues depends on the environmental conditions. Active apoptosis 
occurs if strong secondary TCR engagement is encountered. Passive apoptosis occurs 
after cessation of antigen and IL-2 stimulation. A small number of cells escape both 
death pathways and these are believed to become the "memory" population.
Printed with permission from Annual Reviews. Annual Reviews of Immunlogy; 
Lenardo Michael; 1999: 17.
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1.11.9.1 Extrinsic apoptotic pathway
The tumor necrosis factor receptor family are a group of proteins that contain a death 
domain in the cytoplasmic component of the polypeptide. Ligation of the appropriate 
ligand to the receptor induces clustering which in turn recruits adaptor proteins that 
also contain a death domain such as F ADD and TRADD (Boldin et al., 1995a; Boldin 
et al., 1995b; Chinnaiyan et al., 1995; Hsu et al., 1995). Fas ligand binds and 
oligomirizes Fas (CD95/Apo-l) which in turn allows recruitment of F ADD. Other 
receptors require the intermediate adaptor TRADD before F ADD can be positioned 
appropriately. F ADD can then recruit procaspase-8 and procaspase-10 via a DED 
interaction (Boldin et al., 1996; Muzio et al., 1998). This increases their activity and 
they are then able to autoactivate (Martin et al., 1998; Muzio et al., 1998) thereby 
continuing the apoptosis chain of events. Additionally, cell surface death receptors 
can lead to events other than apoptosis. TNFRl ligation can activate transcription 
factors such as NF-KB and AP-1 through the recruitment of various adaptor proteins 
and kinases such as TRADD, RIP, NIK and TRAP. NFKB is able to initiate the up­
regulation of inflammatory responses (Ashkenazi and Dixit, 1998; Wallach et al., 
1998), even promoting proliferation of the cell (Tartaglia et al., 1993). FLIP 
molecules are a group of negative regulators of death receptor-induced apoptosis that 
resemble caspase-8 but lack its enzymatic activity. FLIP is able to bind to F ADD 
thereby subverting the processing of Caspase 8 which in turn interferes with the death 
cascade (Yeh et al., 2000).
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Figure 1.13: Signaling by Fas/APO-l/CD95, TNFRl and TNFRl.
For active apoptosis, trimeric death cytokines, FasL, and TNF interact with trimers 
formed by individual receptor molecules. This interaction promotes the recruitment of 
downstream signaling molecules distinct for each receptor. Fas induces apoptosis via 
recruitment of FADD and caspase-8. Shown are the signaling impediments caused by 
the ALPS mutations in the death domain and by FLIPS in FADD: caspase-8 DED 
interactions. TNFRl can signal either for apoptosis through TRADD and FADD, or 
deliver anti-apoptotic signals via recruitment of alternate signaling complexes 
consisting of TRADD, RIP, and TRAF-2. The anti-apoptotic signaling complex 
probably activates the NF-kB pathway through the NIK kinase that binds TRAF-2. 
NF-kB presumably induces the expression of as yet unidentified survival molecules. 
Signaling through TNFR2 proceed through the recruitment of TRAF proteins, most
74
likely a complex of TRAP 1/2 as indicated, although other TRAP proteins can bind 
TNPR2 in vitro. The TRAP 1/2 complex can also activate NP-kB, but experiments in 
TRAP-2-deflcient mice have revealed other NP-kB-independent anti-apoptotic 
pathways. Paradoxically, TNPR2 signaling may also sensitize cells for apoptosis 
through TNPRl (dashed line), although the mechanism is not well understood. The 
cytoplasmic mechanism of caspase activation is apparently initiated by a 
mitochondrial permeability transition that allows the release of cytochrome c. 
Cytochrome c causes the association of APAPl and caspase 9, leading to the 
activation of caspase 9 and triggering a caspase cascade. Bcl-2 family proteins can 
block apoptosis at the point of mitochondrial permeability transition and possibly by 
directly inhibiting the APAP-l/Caspase-9 complex, which activates downstream 
caspases.
Printed with permission from Annual Reviews. Annual Reviews of Immunlogy; 
Lenardo Michael; 1999: 17.
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1.11.9,2 Intrinsic apoptotic path way
The intrinsic death pathway is influenced by growth factor deprivation, DNA damage 
or TCR triggering (Krammer et al., 2007; Strasser et al., 1995) and is governed by 
members of the Bcl-2 family, which can be divided into two groups: the negative and 
the positive regulators.
At least 24 proteins, encoded by 20 genes (Adams and Cory, 1998), function by 
sensing cellular stress via signals from various sources such as the endoplasmic 
reticulum, the cytoskeleton, the nucleus and the mitochondria.
Anti-apoptotic members include Bcl-2, Bcl-XL, Bcl-w, Boo, A l, Mcll and BclB 
(Boise et al., 1993; Gibson et al., 1996; Ke et al., 2001; Kozopas et al., 1993; Lin et 
al., 1996; Song et al., 1999; Tsujimoto et al., 1985). The anti-apoptotic members of 
the family all share 3 or 4 homology domains called BH (Bcl2-homology) regions. 
They localize to the mitochondrial outer membrane (Nguyen et al., 1993) as well as 
the cytoplasmic faces of the endoplasmic reticulum (Krajewski et al., 1993) and 
nuclear envelope (Lithgow et al., 1994).
The pro-apoptotic members include Bax, Bcl-Xs, Bak, Bok, Bad, Bik, Bid, DP5, Blk, 
Noxa, Puma, Bcl-G, Bmf and Bim (Oltvai et al., 1993),(Boise et al., 1993), (Kiefer et 
al., 1995),(Hsu et al., 1997),(Yang et al., 1995),(Boyd et al., 1995),(Wang et al.,
1996),(Imaizumi et al., 1997),(Hegde et al., 1998),(Oda et al., 2000),(Nakano and 
Vousden, 2001), (Guo et al., 2001), (Puthalakath et al., 2001),(0'Connor et al., 1998).
These proteins can be divided into two groups based on the number of BH domains 
that they contain. Bax, Bok, Bak, Bcl-Gl and Bcl-Xs contain multiple BH domains 
whereas Bik, Blk, Hrk, Bad, Bid, Bcl-G, puma, noxa, bmf and Bim contain a short 
BH domains and are therefore refereed to as BH3-only proteins (Huang and Strasser, 
2000).
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These proteins induce apoptosis by binding and antagonizing pro-survival members 
(Kelekar and Thompson, 1998). Cell is death normally avoided by sequestering these 
proteins away from the prosurvival members; key triggers facilitate their release 
(Puthalakath et al., 1999; Puthalakath et al., 2001) thereby allowing them to interfere 
with the apoptosis repressors.
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Figure 1.14: Illustration of apoptosis driven by Bcl-2 family members in 
activated T cells.
Pro-apoptotic BH3-only Bcl-2 family members Bad and Bim (BIMEL signifies ‘extra 
long’ Bim) are sequestered in the cytosol by 14-3-3 and light chain 8 (LC8) of the 
dynein motor complex, (a) Apoptotic stimuli (i.e. activation of T cells by antigen in 
vivo) by an unknown mechanism signal Bim to release from microtubules, (b) High 
levels of Bcl-2 may prevent death because they sequester Bim. High levels of Bim by 
an unknown mechanism signal (c) Bax and/or (d) Bak to form pores in mitochondria 
and, in association with VDAC, cause the release of cytochrome C (Cyt C) from 
mitochondria, (e) Bcl-2 has also been shown to block Cyt C release from 
mitochondria, (f) Once released, Cyt C interacts with APAF-1 and procaspase-9. This 
complex favors the activation of caspase-9 which, when activated, cleaves and 
activates caspase-3 which in turn cleaves other caspases, the inhibitor of caspase- 
activated DNAse (ICAD) and molecules important in cell integrity.
Printed with permission from Elsevier Limited. Current Opinion in Immunology; 
Hildeman, DA; 2002: 14(3).
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The Bcl-2-interacting mediator, Bim, is particularly relevant to chronic viral infection 
because it is capable of down-regulating antigen-specific CD8+ T cell responses 
(Bouillet et al., 1999; Grayson et al., 2006; Hildeman et al., 2002; O'Connor et al., 
1998; Pellegrini et al., 2003).
Both cytokine deprivation as well as TCR triggering contributes to increases in Bim 
expression (figure 1.15), however the latter mechanism appears to be particularly 
important given the context of repeated antigenic stimulation during persistent 
infection.
The upstream pathway is not well understood, however, downsteam events involve 
the adaptor protein Apaf-1 that is required to cluster Caspase-9 in order to enhance its 
autocatalytic activity which in turn is necessary for apoptosis. Cytoplasmic Apaf-1 is 
activated following engagement with cytochrome c which is normally sequestered in 
the mitochondria; the accessory proapoptotic mediators Bax and Bak mediate the 
release of cytochrome c but are normally maintained in an inactive state by Bcl-2 and 
its homologues (Cheng et al., 2001; Zong et al., 2001).
However, the binding of Bim to Bcl-2 initiates Bax and Bak functionality (Willis et 
al., 2007). The difference between cell survival and cell death is governed by the 
equilibrium between the pro and anti-apoptotic Bcl-2 family members. IL-7 can 
upregulate the Bcl-2 family members (Akashi et al., 1997; Maraskovsky et al., 1997) 
whereas the proapoptotic proteins can be increased by alternative extracellular ligand 
signalling (Puthalakath et al., 2001; Zha et al., 1996).
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Figure 1.15: Mechanisms for BIM activation in lymphoid cells.
(a) Cytokine deprivation can activate the pro-apoptotic activity of Bim (B-cell 
lymphoma 2 (BcL-2)-interacting mediator of cell death) in lymphoid cells through at 
least two pathways. Loss of cytokine-receptor stimulation causes inactivation of the 
kinase AKT, which in turn leads to activation of the transcription factor F0X03A 
(forkhead box 03A), resulting in increased BIM mRNA synthesis. Cytokine 
deprivation also leads to inactivation of the kinase ERK (extracellular signal- 
regulated kinase), causing loss of BIM phosphorylation, which targets BIM for 
ubiquitylation and proteasomal degradation.
(b) During apoptosis induced by antigen-receptor crosslinking, increased levels of 
BIM mRNA and BIM protein have been observed, but little is known about the 
signalling pathways that are responsible for this. BCR, B-cell receptor; TCR, T-cell 
receptor.
Adapted with permission from Nature Publishing Group. Nature Reviews 
Immunology; Strasser, A; 2005: 5(3)
80
1.11.10 Caspases
Caspases are aspartate-specific cysteine proteases that specifically cleave critical 
cellular substrates (Thornberry and Lazebnik, 1998) that are normally maintained in 
an inactive state (Enari et ah, 1998). They are divided into two groups based on their 
structure and function: initiator and effector caspases. Initiator caspases contain 
protein-protein association domains that enable them to bind to adaptor proteins. 
Caspase 8 and caspase-10 contain two death effector domains (DED) allowing them 
to interact with F ADD through its DED motif. Caspase -1, -2, -4, -5, -9, -11 and -12 
contain instead a caspase recruitment domain (CARD). Caspase-9 is able to bind 
Apaf-1 via its CARD motif. Adaptor proteins such as F ADD and Apaf-1 exert their 
effects by aggregrating the initiator caspases and this allows their low-level 
enzymatic activity to influence autocatalytic processing, thereby triggering the death 
cascade. These activated initiator caspases then interact with the effector caspases. 
Subsequent proteolytic clevage of cellular proteins contributes to destabilizing the 
integrity of the cell. Ultimately, a caspase activated DNAse (CAD) digests the 
genomic DNA.
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LI L U  Cross-presentation of antigen to CD8+ T cells
The majority of naive and resting T cells are located in secondary lymphoid tissue 
(SLT) that includes the spleen, lymph nodes and peyers patches (figure 1.16). These 
cells continually recirculate between different parts of these organs in a cycle that 
takes approximately one day to complete. This trafficking ensures that each 
individual compartment of the secondary lymphoid tissue has an optimally diverse 
TCR repertoire. Professional antigen presenting cells (pAPCs) stationed throughout 
the body transport antigen from peripheral tissues to lymph nodes where they are 
presented to the residing population of T cells.
CD8+ T cell priming requires presentation of antigen by MHCI complexes (Bevan,
1987). This normally occurs in all infected cells and serves to identify intracellular 
pathogens to facilitate their destruction and limit replication. However, certain 
(uninfected) APCs are capable of taking-up exogenous antigen and presenting it on 
MHCI complexes on the cell surface (Pozzi et al., 2005). This is particularly 
important as it prevents viruses escaping immune recognition through the 
downregulation of MHC expression (Ahn et al., 1996a; Fruh et al., 1995; Levitskaya 
et al., 1997; Ploegh, 1998; Tortorella et al., 2000). One of the earliest observations of 
cross-presentation in humans was made during an investigation of human T cell lines 
specific for HBsAg (Jin et al., 1988).
Subsequent studies have shown that soluble antigen that enters APCs by fluid-phase 
endocytosis is cross-presented less efficiently compared to particulate matter unless 
present at high concentrations (Carbone and Bevan, 1990; Falo et al., 1995; Rock et 
al., 1990). Particulate antigens > lpm  in size are taken up by phagocytosis (Allen and 
Aderem, 1996), whereas smaller particles and soluble antigen are taken up by 
macropinocytosis.
8 2
Figure 1.16: Schematic illustrating the location and distribution of lymphoid 
organs in the body.
(http : // W W W . ne vdgp. org. au/ info/cc v/patients/images/ly mphatic. gif)
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The mechanism of cross-presentation is thought to involve fusion of phagosomes 
with endoplasmic reticulum-derived vesicles bringing together the antigen, MHCI 
complexes and the components required for loading (Ackerman et al., 2003; 
Cresswell et al., 1999; Guermonprez et al., 2003; Houde et al., 2003) (figure 1.17). 
The antigens are then transported to the cytosol adjacent to the phagosome and are 
degraded by proteasomes into peptides that are transported back to the phagosome by 
the TAP complex for loading (Jarosch et al., 2002; Matlack et al., 1998; Romisch, 
1999; Wiertz et al., 1996b). Finally, the fusion of phagosomes with the surface 
membrane exposes the peptide loaded MHCI. Alternatively, a TAP/proteasome- 
independent vacuolar pathway can also contribute to antigen cross-presentation but 
has not been fully characterized (Bachmann et al., 1995; Rock, 1996; Shen et al., 
2004). Other, studies have demonstrated that cross-presentation of soluble proteins 
from HBV, HCV- and HIV-1 can be enhanced by reducing endocytic acidification by 
cholorquine or ammonium chloride treatment (Accapezzato et al., 2005).
Although B cells (Ke and Kapp, 1996), endothelial cells (liver sinusoidal endothelial 
cells) (Limmer et al., 2000) and macrophages (Debrick et al., 1991) are all capable of 
cross-presenting antigens that include soluble proteins, immune complexes, 
intracellular bacteria, parasites and cellular antigens (Kurts et al., 1996), (den Haan 
and Bevan, 2002), (Pfeifer et al., 1993), (Belkaid et al., 2002), (Albert et al., 1998). 
CD8+ DCs are the main subset that can effectively cross-present antigens to CD8+ T 
cells (lyoda et al., 2002; Valdez et al., 2002).
84
MHC class
Cytosol
Egress 
SEC61? to cytosol
ER-phagosome?
Phago-lysosome
Pfoteasome
Peptides
ER-lumen
CurTBfil Qptnioc in IfTimunotogy
Figure 1.17: Major histocompatibility complex (MHC) class I presentation 
pathways.
Possible routes that phagocytosed antigens take to reach proteasomes in the cytosol. 
In (a), ER-derived phagosomes were proposed to shelter phagocytosed antigens and 
to transport them to the cytosol via the Sec61 channel. The pathway outlined in (b) 
represents the conventional route of phagocytosis, whereby the plasma membrane 
engulfs the incoming particles to create a nascent phagosome, which then fuses with 
elements of the lysososmal system. From there antigens would access the cytosol. 
According to (c), ER-derived phagosomes contain the necessary components for 
cross-presentation, mediating retrotranslocation via Sec61 to access proteasomes on 
the cytosolic surface of the phagosome, resulting in peptides further re-imported via 
TAP into the phagosome for loading onto MHC-I molecules, followed by transport to 
the plasma membrane.
Printed with permission from Elsevier Limited. Current Opinion in Immunology; 
Monu, N; 2007: 19(1)
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1.11.12 Cross-tolerance
APCs that are not exposed to specific infiammatory stimuli (Fuchs, 1992; Janeway et 
al., 1989; Matzinger, 1994) do not transit from an immature to mature status. This 
cellular differentiation is normally associated with an upregulation of costimulatory 
ligands [CD8+0, CD8+6, OX40L, CD70 (CD27L) and 4-lBBL] that is required for 
optimal T cell priming (Bertram et al., 2004b); CD8+ T cells that engage with 
immature cross-presenting APCs are tolerised (Nurieva et al., 2006; Steinman et al., 
2003b).
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1.12 Gene expression analysis
Cellular responses are the result of complex intracellular events that involve multiple 
players acting either in parallel or in series. The cellular genome itself contains the 
information that is necessary to initiate such a response. In accordance with this 
central dogma, information travels from genomic DNA to RNA and finally to 
protein; the cellular genome is transcribed into messenger RNA (mRNA) and this is 
then translated by ribosomes into polypeptides, the majority of which require 
subsequent modification to confer functional activity.
The most common approach towards understanding specific cellular function (and 
dysfunction) follows a reductionist method based on the identification of a single 
gene or its protein product followed by attempts to relate it to the phenotype under 
investigation. Traditional methods uses in these studies have been northern blots, 
RNase protection assays, western blots and more recently flow cytometry. Studies 
utilising this approach have contributed significantly to our understanding of specific 
cellular processes, however they are limited in scope, particularly when complex 
serial and/or parallel multi-gene events are involved.
Changes in protein content are subsequent to mRNA transcription, therefore cellular 
levels of mRNA are to some extent representative of protein content. Specifically, an 
increase or decrease in the expression of a particular mRNA species is indicative of 
an increase or decrease in the expression of the corresponding protein respectively. 
High throughput gene expression analysis is therefore a highly effective tool to assess 
cellular function by simultaneously measuring the quantities of multiple gene 
transcripts.
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1.13 DNA Microarrays
Several methodologies have been used for the analysis of gene expression. These 
include serial analysis of gene expression (SAGE), cDNA library sequencing, 
differential display, cDNA subtraction, QPCR, and gene expression microarrays. The 
particular advantage of microarray analysis for comparative studies on biological 
samples is the capacity to simultaneously examine the gene profile of a very large 
number of genes from a relatively small sample. Microarrays measure the 
hybridization between DNA that has been immobilized to a rigid platform (glass, 
nylon, plastic) to some form of mRNA representation from the sample under study. 
The DNA is arranged in concise spots in an ordered matrix pattern and allows a 
separate but simultaneous analysis to occur for each distinct spot. This makes it 
possible not only to measure the quantity of a specific gene transcript but also to 
assess the relationship between different transcriptional specificities. Gene expression 
microarray technology is mainly conducted using oligonucleotide or cDNA arrays, 
differing in the manner in which the DNA sequences are put onto the array as well as 
the length of the sequences used.
1.13.1 Oligoarrays
This approach to microarrays has been popularized by Affymetrix with their range of 
GeneChips, that involve the use of oligonucleotides that are covalently linked to glass 
slides. These arrays utilize a comparison of the hybridization of the sample mRNA 
(which has been labelled with a specific marker - biotin) to a pair of probes for each 
gene that are composed of 11 to 20 pairs of oligonucleotides of 25 bases in length. 
One probe sequence is a perfect match [also referred to as the perfect match (PM)] 
and is obtained from the gene sequence. The second probe is an imperfect match 
[known as the mismatch (MM)] and is constructed by purposely altering the middle 
(13th) base of the PM to alter the efficiency of binding. The purpose of MMs is to 
control for experimental variation and non-specific hybridization in the sample. 
Ultimately, oligonucleotide arrays measure the fluorescence intensity of one reporter
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dye (streptavidin -  PE) and obtain two sets of readings; one for the PM and the other 
for the MM, from which the expression of specific genes is evaluated through 
accessory computational algorithms.
1.13.2 cDNA arrays
In DNA arrays, mRNA from a biological sample is converted to cDNA by reverse 
transcription using dNTPs that are labelled with a fluorescent dye. Although basic 
modifications of the labelling process do exist they ultimately result in a fluorescently 
tagged anti-mRNA sequence. This product is then hybridized to DNA sequences 
(which can be cDNA generated from PCR products or oligonucleotide sequences) 
that have been immobilized to a rigid platform such as a glass slide, with unique 
DNA sequences spotted in discrete circular areas or spots.
Following hybridization and removal of unhybridized sample, a laser scanner is used 
to measure the fluorescence intensity and stores data at the level of individual pixels. 
Higher fluorescence corresponds to higher hybridization; this in turn corresponds to 
the quantity of the transcript in the sample tested. Computational image analysis 
algorithms are then used to calculate the fluorescence intensity of individual spots as 
well as defined areas of background fluorescence for each spot.
1.13.2.1 Comparative analysis through dual fluorescence
An extension of the basic principal of DNA microarrays involves the use of two 
different fluorescent dyes and is known as dual-colour microarrays. Here, mRNA 
from the sample, referred to as the test RNA, is reverse transcribed into cDNA in a 
reaction that incorporates a fluorescently labelled dye (Cy5; red). A second source of 
mRNA is also reversed in the same way but with another fluorescent colour (Cy3; 
green); this is referred to as the reference RNA. Equivalent amounts of the labelled 
cDNAs are then mixed together and applied onto one array where they competitively
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hybridise to their respective probes. Thus, if a specific transcript is highly expressed 
in the test sample relative to the reference, it will appear more red than green when 
the array is scanned. This quality can be measured precisely and results in two values 
corresponding to the fluorescence intensity for Cy5 and for Cy3 for each gene spot on 
an array (figure 1.19).
The use of a unique stock of reference RNA on multiple arrays each with a different 
test RNA sample creates the possibility of cross comparing gene expression data of 
different arrays by comparing the ratio of Cy5 to Cy3 for any given gene.
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Figure 1.18: cDNA microarray schema.
Templates for genes of interest are obtained and amplified by PCR. Following 
purification and quality control, aliquots are printed on coated glass microscope slides 
using a computer-controlled, high-speed robot. Total RNA from both the test and 
reference sample is fluorescently labelled with either Cy3- or Cy5-dCTP using a 
single round of reverse transcription. The fluorescent targets are pooled and allowed 
to hybridize under stringent conditions to the clones on the array. Laser excitation of 
the incorporated targets yields an emission with a characteristic spectra, which is 
measured using a scanning confocal laser microscope. Monochrome images from the 
scanner are imported into software in which the images are pseudo-coloured and 
merged. Information about the clones, including gene name, clone identifier, intensity 
values, intensity ratios, normalization constant and confidence intervals is attached to 
each target. Data from a single hybridization experiment is viewed as a normalized 
ratio (that is, Cy3/Cy5) in which significant deviations from 1 (no change) are 
indicative of increased (>1) or decreased (<1) levels of gene expression relative to the 
reference sample. In addition, data from multiple experiments can be examined using 
any number of data mining tools.
Printed with permission from Nature Publishing Group. Nature Genetics; Duggan, 
DJ; 1999: 21.
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1.13.2.2 Experimental variability and counter strategies to minimize it
A major advantage of using two-colour arrays is the possibility to overcome cDNA 
spot printing variations that can occur during the manufacturing stage. If spotting is 
not consistent, certain arrays may have significantly different sized spots for any 
given gene and therefore the interpretation of single-colour hybridizations would not 
accurately represent true gene expression. As two-colour arrays are based on a 
competitive hybridization, variations in spot size do not matter; Cy5 to Cy3 ratios 
would be unaffected.
Variability in data measurements can however occur at multiple levels and can 
obscure the essential biological signals that are being sought. Such error arises at 
various stages of array preparation and processing and must be acknowledged and 
vigorously controlled where possible to minimize overall error. For example, 
manufacturing error can be traced to amplification of the gene sequence, purification 
of the product, concentration of DNA used for spotting, efficiency of immobilization 
of DNA to the array and morphology of the spot. Sample preparation may suffer 
variations in RNA extraction and amplification procedures and differential labelling 
efficiencies. Dye specific variations include standard rates of decay, susceptibility to 
environmental factors such as ozone, and differential incorporation efficiencies due to 
physical size. Hybridization can be subject to variability as a result of cross­
hybridization due to similarity of probe sequences, changes in temperature and 
humidity, environmental contaminants, and efficiency of the subsequent washing 
procedure to remove non-hybridized sample. Lastly, variable background 
fluorescence in the scanned arrays can interfere with the true spot intensity by 
decreasing the signal to noise ratio. High scanning intensities improves signal quality 
but concomitantly increases the risk of signal saturation that occurs when certain 
spots fluoresce above maximum intensities thresholds of the scanner.
Ultimately, the most favoured strategy for dealing with uncertainties at the individual 
spot level is to mark the spot under question for exclusion in the final analysis. As for
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the spots that pass this screening, although the extent of the individual errors may be 
minimal, the cumulative effects as described above can translate to significant 
deviations in the final data and thus must be complemented with appropriate controls.
Replication in arrayed samples strengthens the reliability of the conclusions. This can 
occur in two forms. One form, biological replicates, involves the analysis of samples 
from different sources and is critical when genome biometry is large. A second form, 
technical replicates, involves multiplications of the same sample that establish the 
fidelity of the processes from initial crude sample (cell lysate), past RNA extraction 
and right through to the scanning of the processed array. To complement this, internal 
controls on each array, such as housekeeping genes and negative controls, help assess 
the source of experimental error.
1,13.2.3 Primary data output
Processed array slides are normally scanned at a resolution of 5 or 10pm; excitation 
and fluorescence is systematically measured over an area of 5 pm x 5 pm or 10pm x 
10mm that correspond to pixels of 25pm^ or lOOmm  ^respectively. After acquisition, 
an algorithm is used to define the location and perimeter of each spot and a local 
background. Computational tools can then be applied to segment and summarize the 
data (mean and median intensity value with standard deviation for Cy5 and Cy3) 
contained in the user-defined zones encompassing each spot. As mentioned 
previously, algorithms also cater to the extraction of local background fluorescence 
for every spot and can subsequently be subtracted from specific spot readings. 
However, if low intensity readings are generally observed, this step can be by-passed, 
while still allowing conservative interpretations of differential gene expression. 
Finally, the quality of the array data can be controlled by visual inspection of 
scatterplots of differential expression against overall intensity of the individual 
channels on an array (Cy5 versus Cy3) commonly referred to as the MA plot. These 
plots can be used to identify intensity-related biases and variances, saturation effects
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and other artefacts. For example, significant fish-tails at low intensities indicate that 
spot-level background subtraction cannot be reliably executed.
1.13.2.4 Data processing
Handling data of thousands of genes of multiple samples requires appropriate tools 
that are able to cope with the volume and complexity of such information. The data 
are normally held and manipulated in microsoft excel into a format that includes three 
main parameters: the gene name, the gene identification number (linked to a unigene 
or genebank accession number - where current detailed information of the individual 
gene can be found) and the absolute or relative expression value.
1.13.2.5 Log transformation
Spot intensity values are usually converted to log values and/or log ratios of 
intensities in order to force the data to approach a normal distribution. This also 
facilitates the interpretation of gene expression changes. The use of a common 
reference gene in all the arrays provides a gene specific constant across all the arrays. 
Log: transformation is preferred to Logio as it allows an easier interpretation of the 
data. In this way, a Log2(Cy5/Cy3) of 1, 0 and -1 correspond to a two-fold up­
regulation, no change, and a two-fold down-regulation respectively.
1.13.2.6 Normalization
In order to compare the gene expression profiles of data across multiple arrays the 
random and systematic variation that are introduced during array manufacture, 
sample preparation, and array processing have to be minimized through a process 
called normalization.
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The basis of array normalization rests on the fact that log transformation forces the 
data into a normal distribution pattern. Global normalization assumes that the Cy5 
and Cy3 intensities are related by a constant factor, and the expression ratio of the 
median gene on the population is zero based on the observation that the majority of 
genes do not alter their expression. Thus, whole data sets can be shifted so that they 
centre about a median of 0 while still conserving the standard deviation (which is a 
measure of the expression ratio data spread) within the dataset.
Despite normalization, within-group variation of individual gene expression can be 
significantly variable due to the heterogeneity of the source sample, and this requires 
statistical tools that are able to weight the differences accordingly. For example, 
within a group, replicates of one sample can be tagged so that the data analysis tools 
can consider this when assessing relationships to other individual samples in the 
group.
1.14 Data analysis
When it comes to the selection of differentially expressed genes, several approaches 
can be used to evaluate the degree of reliability of the data. The use of p-values has 
been criticised due to the multiplicity of the comparisons involved. A second method 
relies on calculating the probability of differential regulation. The third and currently 
most popular approach is to use the false discovery rate (FDR) that is an estimate of 
the fraction of genes that are truly altered among a selection of genes that are 
regarded as significant (Benjamini and Hochberg, 1995).
1.14.1 Significance Analysis of Microarrays
Significance Analysis of Microarrays (SAM) is an analytical tool that was developed 
by Tusher et al. (Tusher et al., 2001). Its main function is to correlate gene expression 
differentials between two groups with an outcome parameter by thresholding an 
appropriate test statistic and reporting the q value and FDR of each test based on a set
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of sample permutations. The statistical demands of identifying differentially 
expressed genes requires multiple hypothesis testing where multiple hypothesis tests 
are conducted simultaneously on all the genes under study. In statistical hypothesis 
testing, a null hypothesis is tested against an alternative hypothesis to determine the 
outcome. The null hypothesis is rejected in favour of the alternative if there is 
sufficient evidence to support the latter. This involves the rejection of the null 
hypothesis if its corresponding statistic lies in a predetermined rejection range. 
Additionally, hypothesis testing also involves an evaluation of the probability of 
rejecting the null hypothesis when it is actually valid (known as a false positive) as 
well as calculating the probability of rejecting the null hypothesis when the 
alternative hypothesis is actually true (termed power).
Differential gene expression involves the execution of four steps. First, a statistic 
must be generated for each gene. Then, the corresponding null distribution is 
calculated, this is followed by the specification of the rejection region, and finally the 
number of false positives must in some way be assessed or controlled. When 
determining the statistical significance of the difference in gene expression between 
two groups, the null hypothesis for each gene is that the observed data has a common 
distributional parameter within the groups. This can be the mean expression level. A 
statistic that is a function of the data is formed for each gene (t) and a significance 
region is defined for this statistic. If the statistic falls in this region the gene is noted 
as exhibiting differential gene expression.
Using this approach, two forms of errors can occur. Type 1 errors (false positives) 
occur when the statistic is significant but the gene is not expressed at a significant 
differential. Type 2 errors (false negatives) occur when the statistic is not significant 
but the gene is in fact differentially expressed. In multiple hypotheses testing each 
gene may includes both type 1 and type 2 errors and the measurement of the overall 
error rate becomes unclear. To overcome this complication, one can define a measure 
of compound error, such as the FDR (Benjamini and Hochberg, 1995).
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In the SAM PLOT (see chapter 4; figure 4.14), the genes conforming to the null 
hypothesis lie along the 45° diagonal line. The dotted tram lines above and below this 
are set according to the user defined FDR. All genes to the right of the tramline 
intersection, regardless of whether they are above or below this line are considered 
significant. The same is true for genes below and to the left of the lower tramline.
Microarray studies involve a large number of individual tests (genes) and are very 
much an exploratory analysis, with the aim of identifying a group of differentially 
expressed genes of which a small proportion are expected to be false positive. 
Ultimately, the aim is to shortlist a subset of genes from the totality of the test data 
that can then be focused on for a more detailed analysis. The power of SAM lies in 
the ability to define the rejection regions to accommodate the proportion and degree 
to which certain genes are over/under expressed. Additionally, a multiple hypothesis 
testing error rate takes into consideration multiple comparisons while simultaneously 
limiting the proportion of false positives that occur within the genes selected as 
significant.
1.14.2 Clustering
Clustering algorithms can be used to arrange a number of objects (such as genes or 
samples) into groups where the expression of genes within groups is more similar 
compared to the whole group.
1.14.2.1 Non-hierarchical clustering
Non-hierarchical clustering locates a single partition without nesting and is more 
suited to identifying candidate subgroups within complex data. K-means clustering 
and self organising maps (SOMs) are the most common methodologies. In K-means 
clustering an algorithm randomly assigns an object to one of several K clusters, the 
number of which have to initially be defined by the user (Hartigan and Wong, 1979).
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Distances between the clusters are then calculated based on the mean vector within 
each cluster. An iterative process is then used to maintain or relocate objects to other 
clusters to increase trans-cluster variance and decrease within-cluster variance. The 
process is terminated when no further improvements can be made. SOMs function by 
reducing dimensionality by generating a map that outlines the similarity among 
object, with similar objects groups together.
1.14.2.2 Hierarchical clustering
Hierarchical clustering on the other hand generates a series of successively nested 
clusters that represent the distances between the expression profiles in a tree or 
dendogram, where the data are made up of a series of partitions that extend from a 
single cluster down to sub clusters and terminate in a single gene or sample. This 
methodology is highly effective at facilitating visual interpretation. Clustering can be 
agglomerative (bottom-up), where every object starts by belonging to its own cluster 
and is then matched to the most similar other object. This process continues until 
there is only one cluster containing all the objects. Alternatively, clustering can be 
divisive, which is the opposite process and starts with all the objects and divides 
groups according to similarity until single objects remain. Each method usually 
produces unique hierarchies. Gene expression analysis are more suited to divisive 
analysis because these clusters are more stable, as the focus is on large clusters and 
fewer permutations are required to generate the clusters (compared to agglomerative 
clustering). Finally, unsupervised clustering can be used to screen data in an 
explorative manner for patterns of differential gene expression, which can then be 
correlated to the composition of objects within the group.
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2 Chapter 2: Material and Methods
2.1 Patients and Volunteers
Patients (table 2.1) were recruited from the Mortimer market centre, London, with 
full ethics approval and informed consent. HBeAg and anti-HBe antibody status was 
tested with the commercial enzyme immunoassay; Murex Diagnostics. HBV DNA 
viral load was quantified by the Roche Amplicor Monitor Assay; Roche Laboratories. 
All patients were negative for antibody to HIV-1 and HIV-2; Ortho Diagnostics. 
None of the patients recruited had received antiviral or immunosuppressive therapy.
2.2 Separation ofperipheral blood mononuclear cells from whole blood
Venous blood was drawn into EDTA tubes and processed on the same day. Blood 
was layered directly onto ficoll at a ratio of 2:1 (bloodificoll) and spun at room 
temperature at IbOOrpm; 24 minutes (brake off). Plasma was removed up to 5mm 
above the interface with the ficoll and the PBMC layer was collected into a 20ml 
universal predispensed with lOmls of RPMI. Following two cold washes in RPMI 
(first spin at ISOOrpm and the second at 1600), the cell pellet was resuspended in 
complete aMEM (10% PCS); ~lm l for each lOmls of blood processed. Cell samples 
were normally placed on ice until required for assays/freezing.
2.3 Cell counting
Cells were counted with a haemocytometer (improved neubauer) under a light 
microscope; lOpl tryphan blue + lOpl of a 1/10 dilution of the stock (lOpl cells + 
90pl RPMI); equivalent to a dilution factor of 20; the dilution factor was altered if 
necessary. Formula for cell yield: Number of cells in the central grid x dilution factor 
X 104 = [cells/ml].
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Table 2.1: Patient details.
Patien t a g e sex viral load ALT sero logy cDNA Bim Mcl-1 Rescue  (VAD)
( lU/ml) a r r a y e d  
( +
purified*)
10
day
10
d ay
ex
vivo
10
d ay
R eso lved
RI NA F ND NA HBsAg- Y* Y Y N Y
R2 NA M ND < 5 0 HBsAg- N Y Y N Y
R3 50 M ND NA HBsAg- N N N N Y
R4 41 NA ND NA HBsAg- Y Y Y N Y
R5 32 M ND 10 HBsAg- N Y Y N Y
R6 38 M ND < 5 0 HBsAg- Y Y Y N Y
R7 25 M ND 32 HBsAg- N Y Y N N
R8 35 M ND < 5 0 HBsAg- N Y Y N N
R9 39 M ND 74 HBsAg- N Y Y N N
RIO NA F ND NA HBsAg- Y* N N N N
R l l NA M ND NA HBsAg- Y N N N N
Chronic
C l 25 M 0.42E 270 HBeAg+ N Y Y N Y
C2 49 F I . I E 151 HBeAg- N Y Y N Y
C3 31 M 180 92 HBeAg- N Y Y N N
C4 29 F 1,100 NA HBeAg- N Y N N N
C5 38 M 510E 206 HBeAg+ N Y Y N Y
C6 28 F 7.9E 261 HBeAg+ N Y Y N Y
C7 50 F 0.22E 63 HBeAg- N Y Y N Y
C8 NA M >10E < 5 0 HBeAg+ Y* N N Y Y
C9 NA M 570 < 5 0 HBeAg- N N N Y Y
CIO 44 M 0.065E 49 HBeAg- N N N N Y
C i l 31 M 4 ,5 0 0 NA HBeAg- N Y Y Y Y
C12 35 M 220E 42 HBeAg+ N Y Y N Y
C13 31 M >10E < 5 0 HBeAg+ Y N N N Y
C14 42 F NA 17 HBeAg- N Y Y Y N
C15 45 M 110 32 HBeAg- N Y Y Y N
C16 71 M 2 ,9 00 22 HBeAg- N Y Y Y N
C17 30 F 770 31 HBeAg- N Y Y N N
C18 33 F BLQ 17 HBeAg- N Y Y N N
C19 NA M >10E NA HBeAg+ Y N N N N
N A =data  n o t  ava ilab le ;  E = x 1 ,0 0 0 ,0 0 0
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2.4 Cell storage
Working quickly, PBMCs were pelleted (1600rpm; lOmins), supernatant decanted, 
resuspended at lOmillion/ml in PCS (10% DMSO), aliquoted into cryovials 
(normally 5million/vial), placed in a Mr. Frosty freezing chamber (Fisher Scientific, 
UK) and put into a -70°C freezer for 24 hours. The vials were then transferred to a 
liquid nitrogen tank for long-term storage.
2.5 Cell retrieval from liquid nitrogen storage
Working quickly, cells were semi-thawed in a water bath (37°C) and dispended into 
20ml of RPMI, mixed well, spun (IbOOrpm; lOmins), re suspended in complete 
aMEM + 10% PCS; approximately SOOpl for every 5million vial and counted 
[dilution factor (with tryphan blue) 1:1].
2.6 Cell Culture (HBV-specific CD8+ T cell enrichment)
lOOpl of cMEM (10% PCS & 40U/ml IL-2) was dispensed into the appropriate 
number of wells in a 96 well round bottom plate. Appropriate peptides (Chiron 
Mimotopes; >90% pure by HPLC analysis) were added where required (2pM). lOOpl 
of cell sample (diluted to 3 x 106/ml) was then dispensed into each well and 
incubated at 37°C; 4% CO2 ; for 10 days. IL-2 (Roche) was supplemented on day 4; 
lOOpl of medium was aspirated from the top of each sample and replaced with 
complete aMEM with 40U/ml IL-2. The frequencies of peptide specific cells were 
evaluated by tetramer staining or by intracellular cytokine staining (ICS) for IPN-y on 
day 10.
2.7 Multimer staining
For tetramer/pentamer staining, total PBMCs were stained with the manufacturers 
recommended quantity of multimer at 37°C, washed (PBS + 1%PBS) and then
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stained with anti-CD8 (BD Biosciences); ISmins in the fridge. The cells were then 
pelleted, staining medium removed, washed once in PBS (Sigma-Aldrich, St. Louis, 
MO) (1% formaldehyde (Anachem) & 1% PCS), resuspended in the same solution.
2.8 Intracellular cytokine staining
For the ICS, lOOpl medium was aspirated from the top of the wells, cells were 
resuspended in the remaining lOOpl and then restimulated with peptide (2pM) for 5 
hours; multiple wells that were stimulated with the identical peptides at t=0 were 
pooled and re-split. lOOpl of complete aMEM (10% PCS & 0.2pg/ml Brefeldin A) 
was added 1 hour after peptide restimulation to block secretion of proteins. Following 
incubation, cells were stained for 15 mins with anti-CD8; in the fridge, fixed and 
permeabilized with cytoperm/cytofix for 20mins; 4°C, stained with anti-lFN-y in PBS 
+ 0.01% Saponin and 1% PCS for 30mins, washed (PBS; 1% PBS) and analyzed by 
flow cytometry. For Bim/Mcl-1 costaining, 0.5pg or 2/100 dilution of Bim and Mcll 
primary antibody was added along with IPN-y, followed by two washes with 
PBS/PCS( 1 %)/Saponin(0.1 %). Samples were then stained with the secondary 
antibody 1/2000 and 1/200 dilution for anti-Bim and anti-Mcl-1 secondaries, for 20 
minutes, followed by two washes with PBS/PCS( 1 %)/Saponin(0.1 %) and finally 
resuspension of the sample in PBS/PCS(1%) for flow cytometry. Antibodies were 
titrated down to these working dilutions to minimize non-specific cross-reactivity to 
intracellular antigens or the other antibodies (CD8 and IPN-y).
2.9 Flow cytometric analysis
Routine flow cytometry was conducted on a FACs calibur. Following staining, cells 
were fixed with PBS + 1%  formaldehyde. Samples were acquired on the same day. A 
live acquisition gate (R l) was set on viable lymphocytes based on the forward (linear 
scale) and side scatter (log scale) profile that represents size and granularity 
respectively. Single stained samples were set-up to compensate for fluorescence 
variations. A null channel was used to gate out non-specific autofluorescence.
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2.12 mRNA extraction
Messenger RNA was extracted with the mRNA Direct Kit (Dynal) according to 
manufacturers instructions. Briefly, 0.3-0.5 x 10  ^ total PBMCs were pelleted at 
3,200rpm on a bench-top centrifuge for 6 mins. The pellet was resuspended in 50pl 
PBS, followed by lysis of cells in 500pl Dynal Lysis buffer. 60pl Dynabeads were 
reconditioned with lysis buffer and combined with the lysate. Samples were rolled at 
room temperature for 10 minutes to allow the mRNA to bind to the beads. The beads 
were then separated magnetically from the lysate, followed by 300pl washes of Wash 
Buffer A (twice), 300pl Wash Buffer B (twice) and lOOpl DEPC water (once). 
mRNA was eluted twice from the beads into 200pl DEPC water containing 5ng/ml 
T7-p(T) primer by heating to 95°C for 2 mins followed by magnetic separation, 
collection of bead-free eluate and reduction of the volume by vacuum centrifugation.
2.13 In vitro amplification
Purified mRNA was amplified twice according to manufacturers instructions 
(Ampliscribe T7-Flash transcription kit. Epicentre Technologies) and 5pg (quantified 
with an Agilent Bioanalyser) was Cy5-labelled (Amersham Pharmacia Biotech).
mRNA from 0.3-0.5 x 10  ^ PBMCs was reverse transcribed with Superscript II 
(Gibco) utilizing a Poly T primer containing a RNA polymerase T7 Promoter. Second 
strand was generated by snap-back priming of the 3’ end of the first DNA strand. The 
double stranded product was purified with phenoI:choIoroform:isoamyl alcohol 
(Invitrogen) for protein extraction and Microcon 100 columns (Millipore) for 
desalting and removal of dNTPs, and reduced to a calculated volume by vacuum 
centrifugation. This product was linearly amplified with the Ampliscribe T7-Flash 
transcription kit (Epicentre Technologies, Madison, WI) according to manufacturers 
instructions, and then purified as described above.
The product of the first amplification (aRNA) was reverse transcribed with random 
hexamers (Amersham-Pharmacia Biotech., UK), followed by second strand
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generation with a T7-p(T) primer. The double stranded product was purified as 
above, reduced in volume by vacuum centrifugation, linearly amplified, and purified 
again (see figure 2.1 ).
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2.14 Quantitation of mRNA
Messenger RNA was accurately quantified with a Bioanalyser (Agilent) using 
NanoChips (Agilent) according to the manufacturers instructions. Briefly, the chip 
was primed with gel-dye matrix, sample and ladder wells were loaded with marker 
and finally Ipl of sample was loaded per well (upto 12 samples/chip) along with Ipl 
(150ng) RNA ladder (Ambion), vortexed and read within 5mins. The ladder was 
heat-denatured at 95°C and snap chilled on ice prior to loading to remove secondary 
structures.
2.15 RNA Labelling
5pg of aRNA were labelled with the Cyscribe First Strand cDNA Labelling Kit 
(Amersham Pharmacia Biotech.) according to manufacturers instructions, with 
random nonamers and Cy5-dCTP (Amersham) for samples and Cy3-dCTP 
(Amersham) for reference, followed by purification (Microcon30) and vacuum 
concentration to the required volume.
2.16 Hybridisation
cDNA arrays (Human cDNA Array Gen2 (Hs_clone_Av2) were provided by the 
Rosalind Franklin Centre for Genomics Research; further information can be found 
on : www.rfcgr.mrc.ac.uk/microarray
The Cy5 and Cy3-labelled samples were combined in hybridisation buffer consisting 
of 12pl x20 SSPE (Sigma-Aldrich), 1.1 pi 0.5M EDTA (Sigma-Aldrich), 2pl Poly 
d(A) (Amersham), 2pl tRNA (Sigma-Aldrich) in a volume of 45pl. Ipl of 10% SDS 
(Sigma) was then added and the sample was incubated at 98°C for 2 mins, followed 
by 37°C for 20mins. Finally, Ipl of xlOO Denhardt’s (Sigma) was added, spun at 
13,000rpm for ISmins and dispensed onto an array which was then topped with a 
coverslip (BDH) and incubated in a humidified chamber (Ambion) at 65°C overnight. 
Arrays were washed (x2 SSPE at 50°C, x2 SSPE at room temperature, xl SSPE at
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RT, xO.l SSPE at RT), spun dry (lOOOrpm; 3mins) and scanned (Axon; Genepix 
software) at a PMT intensity such that white spot over-saturation was minimized. A 
lower and higher PMT was also taken in order to be able to evaluate low and highly 
expressed genes, respectively.
2.17 Primary array analysis
The scanned images were initially gridded with a standard algorithmn and 
subsequently fine tuned manually with genepix software. Data was then extracted and 
exported as an excel-compatible file, of which only the following 11 data columns 
were retained:
Block
Column
Row
Name
ID
F635 Median 
8635 Median 
F532 Median 
8532 Median 
Median of ratios (635/532)
Flags
From these, the signal-background for the two fluorescence channels were generated. 
Log: transformed and then the signal to noise ratios (SNR) for Cy3 and Cy5 were 
calculated. The first row of each of the 48 blocks of spots on each array that 
contained the control genes were selected and pasted into a new worksheet entitled 
“Scorecard” and were sorted according to ID. Within these were 15 spots 
corresponding to negative control genes that included the yeast intergenic region from 
Chromosome VII, X I, XII and XIII, the arabidopsis thaliana protein G lp, a poly-dA 
oligonucleotide, spotting buffer and a Bacillius subtilis gene. The mean Cy5 and Cy3
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SNR of these 15 negative genes was used as the cut-off to filter out genes with a low 
SNR thereby only selecting data above the background. Only genes that passed both 
Cy5 and Cy3 SNRs negative control filtration were selected thereby producing a 
single column of quantitative numerical data of the relative expression of each gene 
on the array.
2.18 Cluster/Treeview analysis
Software obtained from : http:Zrana.lbl.gov/EisenSoftware.htm.
Manipulation by CLUSTER was performed in 21 stages:
1) The data were compiled into a single excel spread sheet and negative and positive 
genes were deleted. The gene expression data (1 to n arrays) was then processed by 
formatting the excel file as follows:
Gene
I.D.
Name GWEIGHT GORDER DATA
SERIES
1
DATA
SERIES
2
DATA
SERIES
n
EWEIGHT I I I
EORDER I 2 n
I.D. o f  A A I I
I.D. o f  B B I I
I.D. o fC C I I
I.D. o f  X X I I
2) save data as a text (delimited) file
3) initiate CLUSTER and load text data file created in step 2
4) adjust data: median center genes and arrays
5) click “APPLY” ten times
6) filter data (%), if required
7) in SELF-ORGANISING MAPS panel, select “organize genes’
8) then “MAKE SOM” (if required)
9) go to excel and open the SOM file created in step 8
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10) insert a column after column C
11) enter “=C3*-1” in D3; extend and D3 cell function to all the adjacent cells in the 
column
12) copy column D
13) paste special into Column C and label it “GORDER”
14) delete column D
15) insert new column titled “GWEIGHT” before GORDER; all cell with a value of 1
16) make all EWEIGHT = 1
17) insert EORDER numbers after EWEIGHT (1,2,3, etc)
18) save as a tab delimited file; include “EDITED” in the name
19) go to CLUSTER
20) load file created in step 18
21) in the hierarchical clustering panel, select average linkage clustering
The final step (22) saves three files in the default folder. The cdt file can be viewed in 
TREEVIEW; the heat-map, gene dendogram and array dendogram can subsequently 
be saved as unique image files. The atr and the gtr file contain the array tree and the 
gene tree respectively and can be viewed in excel.
2.19 Significance analysis o f microarrays (SAM)
SAM was obtained from: http://www-stat.stanford.edu/~tibs/SAM/index.html 
Gene expression data, normalized in CLUSTER (median centring), was formatted to 
SAM requirements as indicated in the manual that was downloaded from the web link 
above.
The basic format was as follows:
1 1 1 1 1 etc 2 2 2 2 2 etc
Name o f  gene 1 I.D. o f  gene 1
Name o f gene 2 I.D. o f gene 2
Name o f gene 3 I.D. o f gene 3
Name o f gene 4 I.D. o f  gene 4
etc etc
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Array data from resolved samples were pasted in serial columns headed with the 
response variable “ 1 ”, followed by array data from chronic samples that was headed 
“2”. Empty data cells were replaced with “NA”. All the data cells were then 
highlighted and the SAM excel add-in was executed. The false discovery rate was set 
as required when prompted by SAM.
2.20 Real time Quantitative PCR
Approximately 5pg of twice-amplified aRNA from resolved or chronic patient 
samples was reverse transcribed with superscript II reverse transcriptase and random 
nonamers in a 25 pi reaction volume, according to manufactures instructions. 10% of 
the reaction was added to an appropriate quantity of Taqman universal PCR master 
mix and the commercially designed gene-specific primer set that included an internal 
fluorescent (FAM) probe in a final volume of 25pi according to the manufacturers 
instructions and run on an ABI prisim 7000 (Applied Biosystems). For normalization 
purposes, each sample was set up in duplicate; one contained the Bim primer/probe 
set and the second contained the internal housekeeping gene (HuPo); the latter was 
kindly provided by J.Huggett (U.K.); both reactions had an equal amount of cDNA 
template. The relative quantification value was calculated as recommended by 
Applied Biosystems, as follows: ACT (Bim) - ACt (HuPo) = AACT, and 2 - AACt = 
relative quantification value.
2.21 Reagents
Agilent Biochip biochips/reagent Agilent 50654476
aMEM Gibco 22571020
Bax inhibitor (VPMLK) Proimmune POG
Bim Assay on Demand Applied Biosystems HsOO197982
b-Mercaptoethanol Gibco 31350010
Brefeldin A Sigma B7651
CMV Peptide Proimmune POBG008
Core 18-27 pentamer Proimmune FOAG023
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Core 18-27 Peptide Proimmune POBG 023
Cot 1-DNA Amersham 15279-011
Cy3- dUTP Amersham Pharmacia PA53021
Cy5- dUTP Amersham Pharmacia PA55021
Cyscribe labelling kit Amersham Pharmacia RPN-6200
Cytoperm/Cytofix Becton Dickinson 554722
Denhardts (xlOO) Sigma D9905
DEPC-treated water Invitrogen 10977.015
DMSO Sigma D4540
DNA polymerase I Gibco 18010025
dNTP Amersham 27203501
EDTA Sigma E7889
Envelope 183-191 pentamer Proimmune FOAG027
Envelope 183-191 Peptide Proimmune POBG 027
Essential amino acids Gibco 11130.036
Fetal bovine serum Invitrogen 10108165
Ficoll Sigma H8889
Formaldehyde Sigma F8775
Hepes Gibco 15630056
Human cDNA Microarrays Rosalind Franklin Centre for Genomic Res(
HuPo Assay on Demand Applied Biosystems
IFN-y secretion assay Miltenyi Biotech 130-054-202
IL-2 Roche 1011456
Influenza peptide Proimmune P007.0A
lonomycin Sigma 10634
Microcon 100 Millipore 42413
Microcon 30 Millipore 42410
mRNA Direct Kit Dynal 61021
Nano RNA600 chips Agilent 50654476
Nonessential amino acids Gibco 11140.035
Penicillin/streptomycin Invitrogen 15070.063
Phenol/Chlorofbrm/Isoamy 1 alcohol Invitrogen 10977015
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Phorbol 12-Myristate 13-Acetate Sigma P8139
Poly A(40-60) Amersham 27.7988.01
QPCR Master mix Applied Biosystems 4304437
Random nonamers Sigma-Aldrich R7647
RNA Ladder Ambion 7152
RNase Zap Ambion 9780
RNasin Promega N2111
RPMI Autogen Bioclear NG52052
Second strand buffer Gibco 10812014
Sodium pyruvate Gibco 11360.039
SSPE (x20) Sigma S2015
Superscript II Invitrogen 18064.014
T4 DNA polymerase Gibco 18005025
T7 transcription kit Epicentre ASF3257
Taqman Universal mastermix Applied Biosystems 4304437
Universal reference RNA Stratagene 740000
Yeast tRNA Sigma R8759
zVAD-fmk BD 550337
2.22 Antibodies
Anti-PE microbeads Miltenyi Biotech 130-048-801
BimEL/L/S (rat anti human) Axxora ALX.804.527
CD127-PE BD 557938
CD3 PerCpCy5.5 BD 332771
CD8 + PE-Cy5 BD 555368
CD8 + APC BD 555369
Goat anti rabbit FITC Insight Biotech SC-2012
Goat anti Rat FITC Axxora A110-109F
HLA-A2 FITC serotec MCA2090F
IFN-y PE R&D IC285P
Mcl-1 (Rabbit anti Human) Insight Biotech 1239-1
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3 CHAPTER 3
An analysis o f the breadth of the HBV-specific CD8+ T cell response in individuals 
with resolved and chronic HBV infection,
3.1 Background
Virally infected ceils within a host need to be rapidly identified and the pathogen 
eradicated. MHCI complexes display fragments of viral antigens for recognition by 
CD8 + T cells that bear complementary receptors (TCRs) (Yewdell and Bennink, 
1992). Hundreds to thousands of antigenic peptide fragments can potentially be 
generated from viral proteins (Yewdell, 2006) but the CD8 + T cell response that is 
evoked is thought to be focused on a limited number of viral determinants. However, 
data generated using more comprehensive up-to-date analytical techniques suggests 
that the antiviral hierarchy may actually be larger than previously thought (Posnett et 
al., 2005; Sacre et al., 2005). Nonetheless, these responses can be very conserved 
across individuals with a similar MHC background (Chen et al., 2000; Fuller et al., 
2004).
In a primary infection, several factors govern the development of this hierarchy. 
These include the efficiency of antigen presentation, the stability of the viral peptide- 
MHCI complex on the surface of professional antigen presenting cells, the presence 
of a population of naïve CD8 + T precursors with the ability to recognize the specific 
peptide, and a phenomenon termed immunodomination where certain specificities 
influence the expansion of others (Kedl et al., 2003; Newberg et al., 2006; Roy- 
Proulx et al., 2001). Additionally, heterologous immunity could influence a primary 
response because cross-reactive memory CD8 + T cell populations of unrelated 
specificities could expand faster than naïve CD8 + T cells; these would therefore 
dominate over simultaneously primed but slower-to-expand naïve cells (Brehm et al., 
2002; Chen et al., 2001; Selin and Welsh, 2004). This latter factor contributes to the 
individual’s private immune hierarchy and depends on each individual’s history of 
exposure to pathogens (Welsh and Selin, 2002).
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The focus of this work relates to several studies that have shown that persistent viral 
infection is associated with an immunodominance hierarchy that is different to that 
established during acute infection (Bergmann et al., 1999; Goulder et al., 2001; 
Hislop et al., 2002; Tewari et al., 2004; Wherry et al., 2003). This suggests that 
perturbations of the response could be responsible for immune failure. 
Multispecificity is important to effective viral control for several reasons. Targeting 
multiple viral epitopes exerts greater (simultaneous) pressure against the virus. This is 
particularly critical to pathogens that attempt to escape through mutation. Certain 
specificities may be better (faster) than others at expanding; this could be due to the 
inherent capacities of the cells involved (Hill, 1999). Assessing the differences 
between virus-specific CD8 + T cell hierarchies associated with good and poor 
outcomes could help us better understand the manner by which the pathogen 
establishes chronic infection. Although several groups have made valuable 
contributions, the majority of the developments on this theme have derived from 
murine experiments.
Hepatitis B virus infection presented an ideal opportunity to study virus-specific 
CD8 + T cell hierarchies in humans because of the natural dichotomous outcome 
where some patients successfully spontaneously resolve infection but others remain 
persistently infected. Several years ago, progress in the study of the HBV-specific 
CD8 + T responses was hampered by the inability to propagate the virus in vitro but 
investigations with primary HBV infected tissue confirmed an active participation of 
these immune cells. The subsequent characterization of HLA-A2 binding synthetic 
peptides (Sette et al., 1994) facilitated the identification, isolation and analysis of 
multiple HBV-specific CD8 + T populations. Further studies demonstrated that 
effective viral control was associated with robust HBV-specific CD8 + T responses 
(Bertoni et al., 1997; Nayersina et al., 1993; Rehermann et al., 1996a; Rehermann et 
al., 1995a). A direct causative effect was then demonstrated by selective depletion of 
CD8 + T cells in HBV infected chimpanzees confirming that this compartment 
contained the critical effector cells that enabled containment of the virus (Thimme et 
al., 2003).
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In humans, these HBV-specific populations were found to persist for decades 
following resolution of the infection (Penna et al., 1996; Rehermann et al., 1996a) 
and immunosuppression has been associated with the resurgence of HBV replication 
suggesting that inactive reserves of virus remain and memory sentinel populations, 
that maintain the capacity to exert effective functional activity, keep the pathogen 
contained.
In striking contrast to individuals that successfully limit infection, those that are 
unable to exert effective control but instead maintain varying degrees of viral 
replication are typically associated with relatively weak or non-detectable CD8 + T 
responses (Rehermann et al., 1995b), but resolution following chronic infection has 
been associated with an increase in the virus-specific populations (Lohr et al., 1995; 
Marinos et al., 1995; Rehermann et al., 1996b), further supporting the evidence for 
their involvement to be a prerequisite to successful viral control.
Structural and non-structural HBV proteins are both highly immunogenic (Bertoletti 
et al., 1991; Nayersina et al., 1993; Rehermann et al., 1995a) but relatively little is 
known about the immunogenic or tolerogenic hierarchies of these individual 
responses in humans. Although animal studies have generated important data, the 
main weakness of the use of a transgenic mouse model of persistent HBV infection 
(Kakimi et al., 2002) is that it is a biological system that is very different to that of 
humans. The difference of MHC composition between mice and men is of particular 
importance; antigen processing, CD8 + T cell priming and precursor frequencies are 
key factors that are not comparable and significantly impact the immune hierarchies 
formed.
The existing human investigations on this subject indicate that the acute phase CD8 + 
T response to HBV in resolvers is multi-specific whereas it is oligoclonal in chronic 
infection (Nayersina et al., 1993; Rehermann et al., 1995a), but the critical weakness 
of these studies is that they were conducted with limiting dilution/chromium release 
assays. Recent developments in techniques for detecting virus-specific CD8 + T cells
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have demonstrated that older methods have greatly under-estimated the true in vivo 
frequencies of the antigen-specific populations (Butz and Bevan, 1998; Maini et al., 
1999; Murali-Krishna et al., 1998). This was partially due to the inherent technical 
limitations that only allowed the detection of cells that maintained in vitro 
proliferative and functional (lytic) capacity. It is now clear that lengthy in vitro 
culture with multiple rounds of peptide stimulation would have rendered the majority 
of the antigen-responsive CD8 + T cells highly susceptible to activation-induced cell 
death (Lenardo et al., 1999).
Novel technologies have now largely replaced older assays, a major advance being 
the development of fluorescently labelled peptide-loaded HLA multimers such as 
tetramers, pentamers, and nonamers. When applied to flow cytometry, these reagents 
allow a highly accurate quantitation and analysis of the antigen-specific CD8 + T cell 
populations.
Our group has successfully applied these new techniques for direct ex vivo analyses 
of HBV polymerase, core, and envelope-specific CD8 + T in a group of 23 acute 
resolvers (Maini et al., 1999) and we have also been able to examine the TCR usage 
of core-specific CD8 + T cells in resolved and persistently infected individuals (Maini 
et al., 2000b). However, only a limited panel of viral determinants were assessed and 
a more comprehensive analysis to better understand immune hierarchies associated 
with resolved and chronic HBV infection was required.
At the time, we also demonstrated that certain individuals with chronic high viral 
replication maintained a peculiar population of HBV envelope-specific CD8 + T cells 
that were unable to bind HLA-matched tetramers (Reignat et al., 2002); this 
phenomenon has been described previously in association with T cell dysfunction 
(Blohm et al., 2002; Demotte et al., 2002; Rubio-Godoy et al., 2001; Spencer and 
Braciale, 2000). The discovery of this phenotypic defect invalidated the use of 
tetramers for a more comprehensive study of the breadth of the antiviral CD8 + T cell 
response in individuals with chronic infection, particularly as it was not clear whether 
other specificities were also prone to this defect. However, as tetramer-negative
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CD8 + T cells maintained the ability to produce IFN-y following in vitro peptide- 
specific stimulation, we were able to apply the technique of intracellular cytokine 
staining (ICS) to identify these specificities (Jung et al., 1993). Although the 
functional capacity of effector CD8 + T cells can be compromised in chronic viral 
infection, this occurs sequentially. It begins with the loss of IL-2 production, 
followed by the inability to lyse target cells that then leads to the loss of TNF-a 
production. The inability to produce IFN-y is the most resistant and this defect occurs 
last (Wherry et al., 2003).
Nonetheless, it is still extremely difficult to detect HBV-specific CD8 + T cells in 
peripheral blood by ICS for IFN-y directly ex vivo, but the frequencies of these scarce 
populations can be significantly enhanced by short-term in vitro enrichment. 
Although these methods cannot be used to determine the true in vivo frequencies, the 
trends observed after enrichment are representative of the patterns observed directly 
ex vivo (Webster et al., 2004).
Thus, in order to avoid overlooking low-frequency specificities due to the limitations 
of the direct ex vivo assay, we chose to maximise our capacity to detect different 
specificities by applying short-term in vitro enrichment. By forfeiting the acquisition 
of data on in vivo frequencies within the range of detection we aimed to obtain a more 
representative profile of the overall specificity of the response that was present in 
each individual studied.
Persistent HBV infection of humans manifests as a highly heterogenous disease 
(Fattovich, 2003); however, individuals can be broadly divided into two groups. 
There are those that have low levels of viral replication (as determined by the 
quantity of infectious viral particles in the serum) that is indicative of partial but 
inefficient viral control. Alternatively, there are individuals with high levels of viral 
replication suggesting a totally compromised immune response. HBeAg antigen, the 
secreted form of the N-terminal elongated core protein, was commonly used as a 
serological indicator of this latter phase of infection but an increase in the incidence 
of a strain containing a precore mutation resulting in the loss of e antigen secretion
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has now invalidated this approach. Currently, viral load is the most representative 
indicator of the status of viral replication.
As differences in the quantity and quality of the CD8 + T cell compartment of 
individuals with low or high levels of chronic infection could influence the overall 
antiviral efficacy it was important to stratify these individuals into two groups. Thus, 
in addition to examining the hierarchy in the resolved patients (HBV DNA negative 
& anti surface antigen antibody positive), we studied persistently infected individuals 
following their segregation into one of two groups: low and high level of viral 
replication divided according to a serum viral load of < 1 0  ^ and > 1 0  ^ copies/ml, as has 
been previously reported (Webster et al., 2004).
Thus, the principal aim of this study was to assess the quality of the antiviral HBV- 
specific CD8 + T cell response by determining the breadth of the antigen specific 
response in individuals with good, intermediate and poor outcomes. Our data have 
confirmed and extended previous knowledge on the association of HBV-specific 
antiviral specificities to different virological outcomes.
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3.2 Results
3.2.1 Detection o f hepatitis B virus core-specific CD 8+ T cells
HBV-specific CD8 + T cells are difficult to identify in the peripheral blood of 
resolved individuals because the frequency of circulating cells are very low; these are 
even more scarce in chronic infection. A short-term enrichment strategy allowed us to 
overcome this problem. Figure 3.1 is a representative example of the staining 
typically observed with cells taken from an individual that resolved HBV infection. 
The cells were enriched over 10 days for core 18-27-specific CD8 + T cells. In this 
example, the direct ex vivo virus-specific CD8 + T cell frequency was found to be 
0.5% of total CD8 + T cells (figure 3.1a). Enrichment by short-term culture increased 
the in vivo peripheral frequency to 20% of total CD8 + T cells (figure 3.1b), 
corresponding to an increase in the antiviral population from 1 in 1000 {ex vivo) to 40 
in 1000 total PBMCs (given that the CD8 + T cell compartment amounted to 20% of 
the gated cells). Unstimulated cells were also stained simultaneously and used to 
evaluate the non-specific background; PMA/ionomycin treated cells allowed us to 
evaluate the functional capacity of the sample following 1 0  days of culture (figure 
3.2). This latter condition also allowed us to determine the fidelity of the overall 
staining procedure.
Importantly, one of the original aims of this work was to attempt to apply Genechip 
technology to study the transcriptional profiles of HBV-specific CD8 + T cell 
populations. In vitro enrichment enabled us to generate the numbers of cells required 
for these assays; enriched samples were more likely to exhibit transcriptional profiles 
reflective of the virus-specific effector population (when activated) rather than 
material sampled directly ex vivo where these populations would only be a very small 
fraction of the total.
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Figure 3.1
Detection of HBV core-18-27-specific CD8+ T cells directly ex vivo and following 
short-term enrichment
Total PBMCs from a representative resolved individual were stimulated with peptide 
for 6  hours directly ex vivo (a) or following 1 0  day expansion (b) in the presence of 
Brefeldin A and stained for surface CDS and intracellular IFN-y.
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Figure 3.2
Negative and positive controls
Unstimulated cells (a) and TCR-independent stimulation with PMA/Ionomycin (b) was 
used to evaluate the non-specific background and the general functional capacity of the 
short-term lines.
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3.2.2 Optimisation of virus-specific CD8+ T cell enrichment
The standard protocol for in vitro enrichment of HBV-specific CD8 + T cells involved 
supplementation of the growth medium with recombinant IL-2 on the fourth day of 
culture. Earlier methods included recombinant HBV core protein in the primary 
stimulation in order to harness endogenous CD4 T cell help to maximise the 
efficiency of proliferation (Missale et al., 1993). Cross presentation could have driven 
the expansion of undesired specificities by providing alternative core-derived 
peptides, and thus core antigen was not used in our studies.
Recent work on HlV-speciflc CD8 + T cells have demonstrated that a sub-optimal 
proliferative capacity that is observed when cultures are supplemented with IL-2 two 
days after antigenic stimulation can be significantly improved if the cells were treated 
with the cytokine at the very start of culture (Yu et al., 2006).
Antigen-specific CD8 + T cells in persistent viral infection are highly prone to 
activation induced cell death as a result of reductions of the intracellular anti- 
apoptotic protein Bcl-2 (Lichterfeld et al., 2004; Meyaard et al., 1992; Petrovas et al., 
2004). However, other work has shown that IL-2 receptor signalling can initiate Bcl-2 
expression through Stat5 signalling (Lord et ah, 2000). It can also encourage cellular 
proliferation by affecting cyclin D2 (Martino et al., 2001) and the proto-oncogenes c- 
myc or Ick (Miyazaki et al., 1995). These data indicated that by treating cells with IL- 
2  at the time of stimulation, it could be possible to antagonize intrinsic mechanisms 
that normally contribute to the death of the activated cells and well as positively 
influence their proliferation.
We therefore sought to further optimise the virus-specific enrichment by modifying 
the IL-2 treatment regime. In order to conserve our limited patient samples, we 
conducted these studies on human cytomegalovirus (HCMV)-specific CD8 + T cells. 
HCMV belongs to the herpes viruses family and typically establishes a low-load 
persistent lifelong infection (Klenerman and Hill, 2005). Up to 70% of the population
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in economically advanced countries have been exposed to this virus and mount a 
successful immune response to it (Harari et ah, 2004; Maecker and Maino, 2004). An 
immunodominant CD8 + T cell determinant of the CMV protein pp65 had been 
described (Wills et ah, 1996) and allowed us to rapidly identify and study this 
response in peripheral venous blood taken from healthy laboratory volunteers.
PBMCs from a healthy HLA-A2 positive individual (previously determined to 
possess CMV-specific CD8 + T cells) were stimulated with an HLA-A2 restricted 
CMV peptide (NLVPMVATV) on day 0. IL-2 was added to the growth medium in 
three variations: at the start of culture only, at day 4 only or at both day 0 and day 4. 
The success of the expansion under these different conditions was determined by re- 
stimulating the cultures on day 10 with the specific CMV-peptide followed by 
staining for intracellular IFN-y. Unstimulated cells that were treated with IL-2 on day 
0  provided a negative control.
Following the standard protocol, we were able to detect CMV-speciflc CD8 + T cells 
at a frequency of 0.84% (of total CD8 + T cells) in stimulated PBMCs exposed to IL-2 
on day 4 only. However, those that received IL-2 at the start of culture had a much 
larger population of 2.05% (of total CD8 + T cells). Furthermore, an even greater 
frequency of 2.47% (corresponding to an overall increase of 294%) was observed by 
the addition of IL-2 both at the onset of stimulation as well as on day 4 (figure 3.3). 
Similar influences following temporal variations of IL-2 treatment were obtained for 
HBV-specifîc CD8 + T cell expansions (personal communication with A.Bertoletti, 
Singapore) and therefore this modified protocol was incorporated into the study.
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Figure 3.3
Influence of the time of IL-2 supplementation on the expansion of virus-specific 
CD8+ T cells
Total PBMCs from an HLA-A2 positive healthy donor were cultured with an HLA-A2 
restricted CMV peptide for ten days. IL-2 was supplemented into the growth medium 
at the onset of culture (b), on day four (c) or at both the onset and on day four (d). 
Unstimulated cells treated with IL-2 on day zero served as a negative control (a). Sam­
ples b, c and d were restimulated with CMV peptide on day 10 followed by staining of 
all four samples, with specific monoclonal antibodies, for surface CD8 + and intracellu­
lar IFN-y. Frequencies of virus-specific cells (as a percent of total CD8 +) are indicated 
in the top left quadrant.
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3.2.3 CD8+ T cell responses to HBV core^  envelope and polymerase
10 resolved individuals and 29 individuals with varying levels of HBV replication, all 
HLA-A2 positive, were screened for HBV-specific CD8 + T responses. Cultures were 
set up using a panel of well-described HLA-A2 restricted HBV determinants (Table 
3.1) located in the core, envelope and polymerase proteins. These were originally 
selected based on conformation to HLA-A2 restricted peptide motifs and 
subsequently tested for in vitro reactivity by intracellular staining for IFN-y. HLA-A2 
restricted CD8 + T cell determinants within the X protein have been described only 
recently (Malmassari et al., 2005). As it is one of only four proteins encoded by the 
virus it would be important to investigate the participation of this protein in the 
overall antiviral response in the future.
In the current study, particularly immunogenic HBV peptides (Chisari and Ferrari, 
1995) were tested individually. These included core 18-27, envelope 183-91, 
envelope 335-43, envelope 338-47, envelope 348-57, polymerase 455-63, and 
polymerase 502-10. Only two HLA-A2 restricted core determinants were used and 
were tested individually. Due to limitations in the availability of the patient samples, 
the remaining peptides (corresponding to subdominant specificities) were tested in 
small pools: envelope pool 1 (comprising of peptides 177-185, 201-210, and 204- 
212), envelope pool 2 (peptides 251-259, 370-379, and 378-387) and polymerase 
pool 1 (peptides 575-583, 655-663, and 816-824).
As stated previously, chronic HBV infection is a very heterogenous disease and 
therefore this group of individuals were segregated into those that exhibit partial viral 
control (low viral load) and others that are unable to contain the virus (extremely high 
viral load). Therefore, patients in the overall study sample fell into one of three 
groups: group one (resolved) consisted of individuals that had undetectable virus in 
the serum and were HBsAg negative and anti-HBsAg antibody positive; classical 
indicators of effective viral control. The individuals with chronic infection were
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assigned to either group two (chronic low; with HBV DNA <10^ copies/ml) or group 
three (chronic high; HBV DNA >10^ copies/ml).
Figure 3.4 is a representative example of the HBV-specific CD8 + T cell staining that 
was typically observed in group one, two, and three (column 1, 2, and 3 respectively) 
in response to stimulation with an immunogenic determinant from each of the three 
major HBV proteins: core, envelope, and polymerase (rows b, c, and d respectively).
We found that the relative size of the responses to all three HBV proteins were 
highest in the resolved individuals but it appeared that these waned as the viral load 
increased; this was particularly obvious for the core response, followed by the 
polymerase response. Core and polymerase-specific CD8 + T cels were not detectable 
in the patients with viral loads > 1 0  ^ copies/ml (with the exception of only one patient 
that exhibited reactivity to a single polymerase peptide). Robust envelope-specific 
CD8 + T cells however, could not only be detected in the majority of the resolvers but 
populations of significant magnitude were also found in chronic infection and even in 
several individuals in the third group that had extremely high viral loads.
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Table 3.1: Synthetic peptides used.
Virus Peptide code Protein Location Sequence
HBV c l 8 Core 18-27 FLPSDFFPSV
HBV cl07 Core 107-115 CLTFGRETY
HBV p455 Polymerase 455-463 GLSRYVARL
HBV p502 Polymerase 502-510 KLHLYSHPI
HBV p575 Polymerase 575-583 FLLSLGIHL
HBV p655 Polymerase 655-663 ALMPLYACI
HBV p816 Polymerase 816-824 SLYADSPSV
HBV el77 Envelope 177-185 VLQAGFFLL
HBV el83 Envelope 183-191 FLLTRILTI
HBV e2 0 1 Envelope 2 0 1 - 2 1 0 SLNFLGGTTV
HBV e204 Envelope 204-212 FLGGTPVCL
HBV e251 Envelope 251-259 LLCLIFLLV
HBV e260 Envelope 260-269 LLDYQGMLPV
HBV e335 Envelope 335-343 WLSLLVPFV
HBV e338 Envelope 338-347 LLVPFVQWFV
HBV e348 Envelope 348-357 GLSPTVWLSV
HBV e370 Envelope 370-379 SIVSPFIPLL
HBV e378 Envelope 378-387 LLPIFFCLWV
CMV CMV pp65 N/A NLVPMVATV
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Figure 3.4
Flow cytometric detection of virus-specific CD8+ T cell responses to HBV core, 
envelope and polymerase proteins.
Total PBMCs from resolved and chronically infected individuals were stimulated with 
HBV core (18-27), envelope (183-91) or polymerase (502-510) peptides (row b, c and 
d respectively). IL-2 was supplemented into the medium at the onset of culture and on 
day four. Cells were restimulated (except negative controls - row a) with relevant 
peptide on day 10 and then stained for surface CDS and intracellular IFN-y. Patients 
were clustered into three groups [resolved, chronic low DNA (HBV <10 million 
copies/ml) or chronic high DNA (HBV > 10 million copies/ml)]; column one, two and 
three respectively. Frequencies of virus-specific cells (as a percent of total CD8 + T 
cells) in three representative patients are indicated in the upper right quadrant.
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3.2.4 Specificity of antiviral CD8+ T cells
In order to gain a comprehensive assessment of the breadth and relative strengths of 
the individual CD8 + T cell specificities able to recognize the virus, we plotted the 
collective data of the frequencies that were detected following enrichment according 
to outcome of infection: RESOLVED, HBV DNA <10^ copies/ml and HBV DNA > 
1 0  ^copies/ml.
3.2.4.1 Resolved infection
In the resolved group the core 18 and envelope 183 peptides were targeted by 7 of 10 
individuals (figure 3.5). In the 5 patients where these responses occurred together 
(patients 1,2,7,9 and 10), the core 18 response was always higher in frequency than 
the envelope suggesting greater immunodominance. In patient 3, the core 18 response 
was found alongside a response to envelope pool 2 ; the core response was again the 
largest. In patient 6  however, the core 18 response was found with a response to 
envelope pool 2 as well as envelope335. Here envelope335 was the largest, followed 
by envelope pool 2 and finally corel8 . In this instance, it appears that the 
enveIope335 response may have displaced the dominant position of core 18-27- 
specific CD8 + T cells. In the two individuals (patients 4 and 8 ) where envelope 183- 
191-specific CD8 + T cells were detectable without the core 18-27 response, no other 
specificity was found.
The most significant polymerase response from the panel that we tested was directed 
against polymerase455, however, this occurred in only two individuals (patients 2 
and 9) but were of significant magnitude. In patient 2 it was smaller than core 18 but 
larger than envelope 183; responses to envelope335, 338 and 348 were also found in 
this person, typifying the multi-specificity of the antiviral response in this patient 
group. In patient 9, the polymerase 455-463 response dominated over core 18-27 and 
envelope 183-191; no other specificities were detected. Responses to the polymerase
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pool were also detectable in patients 5 and 7; they were independent of other 
specificities in patient 5 but were the smallest of several others in patient 7. Thus, it 
appears that the polymerase response can on occasion rise above the general 
immunodominace of the core 18-27 response that is normally considered to be the 
dominant HLA-A2 restricted HBV determinant, emphasizing the complexity 
involved in the establishment of immunodominance hierarchies.
3.2.4.2 Chronic infection (low level viral replication)
Within the group with HBV DNA <10^ copies/ml (figure 3.6), core 18 was still the 
most frequently recognised determinant (7/18 individuals; 39%) followed by 
envelope 183 (4/18 individuals; 22%) and envelope338 (3/18 individuals; 17%). Core 
18-27-specific CD8 + T cell were the only type detectable in patient 8 , 12 and 17. 
When this response was detected alongside others, the position within the overall 
hierarchy varied; it was the highest in 2 individuals (patient 3 and 10), second 
smallest in one (patient 13) and smallest in one (patient 15). The envelope 183-191 
response appeared alongside a core 18-27 response in only one individual (patient 
10), and was lower in frequency. In the three other individuals where envelope 183- 
191-specific CD8 + T cells were detected (patients 2, 7 and 14), it was the dominant 
specificity.
3.2.4.3 Chronic infection (high level viral replication)
In the group with HBV DNA>IO^ copies/ml (figure 3.7), 4/11 individuals 
demonstrated responses to envelope 183; no other accompanying specificity was 
observed. One patient mounted a relatively small response to envelope pool 1 (el77- 
185, e201-210, and e204-212). Polymerase502 was recognised by 3% of total CD8 + 
T cells but in only one individual. None of the 11 patients studied mounted any 
response to core.
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Figure 3.5
Frequency of HBV-specific CD8+ T cell responses in resolved individuals
Short-term lines from resolved individuals restimulated with appropriate peptides and 
stained for CDS and IFN-y. Frequencies correspond to IFN-7 + of the total CD8 + T cell 
population.
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Figure 3.6
Frequency of HBV-specific CD8+ T cell responses in chronic HBV infection 
(<10mil.copies/ml)
Short-term lines from persistently infected individuals restimulated with appropriate 
peptides and stained for CDS and IFN-y. Frequencies correspond to IFN-y+ of the total 
CD8 + population.
135
^  100
10
IF N -y f
(%)
□
0.1
sies
■  c1 8  
> <  c1 0 7  
▲  e2  
e7  
^  e8
#  e9  
□  6789  
A  e  pool 
▼  p3
#  p4
#  p pool
Patients
Figure 3.7
Frequency of HBV-specific CD8+ T cell responses in chronic HBV infection 
(>10mil.copies/ml)
Short-term lines from persistently infected individuals restimulated with appropriate 
peptides and stained for CD8 and IFN-y. Frequencies correspond to IFN-yf of the total 
CDS T cell population.
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5.2.5 Diversity o f  viral determinants targeted by CD8-  ^ T cells
Apart from the individual determinants that were targeted within the three groups 
studied, we also wanted to evaluate the overall diversity of the antiviral specificity 
per individual between each study group.
Our data indicated that all the resolved individuals targeted at least one of the 18 
determinants that were tested with 70% of the group recognising two or more (Figure 
3.8). The maximal diversity observed in this group was to six different peptides (one 
individual). In the group with HBV DNA <10^ copies/ml, 5/18 subjects did not 
recognise any determinants at all and 6/18 recognised only one. The maximal 
diversity observed here (one individual) was towards 4 peptides. Finally, among the 
individuals with HBV DNA >10^copies/ml, 6/11 patients recognised only one 
determinant whereas the remainder did not exhibit a response to any of the HBV 
peptides that were tested.
It appears that CD8 + T cell antiviral diversity was highest in the resolved individuals, 
lower in those with HBV DNA <10^ copies/ml, and least in individuals with high 
levels (>10^ copies/ml) of viral replication. Thus, confirming previous reports, our 
studies have demonstrated that good viral control is indeed associated with a 
multispecific CD8 + T cell response, and the narrowing of this immune compartment 
is associated with the loss of viral control.
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Figure 3.8
Diversity of the CD8+ T cell response to HBV
The number of different HBV-specific epitopes targeted by CD8 + T cells after short 
term enrichment with relevant HBV peptide is demonstrated in patients segregated 
according to viral load: resolved (undetectable DNA), chronic low DNA (<10 million 
copies/ml) and chronic high DNA (> 10 million copies/ml).
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3.2.6 HBV-proteins targeted by the antiviral CD8+ T response
We next sought to investigate whether there could be an association between 
virological status and the particular HBV protein that was targeted. To do this, we 
calculated the cumulative response for each protein (i.e. the sum of the antiviral 
frequencies that were observed against the individual determinants within the core, 
envelope and polymerase proteins) and segregated these data according to virological 
outcome as described previously (figure 3.9).
We observed that 9/10, 7/10, and 4/10 of the individuals in the resolved group 
mounted significant responses to envelope, core, and polymerase respectively. The 
high incidence of envelope (90%) may be a reflection of the relatively large number 
of determinants of this protein that were tested in this study ( 1 1  in total), however, the 
core protein was represented by only two determinants yet it was targeted in more 
individuals than was polymerase which was represented by five. Thus, apart from the 
differing ratio of the individual determinants selected, the relative quantity of each 
protein could be dictating their relative immunogenicity -  polymerase, although 
required for the earliest steps in replication, is produced in trace quantities compared 
to the structural proteins and this would bias the T cell priming towards envelope and 
core-specifîcities. Nonetheless, as anti-polymerase CD8 + T cells can still be 
observed, it indicates that factors other than the relative gross quantity influences the 
immune hierarchy.
In the intermediate group (HBV DNA <10^ copies/ml) 7/18 individuals (39%) 
mounted significant responses to envelope, a similar number responded to core and 
only 5/18 (28%) responded to the viral polymerase. Here, envelope appears to be less 
immunogenic, however, the CD8 + T cell populations in these individuals are 
constantly exposed to viral antigens, surface antigen in particular. Thus, quantitative 
differences in antigen load cannot explain the decrease in immunogenicity, but it is 
more likely that tolerogenic mechanisms begin to over-rule immunogenic potential.
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Finally, in the group with HBV DNA >10^ c/ml, none of the 11 subjects that were 
studied exhibited any response to the core protein but one individual had a response 
to polymerase. 5/18 patients (28%) however maintained a response to the envelope 
protein. Again, relative protein quantities cannot account for immunogenicity. These 
individuals have high levels of circulating virus, as well as envelope subviral particles 
and e antigen. Polymerase is by far the least available protein. It is apparent in this 
group that the core protein is highly tolerogenic as it has eradicated this response. 
Envelope is also highly tolerogenic but not exclusively - a small proportion of these 
patients maintain responses. The presence of polymerase-specific CD8 + T cell is 
perplexing. It is possible that an escape mutation could have arisen thereby allowing 
persistence of the originally primed population but this patient needs to be 
investigated further. Previous studies have indicated that polymerase is less 
tolerogenic than envelope (Kakimi et al., 2002) but a response was only seen one 
patient, therefore, it appears that the relatively limited quantity of this non-structural 
protein may affect its immunogenicity.
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Figure 3.9
HBV-proteins targeted by antiviral CD8+ T cells
The plots indicate the cumulative frequencies of core-, envelope- and polymerase- 
specific CD8 + T cell responses that were detected in short-term lines. Patients were 
clustered into one of three groups: resolved (HBV DNA negative), chronic low DNA 
(<10 million copies/ml) and chronic high DNA (>10 million copies/ml.
141
3.2.7 Progressive loss o f core- but not envelope-specific CD8+ T cell 
responses occurs with an increasing viral load
To conclude this analysis, we investigated whether there was a relationship between 
the strength of response of the most immunogenic determinants that were identified 
in the resolved individuals (core 18-27 and envelope 183-191) and progressive loss of 
viral control.
This part of the study was performed in close collaboration with G.Webster et al., 
(U.C.L) who were conducting a parallel longitudinal analysis of HBV-specific CD8 + 
T in patients with varying outcome that involved a similar 10 day screening of 
PBMCs from patients for core 18-27 and envelope 183-191 responses (Webster et ah, 
2004). These data were incorporated in to our results in order to increase the patient 
numbers within the individual groups of this analysis.
We observed a statistically significant difference in the median frequency of the core 
18-27-specific CD8 + T cell response between the resolved and the HBV DNA <10^ 
copies/ml group (p<0.0001). This was also evident between the HBV DNA <10^ 
copies/ml and the HBV DNA >10^ copies/ml group (p=0.001) (figure 3.10 -  top) and 
suggested that this specificity was specifically being silenced by some factor 
associated with an increase in antigen load. By contrast, the frequencies of envelope 
183-191-specific CD8 + T cells did not exhibit a significant stepwise reduction with 
increasing viral load as observed for core 18-27 (figure 3.10 -  bottom).
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Figure 3.10
Increasing viral load associated with loss of core- but not envelope-specific CD8+ 
T cell responses
The mean (with standard error) frequencies of core 18-27- (a) and envelope 183-92- 
specific (b) CD8 + T cells detected after short-term culture are plotted. Patients were 
groups into the three categories: [(resolved (undetectable DNA), chronic low DNA 
(<10million copies/ml) and chronic high DNA (>10 million copies/ml)]. The statistical 
significance of differences between categories (gaussian approximated two-tailed 
Mann-Whitney test) for the core and envelope responses is indicated above the plots.
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3,3 Discussion
The peripheral circulation of resolved individuals contains very low frequencies of 
HBV-specific CD8 + T cells and these are much lower (if not undetectable altogether) 
in individuals with chronic infection. In the former group, these cells are most likely 
to be transient populations sampled as they transit between secondary lymphoid 
organs. In this way they are able to carry-out systemic surveillance to better respond 
to a secondary infection or a resurgence of residual virus contained but not cleared 
after the primary infection. In chronic infection, the antigen-specific cells that can be 
detected in the peripheral circulation may be those recently released from draining 
lymph nodes following priming, or those that have escaped arrest at the liver.
The CD8 + T cell compartment comprises approximately 20% of the total 
mononuclear cell population. This meant that a direct-ex vivo antigen-specific 
population of 0.5% (of total CD8 + T) amounted to one antigen-specific CD8 + T cell 
per 1000 total PBMCs. Therefore, to confidently determine the frequency of antiviral 
CD8 + T cells by flow cytometry in any given PBMC sample, a very large number of 
(stained) cells had to be acquired; - 1 0 0 ,0 0 0  total cells to detect 1 0 0  virus-specific 
cells.
However, these data are difficult to interpret objectively because of the variable 
background false-positivity that arises due to fluorescence resonance energy transfer 
or non-specific binding; this increases proportionally in relation to the quantity of 
cells acquired. These factors significantly complicated the evaluation of low- 
frequency populations - in our hands the typical background amounted to 0 .2 % of 
total CD8 + T cells (effectively 40 of 100,000 total flow cytometric events acquired).
Recently, a technique involving magnetic enrichment of multimer-labelled cells has 
been reported that enables the detection of specific antiviral CD8 + T cells that 
normally fall below the sensitivity of a direct analysis (Barnes et al., 2004). Although 
this technique cannot be applied to virus-specific CD8 + T cells that do not bind 
multimers, this could be over come by adapting the technology so that selection is
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performed on the basis of effector function such as IFN-y production/secretion or 
degranulation (CD107a/b), however, the major limitaton is the requirement for a 
relatively large quantity of biological material.
For these reasons, we decided to execute our study by employing a short-term (10 
day) in vitro virus-specific CD8 + T cell enrichment procedure (previously optimized 
by our group). A single round of stimulation with HBV peptide followed by culture 
was used to drive activation-induced proliferation of the CD8 + T cells capable of 
recognising and responding to the specific stimulus. Supplementation of the growth 
medium with IL-2 on day 4 sustained the dividing cells up to the tenth day of culture. 
On day 10 a second peptide stimulation initiated IFN-y production in the expanded 
antigen-responsive cells; these were then quantitated by flow cytometry following 
appropriate antibody staining.
The most effective technology that should have been used for this study would have 
been the ELISPOT assay in conjunction with overlapping peptides (Tobery et al.,
2001). Apart from being comparatively less-labour intensive, ELISPOT assays are 
capable of very high sensitivity (1/50,000 of total CD8 + T versus 1/2000 by ICS 
(Yewdell, 2006)). Moreover, as it is not HLA-restricted, it offers an unbiased global 
screen for all possible CD8 + T reactivity. By starting off with several pools of 
peptides, one is able to focus-in and to delineate individual viral determinants, which 
can then also be reconfirmed by ICS. In this way, the investigator can generate a 
profile of the immunodominance hierarchy of the individual under study that is 
unrivalled by the competing techniques. The major limitation is the difficulty of 
utilizing peptides corresponding to the specific viral genotype involved.
We decided to focus specifically on HLA-A2 restricted individuals. The peptide 
binding motifs for these molecules were the first to be discovered and as a result the 
immunogenicities of all HBV determinants with the potential to bind HLA-A2 
complexes were characterised (Falk et al., 1992; Ferrari et al., 1992; Hobohm and 
Meyerhans, 1993; Lim et al., 1996; Rotzschke et al., 1992). A large panel of those
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previously found to be immunogenic and therefore likely to be targeted by other 
HLA-A2+ individuals were selected and employed in our screening assay.
The results from this work generated with up-to-date assays are consistent with the 
findings from earlier studies that demonstrate that the HBV-specific CD8 + T cell 
response in resolved infection is quantitatively more robust and qualitatively more 
diverse in individuals that have resolved infection compared to those that maintain 
chronicity (Bertoni et ah, 1997; Nayersina et al., 1993; Rehermann et al., 1995a; 
Rehermann et al., 1995b).
HBV does not exhibit high rates of mutation during chronic infection (Rehermann et 
al., 1995b) unlike retroviruses such as HIV and RNA viruses such as HCV thus 
polyclonality (at the level of individual specificities as demonstrated for HIV (Lopes 
et al., 2003)) would not appear to be a quality that contributes particularly critical 
antiviral function. We did however find that HBV core-specific CD8 + T cells were 
able to tolerate mutated determinants during the persistent phase of the infection 
(Maini et al., 2000b) and that distinct CD8 + T cells could be primed to natural 
variants of HBV (Riedl et al., 2006), therefore we cannot eliminate a role for 
polyclonality.
Our data however, supports the theory that the ability to contain this virus is related to 
a strong CD8 + T cell response that targets multiple viral components (Bertoni et al., 
1997; Chisari and Ferrari, 1995; Rehermann et al., 1995a). This study was focused 
specifically on the HLA-A2 restricted response, and does not account for the overall 
antiviral immunity present. The inclusion of the HLA-B and HLA-C would 
potentially increase the quantity of viral determinants that could be displayed and this 
could be increased even further by heterozygosity at these alleles. Although studies 
have shown that a greater allelic diversity associates with better viral control (Nelson 
et al., 1997), particularly with rapidly mutating pathogens, HBV is a very small virus 
and is very efficiently organized. It contains only four open reading frames that 
overlap each other. Despite the involvement of a reverse transcriptase during viral 
replication (that can contribute to an increased rate of mutation) there are likely to be
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significant structural and functional constraints that limit protein modification and 
thus viral change. This imposes a ridigity and consistency of viral determinants that 
are presented by the hosts MHCI, but there are rare exceptions (Bertoletti et ah, 
1994). In this case, mutations could have been forced by certain underlying factors, 
perhaps HLA homozygosity, which could place acute pressure at a particular 
determinant forcing the development of the mutant thereby allowing persistence of 
the modified virus.
Nonetheless, acute infections are normally associated with multi-specific CD8 + T 
cell responses thereby making it extremely difficult for the virus to escape through 
multiple simultaneous morphological adaptations, particularly in heterozygous 
individuals where even more viral targets may be available. Therefore, rather than 
survive by escaping detection it is highly likely that HBV utilizes survival 
mechanisms exerted through overt presentation of viral antigens, also termed high 
zone tolerance, as has been demonstrated in LCMV infection (Moskophidis et al., 
1993).
The majority of individuals in this study with effective viral control exhibited 
vigorous multi-specific CD8 + T cell responses that in addition to limiting viral escape 
through mutation would have conferred a better capacity to more rapidly contain and 
purge the pathogen before it was able to stably colonize the host and expedite 
survival mechanisms to enable its persistence. This is critical in view of the 
propensity of CD8 + T cells to exhaustion following prolonged or excessive antigenic 
stimulation (Moskophidis et ah, 1993; Wherry et ah, 2003).
Polymerase-specific CD8 + T cells were only detected in a minority of the resolved 
individuals that we tested, suggesting that this specificity, although capable of 
achieving immunodominance, did not normally occupy a prominent position in the 
overall antiviral immune hierarchy. The infrequency of these populations in the 
resolved group did not permit a relative assessment with increasing viral load; only 
2 0 % of the resolved sample and 13% of the chronic carriers responded to polymerase. 
We did however observe polymerase-specific CD8 + T cells in one individual with
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high viral load but we were not able to assess the tetramer-binding capacity of these 
cells at the time; this could have permitted escape from deletion as has been observed 
and implicated for envelope-specific CD8 + T persistence (Reignat et al., 2002). 
Alternatively, a mutation in the viral determinant could have allowed persistence of 
populations primed with the original determinant, as demonstrated in two patients 
infected with HBV with an altered core 18-27 determinant that maintained CD8 + T 
specific for the wild-type determinant (Bertoletti et al., 1994).
Unlike core and surface antigen, the polymerase protein is expressed at a much lower 
quantity. There is no described secreted form apart from that contained in infectious 
viral particles. Each virus particle contains greater than 100 envelope proteins for 
every polymerase polypeptide and core proteins that form the nucleocapsid also occur 
in greater excess compared to the polymerase (Kakimi et al., 2002). It is very likely 
that peptides from HBe, core and envelope antigen could be preferentially saturating 
the MHCI presenting complexes on the pAPC surface thus biasing the priming 
towards HBe/core antigen and envelope specificities rather than to polymerase. This 
is not exclusively the case in all individuals; polymerase peptides do have high 
immunogenic potential as observed in two resolved patients that harboured this 
response. It was found to be stronger than envelopeI83-191 and even dominated 
core 18 in one individual. Nonetheless, it is unlikely that polymerase specificities are 
subject to overt peripheral or central tolerance as we propose is occurring in chronic 
infection with core and envelope specificities.
It is more probable that the low incidence of these populations could be due to 
competition of determinants for MHCI binding following intracellular processing that 
then extends to competition between different CD8 + T cell specificities for T cell 
priming by the pAPCs. Alternatively, suboptimal functional avidity could be 
responsible; polymerase-specific CD8 + T cells exhibited 20 fold lower differences in 
effector function compared to envelope-specific CD8 + T cells (Kakimi et al., 2002). 
However, one needs to take account that these results were based on murine studies 
comparing two CD8 + T clones generated after multiple rounds of peptide stimulation 
and prolonged in vitro culture. A third possibility could simply be down to the
148
random nature of antigen encounter that would be influenced by differences in the T 
cell repertoire exiting the tbymus (Attuil et al., 2000); immunodominance would in 
this instance be attained by specificities that were present at higher precursor 
frequencies.
Among the other responses detected in the resolved group, core 18-27-specific CD8 + 
T cells were frequently observed consistent with several studies that demonstrated a 
strong association of this specificity with self-limited infection (Bertoletti et al., 1993; 
Bertoletti et al., 1991; Bertoletti et al., 1997b; Maini et al., 1999; Webster et al., 
2004).
This bas important significance with regard to the initial CD8 + T cell priming event 
as well as the immuonogenicity of this particular viral determinant: Although naïve 
CD8 + T cells can be primed at the site of infection (Bertolino et al., 2001; Bertolino 
et al., 1998), this is unlikely to be a frequent event; the majority of naïve CD8 + T 
cells reside in secondary lymphoid organs and according to current dogma priming 
occurs in local draining lymph nodes not at the surface of the bepatocyte. Antigen 
presenting cells within the liver such as Ito and Kuppfer cells have been implicated in 
T cell priming (Unanue, 2007; Winau et al., 2007) but the impact on viral infection 
has yet to be demonstrated. The infection of pAPCs by HBV is not well supported 
(Untergasser et al., 2006), therefore in order to prime core 18-27-specific CD8 + T 
cells, pAPCs must be able to capture, efficiently process and finally cross-present 
core protein that is most likely derived from whole viral particles or circulating e 
antigen. Given the relatively high quantity of surface antigen that is also present, the 
dominance of the core 18 determinant suggests either a stronger and more stable 
affinity to the MHCI complex, the presence of a higher naïve precursor frequency of 
CD8 + T cells specific for this peptide or alternatively, that the functional avidity of 
c l 8-27 specific precursors may be greater than those specific for alternative viral 
targets. It is possible that more than one of these factors could have occurred 
simultaneously.
The implication of the overall dominance of core 18 in the majority of resolved 
individuals is that this determinant bears some physiological advantage that allows it
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to out-compete others and this highlights its immunogenic superiority and relevance 
to effective viral control. However, although this may be the case in resolved 
infection our data indicates that there is a particularly strong inverse association of 
this specificity with increasing viral load. This may be because the antiviral CD8 + T 
cells are being sequestered in the liver, however, viral load was found to be inversely 
proportional to the frequency of intrahepatic core 18-27-specific CD8 + T cells (Maini 
et al., 2000a; Reignat et al., 2002). Otherwise, viral mutants may be implicated; 
although we have not sequenced the viral genomes in our study sample it is unlikely 
that a core variant has occurred in all the chronic individuals that exhibited the loss of 
this specificity. This is supported by another study with a large number of chronically 
infected patients associated with loss of core 18-specific CD8 + T cells that did not 
reveal any core variants (Reignat et al., 2002).
The most plausible explanation for the loss of core 18-27-specific CD8 + T cells in 
chronic infection may simply be due to the fact that they are gradually being 
overwhelmed by persistent antigenic encounter and driven to exhaustion as has been 
reported previously (Fuller and Zajac, 2003; Moskophidis et al., 1993; Tewari et al.,
2004). High levels of viral replication is associated with the secretion of large 
quantities of virus but also of e antigen (the modified version of core), a protein that 
has been reported to be more efficient at eliciting T cell tolerance than HBcAg (Chen 
et al., 2005). This by-product of viral replication, as well as surface antigen and 
whole virions, has the potential to exert anti-immune function through multiple 
mechanisms:
1) Professional APCs are capable of capturing, processing and presenting the e 
antigen and preferentially priming naïve T cells specific for the core 18-27 
determinant. In this way early specificities may be more prone to exhaustion 
following continuous encounter with antigen, as has been observed in other persistent 
viral infections (Fuller and Zajac, 2003; Probst et al., 2003; Wherry et al., 2003).
2) Studies in transgenic mice models of persistent HBV infection have demonstrated 
that the tolerogenic activity of e antigen could be mediated by driving the T helper
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response to a type two profile (Milich, 1997; Milich et al., 1998) typically 
characterised by the production of IL-10. This cytokine can suppress antigen-specific 
CD8 + T responses (Abel et al., 2006; Elrefaei et al., 2007) and may well be 
suppressing core 18-27-specific CD8 + T cells.
3) pAPCs capture circulating antigen and migrate to the thymus thereby inducing 
central tolerance (Bonasio et al., 2006). Interestingly, not all “self-reactive” CD8 + T 
cells are deleted; some antigen-experienced specificities exit and circulate among the 
peripheral compartment but are functionally silenced; this is more relevant to 
envelope-specific CD8 + T cells and is addressed in the subsequent section.
4) The modulation of surface CD8  expression can dramatically influence the effector 
response (Maile et al., 2005). High avidity CD8 + T cells can overcome this but sub- 
optimal responses are generated by low avidity populations. Although some evidence 
suggests that core 18-27-specific CD8 + T cells are high-avidity populations, these 
data are derived from assays utilizing extensively cultured T cell clones; further 
studies into the expression and interaction of this co-receptor are necessary.
5) Cross presentation of antigen by APCs has been shown to mediate peripheral 
CD8 + T cell tolerance (Belz et al., 2002a; Belz et al., 2002b; Belz et al., 2002c; 
Davey et al., 2002; van Endert and Villadangos, 2007; Villadangos, 2007; 
Villadangos et al., 2007). This could be because antigen capture without appropriate 
inflammatory danger stimuli may not initiate appropriate maturation (Anderson et al., 
2001; Gallucci and Matzinger, 2001; Matzinger, 2002). HBV is a non-cytopathic 
virus and chronic infection can be maintained for very long periods without any 
obvious liver damage (as determined by the level of serum ALT). Uptake of HBV 
antigens in the absence of inflammatory signals may only result in suboptimal 
maturation of the pAPCs and the subsequent priming of core 18-27-specific CD8 + T 
cells by these APCs could potentially initiate apoptosis leading to deletion. Antigen 
specific B cells able to function as antigen presenting cells have also been implicated 
in this mechanism (Raimondi et al., 2006a, b).
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These factors acting either independently at different phases of the infection or in 
unison could account for the loss of the core 18-27-speciflc response during viral 
persistence. Further work is necessary to identify and understand better the precise 
mechanism that influences this critical CD8 + T cell specificity and tips the balance 
from effective viral containment towards chronic and uncontrolled viral replication. 
Envelope 183-191-specific CD8 + T cell responses were, following core 18-27- 
specific CD8 + T cells, the next most vigorous and frequent T cell population that we 
detected in the resolved individuals indicating that this determinant also had good 
immunogenic potential and could be contributing important antiviral function 
necessary to achieve viral control. The reduction in the overall robustness of this 
response in chronic infection suggested either a proliferative impairment or a 
propensity to exhaustion similar to that seen for core 18-27-specific CD8 + T cells.
Importantly, envelope-specific CD8 + T cells still persisted in several individuals 
despite extremely high levels of circulating antigen. Although persistent infection is 
associated with the secretion of subviral particles composed of envelope protein at 
quantities of l-300pg/ml - 10  ^ to 10  ^ fold in excess over whole virions (Kim and 
Tilles, 1973), it was striking that these specificities did not exhibit a reduction with 
increasing viral load as was observed with core 18-27-specific CD8 + T cells. This 
phenomenon of CD8 + T cell escape has been reported previously but is not properly 
understood. It is not unique to HBV, but may be the outcome of some as yet 
unidentified common mechanism allowing certain antigen-specific CD8 + T cell to 
escape high antigen load exhaustion (Spencer and Braciale, 2000). A mutation in the 
determinant could have explained persistence (akin to the core 18-27 mutation) -  the 
inability to engage an altered determinant would rescue the population from deletion. 
This could also account for the inability to exert significant immune pressure in vivo, 
however, mutations were not found in several individuals in whom the virus was 
sequenced (Reignat et al., 2002). Additionally, TCR down-modulation was not 
obvious and neither was lowered peptide avidity - envelope-specific CD8 + T cells 
from chronic infection exhibit good IFN-y production, proliferative potential and 
cytotoxicity when exposed to viral peptides or antigen loaded target cells (Reignat et 
a h ,2 0 0 2 ).
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It is certainly likely that some of these cells are exhausted perhaps through 
mechanisms proposed for the deletion of the core 18-27 specificity; this would 
explain the overall reduction in the strength of this response in chronic infection. The 
populations that do manage to persist may be the exceptions and the most likely 
explanation for their survival could be related to their altered phenotype; their 
inability to bind HLA-matched tetramers suggests defective TCR organization. 
Incomplete maturation could also be a factor (Spencer and Braciale, 2000) but 
additional studies into membrane fluidity, lipid raft organization and TCR 
recruitment are needed to further understand them.
As this response was associated with effective viral control in the absence of the core 
18-27 CD8 + T cell population our data indicate that successful immunity can be 
achieved by lesser-dominant specificities. However, we cannot overlook the fact that 
a CD8 + T cell population specific for a viral determinant not included in our peptide 
panel could be contributing the antiviral activity responsible for the effective viral 
suppression. This would have been clarified if we had screened for CD8 + T cell 
reactivity with overlapping peptides covering all HBV proteins.
Nonetheless, these findings are very relevant to patients with chronic infection where 
the immunodominant core response has been deleted but other specificities remain, 
principally because it presents an opportunity to return effective antiviral 
functionality to persisting populations; this is also an encouraging prospect given that 
subdominant responses have previously been implicated in the clearance of chronic 
infection (Frahm et al., 2006; van der Most et al., 1998; van der Most et al., 1996).
Unlike expansion and contraction that is programmed during the initial priming (lezzi 
et al., 1998; Kaech and Ahmed, 2001; van Stipdonk et al., 2001), T cell function is 
modulated at later stages, and functional T cell inactivation that occurs early in 
persistent infection is reversible and can be altered by reprogramming (Brooks et ah, 
2006a). This was achieved by removing the cells from the antigenic environment and 
also by artificially reducing the antigenic load through the administration of antiviral
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drugs. These authors also suggested that an extended period of inactivation resulted 
in the accumulation of intrinsic functional defects. A better understanding of the 
precise nature of this dysfunction would help address better the mode of correction 
that would be required.
In this study the hierarchies of various antiviral-CD8 + T cell populations in resolved 
and chronic infection have been evaluated using selected HLA-A2 restricted viral 
peptide determinants and although we observed that hierarchical trends were similar 
to the respective proteins, it is not entirely possible to determine whether the 
differential immunogenicity is due to the protein derivation: core, envelope or 
polymerase.
The inability of HBV to infect pAPC (Untergasser et al., 2006) suggests that 
differential protein expression kinetics would not influence the immunogenic 
hierarchy that is generated as has been reported for other viruses (Hislop et al., 2002). 
Although polymerase is one of the earliest HBV proteins to be synthesized, this 
occurs within the infected hepatocyte and as infection is not cytopathic there should 
not be any release of polymerase protein into the circulation until the initiation of the 
innate immune response; the exception would be circulating virions, however core 
and envelope proteins make up a much larger proportion of the total.
In the interim, prior to the NK activity that we have recently shown to be responsible 
for the initial liver damage following the immunotolerant phase (Dunn et al., 2007), it 
is most likely that peripheral dendritic cells that have encountered and taken-up 
soluble HBV products such as subviral particles, e antigen and whole virions, would 
have migrated to local draining lymph nodes. At that location there would be a 
preferential exhibition of determinants derived from core and envelope proteins 
favouring the observation of a preferential immunodominance by core and envelope- 
specific CD8 + T cells in resolved individuals. These immunodominant specificities 
may suppress subdominant ones, especially when the antigen is limited (Hislop et al.,
2002). Persistent antigenic stimulation due to the inability to effectively reduce viral 
replication is likely to gradually erode the primary immunodominant specificities
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such as core 18-27- and envelope-183-191-specific CD8 + T cells unless they either 
naturally possess or adapt mechanisms for survival. Data from a transgenic mouse 
study indicate that the HBV envelope protein but not the polymerase is tolerogenic 
and the authors suggest that the cause for this is a relatively lower level of expression 
coupled to low functional avidity for the antigen (Kakimi et al., 2002).
This raises another issue: intrinsic properties of individual determinants including 
efficiency of presentation and MHCI binding affinity are also key factors very likely 
to govern immune hierarchies. Several studies have indicated that the abundance and 
stability of viral peptide presented by the host MHC correlates with the magnitude of 
the virus specific CD8 + T cell response (Busch and Pamer, 1998; Gallimore et al., 
1998c; Pion et al., 1999). Furthermore, protective immunity has been reported to be a 
function of the affinity of the interaction between the individual CD8 + T cell and the 
target cell (Anton et al., 1997; Gallimore et al., 1998a; Gallimore et al., 1998b; 
Gallimore et al., 1998c; Restifo et al., 1995; Tsomides et al., 1994) with importance 
placed on the ability of the antiviral cells to detect low concentrations of viral peptide. 
In contradiction with these findings a study of EBV infection has suggested that 
immunodominance may not necessarily correlate with viral peptide abundance 
(Crotzer et al., 2000), however, the authors have acknowledged that chronic 
stimulation by abundant determinants could have resulted in the deletion of certain 
specificities. Nonetheless, apart from peptide abundance the study raises the 
possibility that alternative factors may influence immunodominance.
An additional factor that is poorly understood but extremely relevant to the priming 
of CD8 + T cells is the precursor T cell repertoire. The generation of a specific CD8 + 
T cell response relies on the presence of naïve CD8 + T cells that are able to recognize 
the presented viral peptide. “Holes” in the repertoire make abundant peptides 
redundant. Additionally, abundant but ineffective peptides have the potential of 
saturating MHCI complexes leaving little room for alternative peptides that do have 
complementary CD8 + T cell populations. Thus, the precursor frequency is a critical 
issue that merits further investigation; it is a very difficult factor to study in humans 
but may be better illuminated through murine studies (La Gruta et al., 2006).
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The precursor frequency in turn highlights the importance of heterologous immunity. 
A large proportion of the studies into immunodominance hierarchies have been 
performed in murine models. While mice are maintained in extremely clean 
environments, humans are constantly exposed to numerous pathogens that steadily 
mould their T cell memory repertoire. A cross-reactive memory response is mounted 
faster than one primed de novo due to a large precursor frequency and the inherent 
ability of these differentiated populations to respond faster (Selin and Welsh, 2004). 
The difference in the response rate may theoretically provide a critical advantage that 
could account for better control (Comberg et al., 2007), however, the opposite is also 
possible. Heterologous viral challenge in a murine study resulted in the generation of 
a relatively restricted and suboptimal repertoire that was associated with viral escape 
(Comberg et al., 2006). Additionally, acute HCV infection resulted in more severe 
hepatitis in individuals that exhibited HCV-specific CD8 + T with cross-reactivity to 
an influenza protein (Urbani et al., 2005). Ultimately, the private repertoire of each 
individual human, as influenced by their previous history of infection, influences the 
CD8 + T cell hierarchy and thus efficacy of subsequent responses. It is important to 
acknowledge that although much has been gained, there are fundamental differences 
between murine studies and humans. Heterologous immunity is a major concern, but 
other important factors including the strain of virus involved, the dose of the 
inoculant, and the route of infection also need to be considered (Tscharke et al.,
2005); these are normally standardized in murine studies and the implications have 
only recently begun to be appreciated in humans.
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In conclusion, these findings have important implications for the selection of 
determinants in the design of vaccines aimed at inducing CD8 + T cell responses in 
chronic infection. According to our data on a limited number of HLA-A2-restricted 
HBV determinants, core 18-27- and envelope 183-191-specific CD8 + T cells are 
highly prevalent in HLA-A2+ individuals that exhibit effective viral control. This is 
most likely due to the abundance of these proteins, suitability for efficient processing 
and the availability of a precursor repertoire during the initial stages of infection. 
However, it appears that these very factors make these populations especially prone 
to exhaustion if viral replication is not effectively reduced within a certain critical 
period. In order to optimize their antiviral efficacy it is imperative that the pathogen is 
reduced to a quantity that is sufficient to initiate but not overwhelm the effector 
response. This is feasible through antiviral drug therapy and is likely to be more 
effective at an early stage of infection when the primary immunodominant responses 
have not yet been deleted. In the event that this has already occurred, alternative 
specificities that were not initially successfully primed could be specifically targeted. 
Lastly, it is still important to understand better the precise nature of CD8 + T cell 
dysfunction that is associated with increasing antigenic load that could also help 
address alternative persistent viruses such as HIV and HCV. The rare populations of 
envelope-specific CD8 + T cells present in chronic infection offered the opportunity 
to further investigate these mechanisms; these studies are the focus the following two 
chapters.
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4 CHAPTER 4
Application of cDNA microarrays to the study of HBV-specific CD8+ T cells.
4.1 Background
Chronic viral infection can cause a complex variety of defects in the virus-specific 
CD8 + T cell population. These include impaired proliferation as well as defects in 
effector function such as sub-optimal cytotoxicity and cytokine production, 
aberrations that have been described in several persistent infections namely LCMV, 
HIV, SIV, HTLV-1 (Appay et al., 2000; Lim et al., 2000; Xiong et al., 2001; Zajac et 
al., 1998). In the previous chapter we demonstrated that this dysfunction can also 
occur in persistent HBV infection. We found that this compartment was markedly 
contracted in a large number of individuals in contrast to a relatively more diverse 
and robust response in individuals that managed to resolve infection. These data, 
supported by the recent work of Thimme et al., indicated that the collapse of the 
virus-specific CD8 + T cell compartment was likely to be a major determinant of 
persistence of this important human pathogen, leading us to investigate the 
mechanism driving the paucity of the HBV-specific response in chronic HBV 
infection.
Although conventional flow cytometry-based phenotyping and functional assays can 
provide highly accurate information on the sample under study, the major limitations 
of the technology are the requirement for a relatively large number of cells and 
restrictions in the number of variables (Pantaleo and Harari, 2006) that can be studied 
simultaneously. The latter is generally confined to a few parameters that are pre­
determined, therefore rendering it an inappropriate methodology for broad 
surveillance-type investigations. cDNA microarray analysis on the other hand is an 
alternative technology that provides the ability to conduct a simultaneous assessment 
of several hundred to thousands of cellular gene transcripts. Importantly, this 
information can be derived from a very limited number of cells.
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Lymphocyte responses that follow a specific stimulus through a surface receptor are 
exerted through specific proteins. With the exception of those that are stored and 
ready for immediate function either through secretion or activation (e.g. 
phosphorylation or méthylation) other proteins are generated following de novo 
transcription from the cellular genome. Transcriptional fluctuations that follow 
specific triggers can therefore be used to predict protein changes related to a cellular 
response. A comparative analysis of the cellular transcriptome of independent 
populations can potentially reveal essential differences, provided that these fall within 
the sensitivity of the assay. Significantly up- or down-regulated genes can 
subsequently be selected for focused investigations into biological involvement.
Thus, in order to broaden the scope of our investigation, we decided to complement 
existing flow cytometry-based assays with a functional genomics approach, allowing 
us to conduct an extensive unbiased comparative study. The responses detected in 
resolved individuals provided the functional gold-standard against which ineffective 
responses associated with chronic infection were compared.
In order to maximize the probability of identifying relevant genes associated with 
viral persistence it was necessary to profile virus-specific CD8 + T cells at the peak of 
their dysfunction. HBV-specific CD8 + T cells from individuals with chronic 
infection with low viral load did not truly represent dysfunctional cells; these 
populations appear to exert partial antiviral function as is reflected by a low level of 
viral replication. Rather, classically dysfunctional CD8 + T cell populations are those 
found in people with high levels of viral replication but these individuals do not 
normally maintain the typical antiviral responses observed in resolved infection, 
neither directly ex vivo nor following short-term culture. However, we were able to 
overcome this obstacle by focusing on rare populations of envelope-specific CD8 + T 
cells that somehow persisted in a very limited number of individuals with chronic 
infection with high viral loads (>10million/ml). These populations did not appear to 
have significant in vivo antiviral capacity, as reflected by the excessive quantity of 
virus and viral antigens present in the serum of these patients.
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The application of cDNA microarrays to the investigation of human virus-specific 
CD8 + T had not been attempted previously and therefore the aim of this work was to 
adapt and optimize existing protocols to be able to study limited numbers of activated 
HBV-specific CD8 + T cells thereby enabling us to conduct a comparative analysis of 
this antiviral immune response in individuals with resolved and persistent HBV 
infection.
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4.2 Results
4.2.1 mRNA Extraction
The assessment of the cellular transcriptome of small numbers of lymphocytes 
necessitated an appropriate RNA extraction methodology. RNAzol B and Trizol 
reagent purification methods are based on the guanidium thiocynate phenol method 
(Chomczynski and Sacchi, 1987) that requires precipitation of the transcripts and 
additional washes to remove traces of organic compounds that could otherwise 
interfere with downstream reactions. This method works best with a very large 
number of cells because significant sample loss can occur (illustrated in figure 4.1). 
This was not conducive to the purification of RNA from the small numbers of 
PBMCs (-300,000) that we intended to analyse and so we turned to a Dynal poly-T- 
linked magnetic beads based approach. The use of this method was supported by its 
successful application in the heteroduplex analysis where sample limitation was a 
major problem (Lopes et al., 2003). However, as genearray studies had not previously 
been conducted with Dynal-purified mRNA it was necessary to determine the 
suitability and validity of this purification method.
A primary evaluation was conducted on PBMCs taken from an individual that had 
resolved HBV infection (figure 4.2). 300,000 cells were seeded in quadruplet: one 
pair of unstimulated and stimulated samples (A-US & A-S) were used to determine 
the frequency of core-specific CD8 + T cells and the other pair were reserved for 
mRNA extraction. The samples were enriched for core-specific CD8 + T cells by 
stimulation with the core 18-27 peptide. At day 10 of culture the cells were pooled 
and reseeded to ensure that the samples were homogenous; two wells were then 
restimulated with the core peptide for five hours. Five hours after peptide 
restimulation, one pair of unstimulated and stimulated samples were stained and 
analysed by flow cytometry. The second pair of unstimulated and stimulated cells (B- 
US & B-S respectively) were lysed in 500pl of Dynal lysis solution, the mRNA was 
extracted, eluted and stored at -70°C.
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We selected a stimulation period of five hours because previous studies have 
indicated that the transcriptional peak of several cytokines, particularly IFN-y 
(characteristic of the HBV core-specific CD8 + T cell effector response in resolved 
infection) was 4 to 6  hours following stimulation (Abdalla et ah, 2003). However, the 
transcriptional levels of certain genes participating in the response could have peaked 
before or after this time point (Teague et ah, 1999) and so the analysis of multiple 
time points could have provided important information. In order to address this, we 
also attempted to analyse a time course by comparing the immediate early response 
(one hour following stimulation), the standard time (5 hours) and the late response 
(16 hours).
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Figure 4.1
Comparison of RNA extraction methods
Schematic illustrating difference between the traditional method of RNA extraction 
(RNAzol) and Dynabead technology.
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4.2.2 Amplification of sample RNA
One million un-stimulated lymphocytes were estimated to yield approximately 0.5pg 
Total RNA. This highlighted a major obstacle as approximately 50-200pg of Total 
RNA [or 2-5 pg mRNA] was recommended for the generation of high fidelity array 
data (Duggan et ah, 1999). Although cDNA microarray studies had previously been 
successfully conducted on immune cells, low yields were overcome by harvesting 
larger numbers of cells either from buffy coats (Raghavan et al., 2002), cell lines 
(Palena et al., 2003) or in the case of murine studies by sacrificing the animal (Ji et 
al., 2003; Zhang et al., 2002). The principal limitation of studies of human virus- 
specific lymphocytes has been the availability of these populations.
Fortunately, certain technical strategies have enabled up to 80-fold amplification of 
nanogram quantities of RNA (Van Gelder et ah, 1990; Wang et al., 2000). 
Importantly, linear amplification ensures that up to 80% of the genes in the amplified 
samples are similarly induced or repressed when compared to non-amplified samples 
(Baugh et al., 2001). Two rounds of amplification were recommended to generate an 
appropriate quantity of RNA from an input of approximately 300,000 human PBMCs 
(personal communication with P.Kellam, U.C.L.).
For this part of the study, we attempted to amplify RNA extracted from the HBV- 
specific CD8 + T cell enriched line from the resolved patient as described in the 
previous section. To do this, Dynal Poly-d(T) purified mRNA derived from the 
patient sample B-US and B-S were subjected to two rounds of in vitro amplification 
and the purified amplified products were stored at -70°C.
4.2.3 Amplification of reference RNA
Comparative cDNA microarray analysis relied on the incorporation of an equal 
quantity of artificial reference RNA into every test sample (see section 1.13.2.1). In
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order to maintain methodological consistency between the reference RNA and the 
sample RNA, the reference was also amplified. Additionally, this enabled the 
production of a large common stock from which identical aliquots could be stored 
and used when appropriate enriched-cell lines were available.
The first amplification of reference RNA was essentially performed on one unique 
primary stock of commercially derived total universal reference RNA (TURR), 
however, three variations of this stock were tested: Test 1 (Ref.A) was conducted 
using only Ipg total TURR, Test 2 (Ref.B) was conducted on 25pg of TURR and 
Test 3 (Ref.C) was conducted on mRNA that was purified from 25 pg of TURR. The 
latter was included to match the RNA extracted from the patient samples. Purified 
amplified products (aRNA-Ref.Al, aRNA-Ref.Bl and aRNA-Ref.Cl) were eluted in 
RNAse free water, aliquoted, and stored at -70°C.
A second round of amplification of reference was conducted on 5pg of aRNA-Ref.Bl 
and aRNA-Ref.Cl; aRNA-Ref.Al was omitted because a quantitative preview 
indicated a poor yield. Highly purified amplification products (aRNA-Ref.B2 and 
aRNA-Ref.C2) were eluted and stored at -70°C.
167
4.2.4 Quantification
The efficiency of Cy5- or Cy3-labelling of amplified RNA could be influenced by 
differences in the quantity of input RNA and it was therefore important to minimize 
these variations. The traditional means of RNA quantitation such as ethidium 
bromide stained agarose gels and spectroscopic determination were inappropriate for 
the quantification of nanogram amounts of aRNA. However, the Agilent Bioanalyser 
was an instrument that offered highly sensitive determination not only of the quantity 
of the aRNA samples but also its quality: a smooth uninterrupted RNA profile 
signified a high quality sample without ribosomal RNA contamination whereas 
jagged curves indicated degradation.
(see http://www.chem.agilent.com/Scripts/PDS.asp?lPage=51 )
In order to determine the quantity of RNA in the first and second round amplified 
samples B-US and B-S as well as the amplified reference RNA (aRNA-Ref.Al, 
aRNA-Ref.Bl, aRNA-Ref.Cl, aRNA-Ref.B2 and aRNA-Ref.C2), a small quantity 
was loaded onto Agilent Biochips and measured. Additionally, 150ng of ladder 
(identical to that used in the designated ladder well) was loaded as an internal control.
The left plot in figure 4.3 is the typical mRNA profile of ISOng standard ladder with 
seven bands (0.2, 0.5, 1.0, 2.0, 4.0 and 6.0kb respectively) that follow the first peak 
that corresponds to the reporter dye; the 0.2kb band is at a concentration of 20ng/pl. 
The right plot in figure 4.3 is a profile of the identical ladder that was used as a 
control to evaluate the fidelity of the quantification. The bioanalyser calculated the 
internal control sample to contain 158ng of RNA corresponding to <5% error margin.
Figure 4.4 demonstrates the profiles of the amplified resolved samples, where the 
total yield was 2.37pg and 2.94pg for once amplified and 44.8pg and 41.4pg for 
twice-amplified samples B-US and B-S respectively; the quantity of the latter pair 
potentially being sufficient for approximately 8 arrays repeats at 5pg RNA/array. 
These data confirmed that by coupling Dynabead mRNA purification technology
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with a modified linear RNA amplification protocol it was possible to generate 
sufficient RNA to meet microarray requirements from patient samples composed of 
only 300,000 PBMCs.
Figure 4.5 (middle horizontal 3 plots) are mRNA profiles for the first round amplified 
reference RNA (aRNA-Ref.Al, aRNA-Ref.Bl and aRNA-Ref.Cl) indicating yields 
of 624, 3584 and 12731ng/pl equivalent to a total of 25, 142 and 381pg and sufficient 
for 5, 28 and 76 arrays respectively. The bottom two plots are RNA profiles 
following the second amplification indicating concentrations of 10.6pg/pl (aRNA- 
Ref.B2) and 8.2pg/pl (aRNA-Ref.C2) corresponding to final recoveries of 59pgs and 
48pgs - sufficient for 9 and 5 arrays respectively.
The best yield of reference RNA obtained was sample aRNA-Ref.Cl (hereafter 
referred as aREF) that at 5pg per array was ample for at least 70 arrays; this was 
sufficient for the quantity of samples that we planned to analyse in this phase of the 
study. Subsequent trials demonstrated that comparably high quality array data could 
be obtained using only 2pg of amplified RNA thereby doubling the quantity of arrays 
that could be produced from the remaining aREF stocks.
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Figure 4.3
RNA Quantification - ladder and internal control
RNA ladder calibration standard (left) and RNA-biochip internal control (right) 
consisiting of 150ng ambion RNA ladder.
170
B-US
(mRNA)
B-US(aRNA-IVTI)
(2 .37ng)
—t i l l ' ' '
B-US (aRNA-IVT2)
(44.8|xg)
E
B-S
(mRNA)
i
B-S (aRNA-IVTI)
(2.94pg)
11 ' ' . ........
B-S (aRNA-IVT2)
(41.4ug)
\A
prim ary sam ple  
( 10 da y  enriched line)
1st round  
am plified products
2n d  round  
am plified products
Figure 4.4
RNA quantification - patient sample
aRNA products from in vitro amplification (two rounds) of mRNA derived from an 
unstimulated and stimulated HBV core 18-27-enriched line.
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Figure 4.5
RNA quantification - amplified universal reference RNA.
aRNA products from an in vitro amplification (two rounds) of reference RNA from 
three source stocks (top boxes - left, middle and right). Middle horizontal 3 plots 
indicate profiles following the 1 st round of amplification and the lowest two plots 
correspond to aRNA profiles following the 2nd round of amplification. The high­
lighted plot indicates the sample that was selected as reference RNA for this study 
(aREF).
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4,2.5 Validation o f cDNA micro array methodology
4.2.5.1 Dye incorporation (Cy5 vs Cy3)
Dual-colour cDNA arrays allow for a highly effective normalization that is 
fundamental to studies aimed at cross-comparing multiple independently generated 
samples. In this study, reverse transcription with Cy5- and Cy3-labelled dCTP was 
used to generate fluorescently labelled strands complementary to both the sample 
aRNA that were being profiled and the reference aRNA. Because these 
fluorochromes are chemically distinct molecules morphological or electrostatic 
differentials could have affected the rate of incorporation during the labelling 
reaction. It was therefore necessary to confirm that this difference did not adversely 
affect the reaction. This was achieved by comparing data generated from a single 
array that was hybridised with two identical RNA samples each labelled with either 
of the two fiuorophores. In this case, aREF was used as the sample under study.
5pg of aREF was labelled with Cy5-tagged dNTPs and a separate 5pg aliquot derived 
from the same stock was labeled with Cy3-tagged dNTPs. Purified products were 
then cohybridized to a cDNA microarray and processed as described in chapter 2. 
Fluorescent intensities of the hybridized transcripts [for -5000 individual genes (in 
duplicate)] were then analysed in excel.
The Cy5 and Cy3 expression data for each spot on the array (-5000 in duplicate) was 
corrected for local background noise, Logi transformed (refer section), and plotted 
against each other. We found that the gene transcripts labelled with Cy5 generated 
fluorescent signals that were highly similar to that obtained when labelled with Cy3 
(figure 4.6; r=0.92) demonstrating that molecular differences between the 
fluorochromes did not have any significant negative influence over the labelling 
reaction and hybridization to the array probes.
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Figure 4.6
Comparative efficiency of Cy5 and Cy3 dye incorporation.
The labelling efficiency of Cy5- an Cy3-labelled dUTP was compared by plotting the 
fluorescence intensities of a fixed quantity of identical reference RNA simultaneously 
labelled with either of these dyes and co-hybridized to an HGMP cDNA microarray.
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4.2,5.2 Two rounds of amplification
The generation of sufficient aRNA from small numbers PBMCs necessitated two 
rounds of in vitro amplification. Although studies have shown that a single round of 
amplification does not significantly alter the gene expression profile compared to 
unamplified samples, we needed to confirm that an additional round of amplification 
would not compromise the fidelity of the data.
To achieve this, 5pg of once amplified RNA (aRNA-Ref.Cl) and 5pg of twice 
amplified RNA (aRNA-Ref.C2) were labelled with Cy5 or Cy3, mixed and co­
hybridized onto an array and processed accordingly. The fluorescence intensities of 
-5000 genes (in duplicate) for Cy5 and Cy3 were extracted, corrected for 
background, log transformed and the data was plotted against each other (figure 4.7).
Once and twice amplified RNA transcripts exhibited a high degree of similarity 
(r=0.96) and confirmed that an additional round of amplification did not significantly 
alter the global gene expression profile. These data supported the application of two 
rounds of in vitro amplification in our study.
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Figure 4.7
Comparison of once and twice amplified aRNA.
The influence of an additional round of amplification was evaluated by plotting the 
fluorescence intensities of once and twice amplified reference RNA that were labelled 
with Cy5 and Cy3 respectively and cohybridised to an HGMP cDNA array.
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4.2.6 Primary evaluation of HGMP cDNA microarrays for HBV-specific
CD8+ T cell analysis
4.2.6.1 Analysis o f  HBV-specific CD8+ T cell-enriched lines
HGMP cDNA arrays contained probes for genes expressed by multiple different cell 
types. Due to the inherent protein variability of different specialized cell types, it was 
likely that multiple genes on the array would be irrelevant to the analysis of 
transcriptional events that occur specifically in CD8 + T cells particularly following 
stimulation and would therefore be redundant in our investigation. Additionally, 
although the universal reference employed in this study included RNA extracted from 
T cells we did not know whether this was satisfactory for the evaluation of activated 
CD8 + T cell-specific transcripts.
It was therefore necessary to demonstrate that it was possible to use HGMP cDNA 
microarrays to generate relevant transcriptional information from twice-amplified 
sample RNA normalized with amplified reference RNA. This was achieved by 
conducting a comparative analysis of the gene expression profile of the HBV-specific 
CD8 + T enriched lines from the resolved individual with and without peptide 
restimulation at day 1 0 .
5pg of twice amplified RNA from the resolved samples B-US and B-S were labelled 
with Cy5 and each were combined with 5pg of Cy3 labelled aREF and processed 
onto arrays. The data was extracted, normalized and log transformed as described 
previously. Although the amounts of input were standardized to lOpg/array (5pg of 
sample + 5pg of reference), subtle differences in hybridization, washing or labelling 
efficiency are expected. Normalization, with CLUSTER, compensated for these 
effects by transposing the data so that the medians overlapped (see section 1.13.2.6). 
This form of global normalization, also referred to as median centring, is based on the 
assumption that the majority of genes (>95%) do not significantly change their level
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of expression and therefore the array data can be centred while still maintaining the 
relationships and the standard deviations within the data (Yang et al., 2002). Logi 
transformation forced the data into a normal distribution and enabled an interpretation 
where a Logi (Cy5/Cy3) ratio of 1 signified that the gene was up-regulated by a 
factor of 2 relative to the reference. In contrast, a gene with a Log2(Cy5 /Cy3 ) ratio of 
-1 was down-regulated by a factor of 2. Unchanged genes had a Log] (Cy5/Cy3) of 0 
(Yang et al., 2002).
The comparative analysis of the normalized data indicated that several of the most 
highly expressed genes were those known to be highly relevant to immune function 
(listed in Table 4.1).
IFN-y and TNF-a transcripts were found to be highly expressed in the short-term 
lines and both were up-regulated following antigenic restimulation in support of data 
generated at the protein level demonstrating that the intrahepatic inactivation of HBV 
by CD8 + T cells is achieved by these cytokines (Guidotti et al., 1996).
Granule exocytosis is a key effector mechanism used by CD8 + T cells to eliminate 
virally infected cells - granule serine proteases (granzymes) released at the 
immunological synapse enter target cells through perforin/granulysin-mediated pores 
and subsequently kill target cells principally by cleaving target substrates in the 
cytoplasm and in the nucleus (Ashton-Rickardt, 2005; Lieberman, 2003).
The cytokine lymphotoxin alpha is a member of the tumour necrosis factor family 
that is known to mediate a variety of inflammatory, immunostimulatory and antiviral 
responses (Banks et al., 2006; Ware, 2005).
IL-18 signalling activates virus-specific CD8 + T cells and drives them to produce 
IFN-y (Raue et al., 2004). Signalling through the IL-18 receptor also promotes 
survival of activated cells through an increase in anti-apoptotic Bcl-2 that is also 
associated with an increase in the expression of IL-2 receptor beta chain (CD 122) (Li 
et al., 2007).
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The fact that several of the most highly expressed (and further upregulated genes) had 
well described roles in antiviral CD8 + T cell responses confirmed the validity of 
using HGMP arrays for the study of antigen-specific CD8 + T cells. It is important to 
note that despite the fact that the enriched samples that were analysed also contained 
transcripts from immune cells other than those that were HBV-core-specific CD8 + T 
cells, we were still able to detect key transcriptional events commonly associated with 
a virus-specific CD8 + T cell response.
Table 4.1: Selection of highly expressed genes with known immune function
Gene B-US B-S
[Log2(Cy5/Cy3)l [Log2(Cy5/Cy3)J
Interferon-y 4.8 7.6
TNF-a 4.9 7
Granzyme K 4.8 6.5
Lymphotoxin-a 1.8 4.3
Interleukin 18 receptor (a  chain) 2.6 5.4
Interleukin 2 receptor (j3 chain) 4.1 6.3
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4.2,6.2 Analysis of purified HBV-specific CD8+ T cells
Stimulated CD8 + T cells respond by exerting effector functions such as the secretion 
of cytokines like IFN-y/TNF-a or modifying expression of cell surface signalling 
molecules. These soluble or cell-to-cell contact-dependent mechanisms have the 
potential of inducing non-specific bystander activation that could influence the data 
relevant to virus-specific CD8 + T cell responses. In order to control for this it we 
sought to complement the cumulative array data that was generated from whole short­
term enriched lines with data from highly purified virus-specific CD8 + T cells. Two 
purification methods were adapted for the selection for HBV-specific CD8 + T cells 
from individuals with resolved and chronic infection.
4,2.63 Purification o f HBV-specific CD 8+ T cells associated with successful 
viral control
Multimer-labelling of HBV-specific CD8 + T cells from resolved individuals coupled 
to fluorescence activated cell sorting allowed for highly specific purification of virus- 
specific CD8 + T cells. This was an ideal method of purification as it is based on the 
selection of CD8 + T cells that express a TCR that is able to recognise a specific viral 
antigen.
10 million cells [with a core-specific CD8 + T cell enrichment of -70%  (of total 
CD8 + T cells)] were stained with an HLA-A2 HBV core 18-27 tetramer and cultured 
for a further 5 hours with the core 18-27 peptide. To ensure optimal staining tetramer- 
labelling was performed prior to the peptide stimulation because TCR expression can 
be down-regulated following activation (Kao et ah, 2005). The engagement of TCRs 
by tetramers could have reduced the subsequent peptide stimulation by effectively 
blocking these from interacting with MHCI-presented peptides, however, tetramers 
themselves have the potential to activate complementary cells which was constructive 
to our experimental design.
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From a total of 4.5 million acquired cells, 1.1 million were positively sorted at a 
purity of greater than 95%. Two rounds of in vitro transcription on mRNA extracted 
from these cells generated 16.2pg aRNA and was sufficient for the generation of a 
high quality array (figure 4.8 left).
In addition to flow cytometry based sorting, we were also able to obtain highly 
purified envelope- and core-specific CD8 + T cells from enriched lines ( 6  and 34 % of 
total CD8 + respectively) by magnetic column-based separation of pentamer labelled 
cells. Purities were 81% and 96% respectively (Figure 4.9).
181
core-18-27
70%
CDS
Tetramer
Figure 4.8
cDNA Microarray analysis of HBV-specific CD8+ T cells from a resolved indi­
vidual
Core-specific CD8 + T cells were purified by flow cytometric sorting of a core- 
pentamer labelled short-term PBMC line from a resolved patient (left plot). mRNA 
extracted from the purified cells was then profiled by dual colour cDNA microarray 
technology (right).
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Figure 4.9
Magnetic purification of HBV-specific CD8+ T ceils from a resolved individual.
Short-term core 18-27 and envelope 183-191-enriched lines were stained with appro­
priate phycoerythrin(PE)-conjugated pentamers. Anti-PE magnetic beads were then 
used to positively select HBV-specific CD8 + T cells. Pre and post-purified samples 
were co-stained with anti-CD8 and analysed by flow cytometry.
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4.2.6,4 Purification o f HBV-specific CD 8+ T cells associated with immune
failure
Tetramers could not be used to purify HBV envelope-specific CD8 + T cells from 
individuals with chronic infection with high viral loads because these cells were not 
able to bind to the multimer (Reignat et ah, 2002). However, these populations 
maintained their ability to produce IFN-y in response to specific viral peptide 
stimulation allowing us to positively select these cells on the basis of effector 
function; see section 2 . 1 0  for further details.
A short-term line [enriched with envelope-specific CD8 + T cells (17% of total CD8 + 
T cells was achieved in one rare chronic individual)] was generated and 10 million 
total cells were restimulated peptide for 5 hours at 37°C to initiate IFN-y secretion. 
Cells were then washed and the IFN-y/CD8  labelling was performed. Subsequently, 
flow cytometry cell sorting was used to capture the virus-specific dual positive 
population.
From a total of 6.7 million acquired cells, 0.32x10^ envelope 183-91-specific CD8 + T 
cells were obtained. These were immediately lysed in an RNAse neutralizing mRNA 
extraction buffer and stored at -70°C. The two rounds of in vitro amplification 
generated 13.8pg of aRNA that was sufficient to produce a high quality array (figure 
4.10).
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Figure 4.10
cDNA Microarray analysis of HBV-specific CD8+ T cells from an individual with 
chronic HBV infection.
Envelope-specific CD8+ T cells were purified by flow cytometric sorting of a short­
term PBMC line from a chronic patient (left and middle plot); HBV-specific CD8+ T 
cells were labelled for IFN-y with the IFN-y secretion assay following a five hour 
peptide stimulation. mRNA extracted from the purified cells was then profiled by dual 
colour cDNA microarrays technology (right).
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4.2, 7  Selection of arrays generated in this study
Gene expression profiles were generated for a total of 48 arrays corresponding to 10 
day PBMC lines (enriched for envelope 183-191- or core 18-27-specific CD8 + T 
cells) that were not peptide re-stimulated at day 1 0 , peptide re-stimulated (for 6  
hours) at day 1 0 , and a limited number of samples that were re-stimulated at day 10  
for either 1 or 16 hours.
We were unable to conduct an analysis of unstimulated versus stimulated samples 
due to low signal intensities or sub-optimal array images of the un-restimulated 
samples in particular because the data from substandard arrays were unreliable. This 
was due to a combination of poor quality of aRNA that was applied onto the arrays as 
well as leaky hybridization chambers that contaminated the hybridization mixture. 
Considering that a large proportion of the arrays were disqualified due to these 
factors, future studies should particularly aim to overcome these problems.
The 1 and 16 hour restimulated arrays were also not of appropriate quality; the lack of 
a continuous set of unstimulated and 1 , 6 , and 16 hour-stimulated samples from one 
individual did not permit a time course analysis to evaluate the dynamics of gene 
transcription changes. As mentioned previously, immediate early as well as late 
transcriptional events could provide important information regarding the 
effectiveness of the antiviral response and deserves, along with the unstimulated 
versus stimulated samples, to be studied in the future.
We were however able to generate high quality data from 19 arrays corresponding to 
peptide re-stimulated 10 day PBMC lines that were enriched for HBV-specific CD8 + 
T cells. The array data generated from these consisted of twelve resolved samples, six 
samples with high-level chronic HBV infection and one sample from an individual 
with low-level chronic infection. Specifically, they included seven core 18-27 
enriched lines, eight envelope 183-91 enriched lines, purified core 18-27-specific
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CD8 + T cells from two patients, and purified envelope 183-91-specific CD8 + T cells 
from an additional two patients (see Table 4.2 below).
Table 4.2: Details of the chronic and resolved samples processed onto cDNA 
microarrays
All samples were restimulated for 5 hours with cognate peptide prior to lysis
ARRAY PATIENT VIRAL SAMPLE % IFN-
DETERMINANT TYPE (ofCD 8
1 R1 Core 18-27 enriched line 34
2 R1 Core 18-27 purified 96
3 R3 Core 18-27 enriched line 3
4 R ll Core 18-27 enriched line 10
5 R6 Core 18-27 enriched line 12
6 RlOa Core 18-27 enriched line 20
7 RlOb Core 18-27 purified 95
8 RlOb Core 18-27 enriched line 70
9 R1 Envelope 183-191 enriched line 6
10 R1 Envelope 183-191 purified 81
11 R6 Envelope 183-191 enriched line 10
12 RlOa Envelope 183-191 enriched line 5
13 C15 Core 18-27 enriched line 9
14 C16a Envelope 183-191 enriched line 4
15 C16b Envelope 183-191 enriched line 4
16 C22 Envelope 183-191 enriched line 1
17 C9a Envelope 183-191 enriched line 3
18 C9a Envelope 183-191 purified 95
19 C9b Envelope 183-191 enriched line 3
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4.2.8 Pre-analysis data processing
4.2.8.1 Selection o f essential data
In addition to the large panel of relevant intracellular genes, each HGMP array 
dataset contained a significant quantity of data that was irrelevant to the CD8 + T 
comparative analysis. These redundant genes included several housekeeping genes, 
blank cells, positive and negative controls (Table 4.3/ figure 4.11/ for a representative 
example of positive and negative genes).
Although the mean Cy5 and Cy3 fluorescence intensities of the negative controls 
were used to filter-out data that fell below background levels, the redundant genes 
were subsequently not required for the comparative analysis between resolved and 
chronic samples and were therefore manually deleted from the master dataset. The 
individual reduced array datasets were then assimilated into a single excel file termed 
Dataset 1-Reduced (Dl-R) containing fluorescence intensities of approximately 5088 
genes, in duplicate.
188
Table 4.3: Details of the negative and positive (bold) control genes spotted onto 
the HGMP cDNA arrays
Gene
number
Gene number Category
1 Yeast Intergenic Region from Chrom XI dynamic range control 1
2 Yeast Intergenic Region from Chrom XI dynamic range control 2
3 Yeast Intergenic Region from Chrom VII dynamic range control 3
4 Yeast Intergenic Region from Chrom V I1 dynamic range control 4
5 Yeast Intergenic Region from Chrom XII dynamic range control 5
6 Yeast Intergenic Region from Chrom XI1 dynamic range control 6
7 Actin gamma-1 house keeping gene I
8 Enoyl Coenzyme A hydrolase, short chain house keeping gene 10
9 Glyceraldehyde-3-phosphate dehydrogenase house keeping gene 2
10 Ubiquinol-cytochrome c reductase core pr house keeping gene 3
11 Casein kinase II beta polypeptide house keeping gene 4
12 EST highly similar to NY-REN-37 antigen house keeping gene 5
13 Human hydroxymethyl glutaryl-CoA lyase house keeping gene 6
14 Neuroblastoma RAS viral oncogene homolog house keeping gene 7
15 Eukaryotic translation initiation factor house keeping gene 8
16 Ubiquinol-cytochrome c reductase core pr house keeping gene 9
17 Arabidopsis thaliana protein G lp negative control 1
18 Poly-dA oligonucleotide negative control 2
19 Spotting buffer negative control 3
20 Bacillus subtilis gene negative control 4
21 Bacillus subtilis gene negative control 5
22 Total human genomic DNA positive control
23 Yeast Intergenic Region from Chrom XII ratio control 1
24 Yeast Intergenic Region from Chrom XII ratio control 2
25 Yeast Intergenic Region from Chrom XI1 ratio control 3
26 Yeast Intergenic Region from Chrom X lll ratio control 4
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Figure 4.11
cDNA microarray negative and positive control genes.
cDNA microarrays contained 26 negative and positive control gene spots; the mean 
value of the former group was used to assess the non-specific background fluores­
cence of the array.
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4.2.8.2 Data normalization
Every gene within an array that passed the filtration criteria was associated with an 
expression value (Log2 Cy5/Cy3). Plotting the frequency of gene expression 
measurements per array produced a bell shaped curve indicating that the data is 
normally distributed (figure 4.15 left plot). Most of the data lay within the 95th 
percentile centred in close proximity to zero indicating that the majority of the genes 
did not change expression. However, the individual array datasets exhibited slight 
differences in median expression as indicated in the shifts of the plots when 
overlapped. This could be due to small variations in input RNA as well as minor 
differences in labelling efficiency. Median centring is a widely accepted method that 
can be used to transpose the individual data sets to correct for these undesirable 
differences without altering the relationships with the data, therefore enabling a cross­
comparison of the data from the 19 arrays.
To execute this, the Cl-R dataset containing the array data of the 19 selected arrays 
was formatted to the requirements of CLUSTER and normalized by median centring 
both genes and arrays thereby generating a dataset termed D l-R Median Centred 
(Dl-R MC). Figure 4.14 (right plot) illustrates the median normalized data of the 19 
arrays.
191
Pre-normalization Post-normalization
c
Î
Fluorescence intensity [Log^(Cy5/Cy3)]
Figure 4.12
Normalization of array data - median centring.
In order to enable a comparative analysis of the gene expression data from the 19 indi­
vidual arrays, the datasets were compiled into a single file and were collectively median 
centre-normalized with CLUSTER. Plots illustrate the distribution of the data of the 
individual arrays pre- and post-normalization.
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4.2.8.3 Data filtration
Data filtration is a component of post-normalization pre-analysis data processing that 
is used to increase the stringency of the dataset. CLUSTER was capable of two forms 
of filtration: first, the exclusion of genes with inter-array expression values falling 
below a user-defined standard deviation threshold (thereby eliminating genes with 
small variations in expression across arrays) and second, the exclusion of genes for 
which array data was not available, the latter being adjusted according to percent of 
data entries present.
The most important transcriptional differences are not necessarily always the largest. 
Certain genes may only require relatively low transcriptional fluctuations to achieve 
the required functional effect. This argued against data filtration aimed at excluding 
genes with subtle gene expression differentials, as could be executed through 
standard deviation criteria. Furthermore, several gene spots were flagged for 
exclusion during Genepix gridding due either to bad gene spotting during array 
production, scratches that occurred during array processing, or fluorescence 
interference from contaminating material. A conservative filtration cut-off of 80% 
resulted in the loss of 1067 genes, 10% of the total dataset, introducing a substantial 
risk of over-looking critical genes. Thus, in order to minimize the incidence of false- 
negatives, an unfiltered dataset (D l-R MC UP) consisting of all 10166 data entries 
was utilized in the comparative analysis.
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4.2.9 Data analysis
4.2.9.1 SOMSf hierarchical clustering and data visualization
In the first phase of the data analysis we decided to explore the relationship between 
the 19 individual samples according to the global gene expression profile without 
forcing a compartmentalization of the samples according to disease outcome 
(resolved versus chronic). To achieve this, CLUSTER (Eisen et ah, 1998) was first 
used to generate self-organized maps and perform average linkage clustering of genes 
and arrays thereby arranging the individual arrays and genes according to similarity 
of the global gene expression profile. TREEVIEW 
(http://rana.lbl.gov/EisenSoftware.htm) was used to visualize the CLUSTER- 
organized data. This complementary PC-based bioinformatics tool generated a heat 
map in which colour intensity reflected the relative gene expression - red and green 
corresponding to up- and down-regulation respectively. An accompanying 
dendogram was produced that illustrated the similarity between the individual arrays 
as well as genes.
We observed that the primary dataset (Dl-R MC UP) branched into two main groups 
(Figure 4.16; C and R). The majority of samples in group C (6 /8 ) and group R (10/11) 
derived from individuals with chronic and resolved infection respectively. The single 
chronic patient whose HBV-specific CD8 + T cell gene expression branched with the 
resolved patients was the only chronic HBV patient included in this analysis that did 
not have high HBV DNA (greater than 10  ^ lU/ml) and may therefore explain the 
aberrant segregation. It is unclear why two resolved samples segregated with the 
chronic samples in group C but could be due to a gene expression differential that 
was relatively quite low resulting in a large proportion of entries that appeared 
unchanged (black on the heat-map). Nonetheless, based on the overall sequestration, 
it was apparent that differences in gene expression between individual samples that
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were induced following HBV antigen-specific activation with peptide were sufficient 
to differentiate samples according to the clinical outcome.
Among all the genes analysed (5088 genes per sample, spotted in duplicate), a clearly 
distinguishable cluster of genes was upregulated in chronic samples and down- 
regulated in resolved samples (compared to reference RNA, figure 4.15, blue box). 
Closer inspection identified a sub-cluster of genes that were functionally-related and 
exhibited a consistent divergence of expression level between the two groups. Of the 
2 0  genes (with known functions) in this terminal sub-cluster, 16 had previously been 
described to participate in apoptosis (highlighted in red). 1 0  of these were found to 
overlap with highly significant genes short-listed by the SAM analysis (see section 
4.2.9.2).
Within the 20 gene subcluster, transforming growth factor beta (TGF-|3), an 
extremely potent inhibitor of lymphocyte function (Lotz et al., 1990) that has been 
shown to suppress several virus-specific CD8 + T cell associated with persistent 
infection including HCV, HIV and HTLV-1 (Alatrakchi et al., 2007; Garba et al., 
2002; Kekow et al., 1990; Nagai et al., 1995), was also transcriptionally upregulated 
in the chronic samples, alluding to a similar involvement of this cytokine in chronic 
HBV infection. Additionally, Bid is a well-described mediator of cell death that 
functions by inducing membrane permeabilization following caspase cleavage 
(Milhas et al., 2005; Reiners et al., 2002; Stoka et al., 2001) displayed a similar gene 
expression differential.
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Figure 4.13
Visualization of cDNA microarray data processed by CLUSTER.
Treeview analysis of average linkage hierarchically clustered (with self-organized 
mapping) gene expression data. The top dendogram represents the similarity between 
individual arrayed samples (vertical plane) based on the global gene expression profile; 
a yellow line segregates the main clusters (C and R). The left dendogram (boxed in red) 
illustrates the clustering pattern according to similarity of expression between different 
genes. The blue box highlights a section of the heat-map where a group of genes exhib­
ited marked upregulation in branch C compared to R (listed with original and current 
unigene references on the right; genes in red participate in apoptosis; genes overlap­
ping with the SAM short-list are indicated by asterisks).
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4.2.9.2 Significance analysis of microarrays (SAM)
SAM was used to process normalized (median centred) cDNA array data to identify 
genes with statistically robust differences in expression; see section 1.14.1. A 
selection of significant genes was determined by adjusting a user-defined tuning 
parameter (A) that is related to a false discovery rate (q) (Tusher et al., 2001); a FDR 
of <5% is generally accepted to be sufficiently stringent for the SAM analysis. An 
unpaired analysis of the array data from the resolved and chronic groups of samples 
at a low median false discovery rate (1.3%) short-listed 105 differentially regulated 
genes; these were sorted according to their d values. The d  score is analogous to the t- 
statistic that in turn is related to the p  value; it can therefore be interpreted as the 
statistical significance of differential gene expression between the two groups. This 
method of short-list sorting was preferred over sorting by fold-change (as a second 
option) prinicipally because larger differences in fold-change at the transcriptional 
level do not necessarily translate to a greater importance in biological function. 
Nonetheless, we did consider the fold-change by focusing only on genes that 
exhibited a minimum 2 -fold difference in relative gene expression.
76 genes had increased and 29 genes had reduced expression, in chronic compared to 
resolved HBV-specific CD8 + T cell samples (figure 4.14, table 4.4 & table 4.5). We 
observed that the up-regulated genes in HBV-specific CD8 + T cells from patients 
with CHB exhibited larger fold-change increases, ranging from 2 to 9 fold. In 
corroboration with our findings from the hierarchical cluster analysis, a large number 
of the genes that were short-listed by SAM were also found to participate in apoptotic 
events. More importantly, multiple apoptosis-related genes from the two 
independently generated short-lists overlapped (figure 4.13, asterisked), confirming 
that a group of functionally-related genes were transcriptionally altered in antigen- 
specific CD8 + T cells in chronic HBV infection.
Figure 4.15 illustrates a sample of five genes that were selected by both methods of 
analysis, with mean and standard deviation of expression levels relative to the
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reference RNA (Mann Whitney test). Bim has been shown to drive the deletion of an 
immunodominant CD8 + T response in a persistent viral infection (Grayson et ah, 
2006). The forkhead transcription factor (GIB), shortlisted in the SAM analysis, was 
also elevated in the responses associated with CHB; forkhead transcription factors 
have been associated to the regulation of Bim (Behzad et al., 2007; You et al., 2006). 
Forkhead transcription factors are in turn related to GADD45-Y (growth arrest and 
DNA-damage inducible response gene) that is upregulated in the antiviral response in 
CHB; GADD45-Y contributes to effector T lymphocyte death (Liu et al., 2005c; 
Zerbini and Libermann, 2005). Additionally, supporting the participation of Bim- 
associated apoptosis, gene expression levels of the tumor necrosis factor receptor 
(TNFFR)-associated factor 1 (TRAF-1) (shortlisted by SAM) were relatively lower in 
the responses associated with CHB; TRAF-1 inhibits antigen-induced apoptosis of 
CD8 + T lymphocytes (Sabbagh et al., 2006; Speiser et al., 1997). The participation of 
these four inter-dependent functionally-related genes supported the involvement of an 
apoptotic mechanism.
With respect to the other four sample genes depicted in Figure 4.15, Cathepsin B has 
been shown to mediate the apoptosis of T lymphocytes (Michallet et al., 2003), 
particularly those that have been subject to supraoptimal activation (Michallet et al., 
2004) suggesting involvement in high dose tolerance. Ox-40 has been shown to 
promote Bcl-Xl and Bcl-2 expression (Rogers et al., 2001). SOCSl is a negative 
regulator of cytokine signalling and impairs proliferation of T cells (Trop et al., 
2001). MAP4KK2 activates MAP kinases resulting in a selective deletion of CD8 + T 
cells (Merritt et al., 2000). For each of these genes, the transcripts were consistently 
raised in HBV-specific CD8 + T cells from CHB, both in highly purified populations 
and enriched 10 day lines. These genes showing highly significant differences 
(increases) in HBV-specific responses from chronic compared to resolved patients are 
all involved in apoptotic pathways that can lead to lymphocyte death. Thus, we have 
shown that data from two independent analyses highlighted overlapping clusters of 
apoptosis-related transcripts that were dysregulated in the HBV-specific CD8 + T cell 
response associated with chronicity.
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Figure 4.14
Statistical analysis of cDNA microarray data.
Significance Analysis of Microarrays (SAM) plot illustrating the most significant 
differentially regulated genes (false discovery rate - 1.3%) between the group with 
chronic and resolved HBV infection.
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Figure 4.15
Selection of differentially regulated genes.
cDNA array data of the mean transcriptional levels (including S.E.M. limits) of five 
apoptosis-related genes in HBV-specific CD8 + T cell responses in resolved and chronic 
infection with stastical significance (Mann Whitney test) as indicated.
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Table 4.4
SAM analysis - 76 genes up-regulated in chronic infection.
76 positive significant genes
Gene Name
Unigene 
ID (Hs.) * Score(d) Fold Change
Bcl-2 interacting mediator 140648 5.20 6.63
EST 330442 4.97 4.81
Complement component 3 1203320 4.96 5.81
Complement component 3 1203320 4.64 5.08
Secreted frizzled-reiated protein 1 7306 4.54 3.75
N-acetylglucosaminidase, alpha 50727 4.37 4.09
Myelin associated glycoprotein 1780 4.32 8.56
insulin-like growth factor binding protein 77326 4.23 9.25
Extracellular matrix protein 2 35094 4.09 3.08
Coiled-coil domain containing 52 477144 4.02 4.42
Growth arrest & DNA-damage-inducible, gamma 9701 3.91 4.15
Contactin 143434 3.91 2.79
Frizzled homolog 2 81217 3.90 2.86
Serine (or cysteine) proteinase inhibitor, clade A 297681 3.84 3.74
Cytochrome c oxidade subunit Va 434076 3.80 3.68
Ki-ras ND 3.77 3.57
Dystrobrevin, alpha 336678 3.76 2.23
Integrin, alpha 6 227730 3.72 4.22
Procollagen (type 111) N-endopeptidase 183138 3.70 2.69
Ribosomal protein S4, Y-linked 180911 3.62 3.48
Matrix metalloproteinase 17 159581 3.62 4.28
Forkhead box G IB 386249 3.60 3.32
Matrix metalloproteinase 13 2936 3.57 2.98
Connective tissue growth factor 7551 1 3.52 7.34
Cathepsin B 3.50 3.33
Profilin 1 75721 3.49 4.12
Chloride channel 4 199250 3.47 2.77
Suppressor o f  cytokine signalling 405946 3.47 4.51
Uracil-DNA glycosylase 78853 3.45 2.49
Pyrroline-5-carboxylate reductase 1 79217 3.45 3.50
Gamma-aminobutyric acid (GABA) A receptor 45740 3.44 3.40
STAT6 ND 3.42 2.84
Cut-like 1, CCAAT displacement protein 147049 3.41 2.74
7297,^0 3.40 3.00
Rho GTPase-activating protein 111138 3.37 4.11
Lysophosphaphatidic acid G-protein-coupled R.2 75794 3.37 3.31
Tryptase beta 1 405479 3.36 3.09
Apolipoprotein A-1 93194 3.35 7.50
Mitogen-activating protein kinasex4 2 g2P7P 3.34 3.34
Catenin (cadherin-associated protein) 80220 3.34 3.30
Acyl-Coenzyme A oxidase 3, pristanoyl 12773 3.33 3.39
Folate receptor 2 24194 3.32 2.94
DNA (cytosine-5-)-methyltransferase 1 201 202672 3.31 4.62
Glycine receptor, beta 32973 3.31 4.68
EST (N55083) 3.31 3.13
Gap junction protein, beta 1 333303 3.29 3.80
EST (R59352) 3.28 2.67
EST (R37350) 3.27 3.11
Amyloid B (A4) precursor protein-binding m.3 17528 3.26 3.87
Human insulin-like growth factor binding 635441 3.26 6.13
Cysteine-rich, angiogenic inducer, 61 8867 3.25 4.89
Transcription factor 21 78061 3.25 3.13
Hypothetical protein LOC27351 570455 3.23 4.16
Chromosome X open reading frame 12 23119 3.22 3.03
Ribosomal protein S4, Y linked 180911 3.22 3.08
Ras homolog gene family, member E 6838 3.21 3.52
Frizzled homolog 4 19545 3.19 3.80
Hypothetical protein L O C I38046 isoform 1 121663 3.18 2.33
Transcription factor AP-2 beta 33102 3.17 3.33
MET ND 3.16 3.31
Fibroblast growth factor 2 284244 3.15 4.01
Suppressor o f cytokine signaling 1 50640 3.15 3.45
EST (A1356286) 3.13 3.04
Baculoviral lAP repeat-containing 3 127799 3.13 4.51
Palmitoyl-protein thioesterase 2 81737 3.12 3.75
Lactotransferrin 105938 3.12 2.92
Angiopoetin 1 ND 3.12 3.14
Acyl-Coenzyme A oxidase 3, pristanoyl 12773 3.11 3.32
Telomerase-associated protein 1 232070 3.11 3.47
Rho/Rac guanine nucleotide exchange factor 2 337774 3.11 3.27
Secreted frizzled-reiated protein 1 7306 3.11 2.49
D component o f complement (adipsin) 155597 3.11 2.27
OX-40 129780 3.09 3.00
Solute carrier family 3 239106 3.09 4.24
EST (R53362) 3.09 2.30
EST (R32170) 3.09 3.15
ND = not defined; EST = expressed sequence tag; * (Genebank ID provided where Unigene ID 
unavailable)
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Table 4.5
SAM analysis - 29 genes down-regulated in chronic infection.
29 negative significant genes
Gene Name
Unigene 
ID (Hs.) * Score(d) Fold Change
Diacyiglycerol O-acyltransferase homo log I 288627 -4.44 0.33
GTP-binding protein Rho7 603111 -4.39 0.29
Interferon, gamma 856 -4.12 0.16
Sjogren's syndrome nuclear autoantigen I 18528 -3.95 0.43
Zinc finger RNA binding protein 173518 -3.80 0.32
E2F transcription factor I 96055 -3.77 0.30
Huntingtin interacting protein 107019 -3.74 0.45
Human D9 splice variant B mRNA, complete 37616 -3.71 0.35
Flightless 1 homolog 83849 -3.70 0.40
Hypothetical protein MGC14480 37616 -3.69 0.37
Hypothetical protein FU JI0432 143187 -3.69 0.37
Fibroblast growth factor i.e. binding protein 7768 -3.63 0.46
Phosphomevalonate kinase 30954 -3.62 0.42
Growth arrest & DNA-damage-inducible, alpha 80409 -3.59 0.38
Integrin beta 3 binding protein 82084 -3.58 0.40
Flightless 1 homolog 83849 -3.57 0.37
ATP-binding cassette, sub-family F 153612 -3.55 0.52
Vestigial like 1 9030 -3.55 0.50
CD37 antigen 153053 -3.54 0.27
Glycine dehydrogenase 380791 -3.52 0.27
Phosphorylase kinase, gamma 2 196177 -3.49 0.39
SET domain containing 1A 297483 -3.46 0.30
Hypothetical protein XP_375359 97805 -3.43 0.36
Hypothetical protein MGC5356 197755 -3.43 0.35
Postreplication repair protein hRA D lSp 21320 -3.42 0.33
K1AA0368 protein 3852 -3.40 0.45
Phosphorylase, glycogen 75658 -3.40 0.38
Integrin-linked kinase 6196 -3.40 0.38
Small nuclear ribonucleoprotein polypeptide A 173255 -3.39 0.46
ND = not defined; EST = expressed sequence tag; * (Genebank ID provided where Unigene ID 
unavailable)
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4.3 Discussion
The main obstacle in our understanding of the failure of HBV-specific CD8 + T cells 
in chronic viral infection has been the inability to obtain a sufficient number of these 
antiviral populations to conduct a broader analysis. Previous studies have focused on 
the analysis of individual phenotypic or functional traits such as migration or 
activation markers, cytokine receptors, cytokine secreting capacity, perforin content, 
cytolytic capacity or proliferative potential (Bengsch et al., 2007; Bertoletti et al., 
1997a; Kaech et al., 2003; Lord et al., 2000; Maile et al., 2005; Paiardini et al., 2005; 
Penna et al., 2007; Xiong et al., 2001), often extending observations reported in other 
persistent viral infections. However, a comprehensive and holistic study of the 
mechanisms underlying HBV-specific CD8 + T cell dysfunction has not been 
possible. A better understanding of these processes would open up new possibilities 
for therapeutic intervention aimed at reconditioning this failing arm of the immune 
response.
Although gene expression profiling had been used to study immune cells (Ji et al., 
2003; Palena et al., 2003; Raghavan et al., 2002; Zhang et al., 2002), it had not been 
applied for the investigation of human virus-specific CD8 + T cells, with the 
exception of a recent study into HTLV-1 infection (Vine et al., 2004). Vine, A.M. et 
al successfully managed to apply Affymetrix genechip technology to analyse HTLV- 
1 specific responses in two group of patients; those with low or high proviral load. 
They demonstrated that circulating CD8 + T cells in the group with low-proviral load 
over-expressed several genes involved in cell-mediated lysis or antigen recognition, 
and proposed that viral suppression was associated with this stronger CD8 + T cell 
cytolytic activity. This work was of particular importance to our study because CD8 + 
T cells were profiled from patients directly ex vivo; these samples contained low 
frequencies of HTLV-1-specific CD8 + T cells, yet they were able to detect 
transcriptional differences of key genes involved in CD8 + T cell antiviral function.
HBV-specific CD8 + T cells circulate at frequencies 10-100 fold less than the HTLV- 
1-specific CD8 + T (Bieganowska et al., 1999; Greten et al., 1998; Maini et al., 1999;
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Nagai et al., 2001; Utz et al., 1996). We therefore decided to further enhance the 
probability of detecting critical differences in anti-viral effector function by 
selectively enriching HBV-specific CD8 + T cells by short-term culture and then 
specifically activating these antiviral populations prior to gene expression analysis. 
Although short-term culture was not ideal due to the possibility of altering the 
populations of concern, studies have indicated that the dysfunction is preserved when 
expansion is performed with only a single round of peptide stimulation; for example, 
the phenotypic defect of tetramer negativity was unchanged (Reignat et al., 2002). 
Additionally, we overcame the main limitation of sample size by applying an 
amplification procedure to linearly increase messenger RNA transcripts in activated 
HBV-specific CD8 + T cells, and subsequently confirmed that these amplification 
procedures did not deviate the fidelity of the gene expression data. By profiling as 
little as 300,000 PBMCs containing HBV-specific cells (at 1-70% of the total CD8 + 
T cell populations), we were able to detect the transcriptional up-regulation of several 
immunologically relevant genes, thereby confirming the validity of this novel 
technology (as well as the particular type of microarrays selected for this study) for 
the analysis of antigen-specific CD8 + T cells. We were subsequently able to process 
multiple samples of activated HBV-specific CD8 + T cells, utilising bulk enriched 
lines or following highly selective purification, from patients with resolved or chronic 
infection.
Thus, the major contribution to the field has been the application of a pre-existing 
technology for the study of limited numbers of human immune cells. Although flow 
cytometry has been previously used successfully to study relatively small numbers of 
virus-specific CD8 + T cells, only a few parameters could be assessed simultaneously; 
these were usually limited to the availability of corresponding monoclonal antibodies. 
With cDNA microarrays, we simultaneously screened thousands of intracellular 
genes.
Our strategy was to compare two groups of samples - effective and ineffective 
responses -  and focus on genes that exhibited differences in expression that had 
strong statistical significance, thereby providing candidate genes for more through
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studies. This had the potential of opening up the possibility of identifying entirely 
novel genes involved in viral persistence in the context of HBV infection. 
Furthermore, as other viral pathogens may survive through the evolution of anti- 
immune mechanisms similar to those employed by HBV, the findings of this 
investigation promised to open-up important new avenues to study novel aspects of 
failed immune responses associated with other persistent microbes such as HIV, 
HCV, EBV and CMV.
In this work, two independent methods of analysis were used to demonstrate that a 
group of genes were up-regulated in HBV-specific CD8 + T cell responses associated 
with chronic infection. Several of these have well defined key roles in cellular 
apoptosis suggesting that functionally-related mechanisms were contributing to sub- 
optimal effector CD8 + T cell activity and thereby permitting viral persistence.
We propose that activated HBV-specific CD8 + T cells associated with persistent 
infection are highly prone to apoptosis compared to their counterparts in resolved 
individuals and this is likely to contribute to the hyporesponsiveness that is observed 
in chronic infection as reported in the previous chapter. Further studies were required 
to validate these findings and subsequently individually investigate promising 
candidate genes to better understand their role (at the protein level) in HBV-specific 
CD8 + T cell dysfunction.
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5 CHAPTER 5
An investigation of Bim-mediated HBV-specific CD8+ T cell attrition.
5.1 Background
In the preceding chapter, cDNA microarray technology was optimized to enable an 
analysis of the effector response of HBV-specific CD8 + T cells following their 
activation with viral peptides. We found a marked up-regulation of several genes in 
the antiviral CD8 + T cell response in persistent infection as compared to responses in 
individuals that spontaneously resolved the virus. A large proportion of the short­
listed genes were known to be involved in cellular apoptosis and this suggested that 
the former populations were preferentially being driven towards death. These data 
were in line with the marked HBV-specific CD8 + T hypo-responsiveness associated 
with chronic HBV infection that was reported in chapter 3.
To continue these investigations, we focused our efforts on the Bcl2-interacting 
mediator Bim (O'Connor et al., 1998) that belongs to the Bcl-2 family of pro- 
apoptotic- proteins (Huang and Strasser, 2000).
Of all the genes short-listed by our bioinformatics analyses (cref), the transcriptional 
differences of Bim, between the groups with resolved and chronic infection, had the 
highest statistical significance. This proapoptotic protein has been shown to play a 
critical role in the thymic and peripheral deletion of T lymphocytes (Bouillet et al., 
1999; Bouillet et al., 2002; Hildeman et al., 2002). More importantly, it is involved in 
CD8 + T cell apoptosis during chronic viral infection. Grayson et al demonstrated that 
in contrast to wild-type mice where there was a decline of virus-specific CD8 + T 
cells following LCMV infection, Bim-deficient mice maintained these populations 
demonstrating the participation of this protein in the down-regulation of the antiviral 
response during persistent infection (Grayson et al., 2006).
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Cross presentation of soluble antigen has recently been implicated in the peripheral 
deletion of CD8 + T cells through a Bim-mediated mechanism (Davey et ah, 2002) 
(Kurts et ah, 1997). Given that chronic HBV infection is associated with the secretion 
of large quantities of viral antigens, this suggested that Bim could be involved in the 
attrition of the HBV-specific CD8 + T cell response in persistent infection.
There are three major isoforms of Bim, (EL, L and S) (O'Connor et ah, 1998; 
O'Reilly et ah, 2000); all of which contain a Bcl-2-homology region type 3 (BH3) 
(Boyd et ah, 1995; Chittenden et ah, 1995) that allows them to interact with the BHl 
and BH2 regions of relevant anti-apoptotic proteins, particularily Bcl-2.
Six novel isoforms of Bim derived by alternative splicing were subsequently 
identified and designated Bimal, a2, bl-b4 (U et ah, 2001) or alternatively, BimAC, 
ABC, AD, ACD, A and ABCD (Marani et ah, 2002); none of these contain the C- 
terminal hydrophobic region and only Bimal and Bima2 contain the BH3 domain (U 
et ah, 2 0 0 1 ).
This structural variety has made the mechanism of action difficult to understand. 
There are however two main processes that are thought to be involved: an indirect 
mechanism (via pro-survival proteins) and a direct mechanism; both converge on the 
multi-domain proapoptotic proteins, Bax and Bak. Dimerization of these effector 
molecules, following activation, allows them to form pores in the mitochondrial 
membrane resulting in the release of caspase-activating cytochrome c that eventually 
leads to nuclear destabilization and cell death.
Some studies have shown that Bim-mediated human T cell deletion occurs through 
gross increases in intracellular levels (Dijkers et al., 2000). Apart from death triggers 
initiated by specific stimuli though cell surface death-inducing receptors such as 
Fas/TNFRI (Goldstein et al., 2001; Hildeman et al., 2002; Nguyen et al., 2002b), 
TCR triggering can specifically upregulate of BimL&S (Sandalova et al., 2006; 
Sandalova et al., 2004). Expression above a relatively low threshold kills cells via the 
caspase pathway (Kumar, 2007; Sehra and Dent, 2006); inhibition of caspases 
antagonized Bim-induced cell death (O'Connor et al., 1998). Increases above this
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threshold can however be tolerated when Bcl-2 expression is highly upregulated 
(O'Connor et al., 1998) supporting an indirect mode of action.
Another facet of Bim-mediated death involves translocation of the protein. Bim 
(EL/L and S) contain a C-terminal hydrophobic region that is important to its 
localization to intracytoplasmic membranes (Kroemer, 1997), independently of its 
association with Bcl-2. BimEL, the predominant isoform in T cells, is normally 
sequestered to microtubules via a direct interaction with tubulin but is released when 
phosphorylated -  this liberated form interferes with anti-apoptotic Bcl-2. 
Furthermore, in the early phase of apoptosis, phosphorylted BimEL (pBimEL) is N- 
terminally cleaved by caspases resulting in a modified form that has higher affinity 
for Bcl-2; this can provide a positive feedback signal ensuring death of the cell (Chen 
and Zhou, 2004).
In contradiction to these findings, Marrack et al. argue that most of the intracellular 
Bim in activated T cells is localized to the mitochondria and not the microtubules 
(Zhu et al., 2004). They favor a mechanism of CD8 + T cell death that is caused by 
the drop in the levels of Bcl-2 that accompanies activation; this results in increases in 
free Bim that may participate directly in the activation of proapoptotic Bax and Bak 
(Harada et al., 2004). In support of this, the novel isoform BimAD, directly engages 
and activates proapoptotic Bax following heterodimerization with BimS (Marani et 
al., 2002), indicating that interactions with the Bcl-2 family of proteins can be 
bypassed. Additionally, a more recent study demonstrated that BimS expression was 
followed by its rapid translocation to the mitochondrial membrane where it initiated 
Bax activation independently of the Bcl-2 proteins (Weber et al., 2007).
The most recent studies have indicated that Bim does not have to engage Bax/Bak to 
initiate mitochondrial permeabilization. Instead, apoptosis is thought to be controlled 
because Bax/Bak is sequestered by pro-survival proteins and neutralization of the 
latter by Bim induces mitochondrial disruption (Uren et al., 2007; Willis et al., 2007). 
The major drawback of our cDNA microarray studies was that although the 
technology allowed an accurate quantification of the global pattern of mRNA
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expression, it is known that gene transcripts are not necessarily translated into protein 
products. mRNA is subject to post-transcriptional regulation; intracellular 
microRNAs (miRNAs) can silence gene function either by repressing translation or 
promoting mRNA degradation (Behm-Ansmant et ah, 2006; Liu et ah, 2005a; Liu et 
ah, 2005b; Rehwinkel et ah, 2005).
It was therefore necessary to confirm that the transcriptional trends observed for Bim 
were present at the protein level. Furthermore, post-translation modifications are 
often required to extend the functionality of a protein either by the attachment of a 
large variety of functional groups (acetyls, phosphates, lipids, carbohydrates), by 
altering the chemical nature of individual amino acids, or by structural changes 
(formation of disulphide bonds or proteolytic clevage); these factors also have to be 
taken into consideration.
We were unable to conduct western blot analysis, that could address some of these 
issues, due to our inability to purify sufficient HBV-specific CD8 + T cells, therefore, 
we decided to further the study by focusing on quantitative differences of the Bim 
protein (isoform unrestricted) by flow cytometry. Given that a consensus regarding 
the mechanism of action of this protein has not as yet been reached, we also decided 
to examine the functionality of Bim in mediating death of HBV-specific CD8 + T 
cells by interfering with the death-pathway further downstream of the molecule at a 
stage that has been accepted. This work concludes with preliminary studies aimed at 
investigating the role of Bim in HBV-specific CD8 + T cell tolerance induced by 
antigen cross-presentation.
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5.2 Results
5.2.1 Validation of microarray data by real-time quantitative PCR
The array data showed more Bim transcripts (6 . 6  fold upregulated) for samples from 
CHB patients than for the resolved samples. In order to assess whether the observed 
transcriptional difference of Bim expression was reliable and not an artifact of the 
cDNA microarray technology, we conducted a quantitative real-time PCR (QPCR) on 
RNA material reserved from four of the original samples used in the array analysis; 
two samples from resolved individuals and two samples from individuals with 
chronic infection (high viral load). This method is considered by experts to be the 
most appropriate method for the confirmation of microarray-generated data 
(Provenzano and Mocellin, 2007).
The comparative analysis of QPCR data involves normalization of each sample to a 
unique cellular gene that does not alter its level of transcription. Traditionally, 
housekeeping genes such as b-actin or GADPH have been employed, however, recent 
data indicate that these commonly used internal normalization genes do in fact exhibit 
subtle transcriptional fluctuations across different biological samples (Radonic et al., 
2004; Thellin et al., 1999).
Data from our own cDNA microarray studies (normalized by global median centring) 
were in support of these findings, demonstrating that the transcriptional expression of 
several housekeeping genes exhibited significant variability between the 19 samples 
that were tested (figure 5.1).
Although these small changes are acceptable to gel-based assays such as northern blot 
analysis or RNAse protection assays they are not appropriate for QPCR 
normalization. This is mainly because the latter is a highly sensitive technology in 
which the smallest transcriptional differences have a large impact on the 
interpretation of data.
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Recent studies have however shown that the human acidic ribosomal protein (HuPo) 
is an acceptable internal control gene; expression was the least variable of several 
reference genes tested (Dheda et ah, 2004; Dheda et ah, 2005). Furthermore, studies 
of a monocytic cell line exposed to varying stimuli (Ifn-g, IL-1 or TNF-a) indicated 
that HuPo was also least variable in comparison to the commonly used internal 
controls, namely b-actin, elongation initiation transcription factor 2A (EITF2A) and 
hypoxanthine phosphoribosyltransferase l(HRPT) (unpublished observations, M. 
Fife, U.C.L.). For these reasons, HuPo was selected as the normalization factor for 
our QPCR analysis.
The Sybr green-based QPCR approach is commonly used in QPCR, however, a major 
weakness is that spurious non-specific PCR products contribute to a false-positive 
signal that leads to an overestimation of the gene-specific transcript of interest. This 
can on some occasions be minimized through optimizations of annealing temperature 
or magnesium concentrations in the PCR reaction mix. However, in order to rapidly 
execute this phase of the study with maximum specificity and accuracy (especially 
considering that only a limited number of the original samples were to be tested), an 
alternative method using commercially designed and pre-optimized gene-specific 
primers and an internal labelled probe were employed. We also applied relative 
quantitation as it overcame the need for a standard curve, the prerequisite for which 
would have been the generation, quantitation and optimization of a Bim-transcript 
control template.
Analysis of the quantity of Bim transcripts in the four samples tested demonstrated 
that the lowest quantity of Bim was detected in resolved sample 1 and this was 8  fold 
higher in resolved sample 2, but in comparison, the expression of Bim was found to 
be 28 and 29 fold higher in chronic sample 1 and 2 (Figure 5.2).
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Figure 5.1
Transcriptional expression of 4 common housekeeping genes.
Normalized (median centred) cDNA array data o f RNA transcripts for 4 internal house­
keeping gens derived from 19 chronic and resolved samples.
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Figure 5.2
Real-time quantitative PCR confirmation of microarray data.
cDNA microarray expression data was validated by QPCR on 4 o f the original samples 
processed onto arrays; the data corresponds to two patients with resolved infection 
(1&2) and two with chronic infection (3&4). The samples were normalized to the 
internal houskeeping gene (human acidic ribosomal protein) and expression was evalu­
ated relative to the sample that contained the least Bim transcript (1).
215
5.2,2 Validation of differential Bint expression at the protein level
A cellular response to a stimulus is ultimately exerted through the activity of proteins. 
Although transcriptional increases are suggestive of subsequent increases at the 
protein level this is not necessarily always the case. It was therefore necessary to 
extend our studies and quantify Bim at the protein level. This was done in a larger 
sample of patients who had HBV-specific CD8 + T cell populations after 10 days in 
vitro expansion - 16 responses from resolved patients and 23 from CHB infected 
patients.
Envelope 183-91- or core 18-27-specific responses were identified by IFN-y 
production following peptide-specific stimulation. These populations were also co­
stained with a Bim mAh and examined by flow cytometry. We found that HBV- 
specific CD8 + T cells from individuals with chronic infection contained a 
significantly higher quantity of Bim protein compared to their counterparts in 
resolved individuals [Figure 5.3, mean MFI of 52.3 compared to 20.7; p<0.0001].
We then focussed on the individuals with chronic infection and a comparison of IFN- 
y+ cells (viral peptide-specific) to IFN-y- cells (those unable to recognise and 
therefore respond to the viral peptide) revealed that Bim expression was significantly 
higher in the former (mean MFI of 52.3 compared to 33.6; p=0.008) (figure 5.4).
Our data suggest that changes in the interactions of the Bcl-2 family due to an 
upregulation of Bim could be perturbing the delicate equilibrium that ensures cell 
survival and instead could be driving these populations towards apoptosis.
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Figure 5.3
Bim expression is increased at the protein level in HBV-specific CD8+ T cells from 
patients with CHB.
Representative example o f Bim expression in HBV-specific CD8+ T cells in individu­
als with resolved and chronic infection (left and middle) and the cumulative data, 
significance tested with the Mann Whitney test (right).
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Figure 5.4
Bim expression at the protein level in HBV-specific CD8+ T cells compared to 
total CD8+ T cells within the same CHB patients.
Representative example o f Bim expression in total CD8+ T cells (T) and HBV-specific 
CD8+ T cells (H) in a patient with chronic infection (left and middle) and cumulative 
data (right)
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5.2,3 Enhanced recovery o f HBV-specific CD8+ T cells upon inhibition o f  
apoptoticpathways in vitro
Bim is able to exert anti-apoptotic activity by inducing dimerization of the 
multidomain proapoptoic protein Bax (Marani et ah, 2002; Weber et al., 2007) 
allowing release of cytochrome c that in turn activates caspases that drive cell death 
(Sehra and Dent, 2006). By artificially interfering with intracellular caspase activity, 
we attempted to block the intrinsic death-signalling cascade and therefore rescue 
HBV-specific CD8 + T cells that had upregulated Bim and were otherwise destined to 
die.
We found that treatment of PBMC from CHB patients with the irreversible pan- 
caspase inhibitor zVAD-fmk prior to antigenic stimulation enabled the detection of a 
significantly larger population of HBV-specific CD8 + T cells following 10 days in 
vitro culture. Both core and envelope-specific responses were reconstituted, with a 
mean three fold increase in virus-specific numbers compared to cells that were 
stimulated without the inhibitor (figure 5.5 A&B; p<0.0001 ; paired t test).
We also found that responses to additional HBV envelope epitopes could 
occasionally be recovered (data not shown), demonstrating that this approach could 
potentially enhance the multispeciflcity of the HBV response. The percent of total 
CD8 + T cells did not increase in these experiments (p=0.48; paired t test), indicating 
that this rescue was restricted to the HBV-specific populations (figure 5.6).
We also examined influenza-specific CD8 + T cell responses in the same persistently 
HBV-infected patients and found that these did not increase following caspase 
inhibition (Figure 5.7) demonstrating that Bim-mediated deletion of lymphocytes was 
restricted to the HBV-specific CD8 + T cell compartment and was not a generalized 
occurrence phenomenon of all virus-specific cells; influenza A virus, was efficiently 
controlled by the host immune response in the CHB infected patients studied.
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Furthermore, HBV-specific CD8 + T cell responses expanded from patients who had 
resolved infection were also not prone to caspase-dependent apoptosis in vitro, as 
evidenced by the inability to increase anti-viral frequencies following treatment with 
the inhibitor (Figure 5.8). This supported the fact that deletion was predominantly 
restricted to HBV-specific CD8 + T cells associated with persistent infection.
Caspase activation can also be triggered by extrinsic mechanisms through cell surface 
death receptors, therefore, inhibition of caspases was not exclusive proof of the 
involvement of this pro-apoptotic protein in the deletion of virus-specific CD8 + T 
cells. The lack of a direct Bim inhibitor complicated these investigations, however, 
we were able to utilize a pentapeptide (VPLMK) that inhibits the proapoptotic 
mediator Bax by suppressing its mitochondrial translocation (Sawada et al., 2003a; 
Sawada et al., 2003b). In this way, we could disrupt the death-signalling cascade 
upstream of caspases but directly downstream of Bim. We found that this inhibitor 
was also capable of enhancing the recovery of HBV-specific responses in culture 
(Figure 5.9) and provided further support for the activity of Bim in the deletion of 
these antiviral populations.
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Figure 5.5
Rescue of in vitro cultured HBV-specific CD8+ T ceils.
Representative flow cytometry plots and cumulative data (below) of the effect of pan- 
caspase inhibition on the detection of envelope and core-specific CD8 + T cells (A & B) 
in 10 day lines of PBMCs from individuals with chronic infection.
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Figure 5.6
Frequency of total CD8+ T cells.
Percent of CD8+ T lymphocytes in peptide-stimulated short-term enriched lines from 
individuals with chronic infection either untreated or treated with the pan caspase 
inhibitor (zVADfmk).
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Figure 5.7
Effect of caspase inhibition on influenza-specific CD8+ T cells in patients with 
chronic HBV infection.
Representative flow cytometry plots and cumulative data (below) of the effect of pan- 
caspase inhibition on the detection of influenza A-specific CD8 + T cells in 10 day lines 
of PBMCs from individuals with chronic infection.
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Figure 5.8
Effect of caspase inhibition on HBV-specific CD8+ T cells in patients with 
resolved HBV infection
Representative flow cytometry plots and cumulative data (below) of the effect of pan- 
caspase inhibition on the detection of envelope and core-specific CD8 + T cells in 10 
day lines of PBMCs from individuals with resolved HBV infection.
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Figure 5.9
Rescue of HBV-specific CD8+ T cells derived from individuals with CHB by inhi­
bition of Bax.
HBV-specific CD8 + T cells rescue in two patients with chronic infection following in 
vitro culture with a specific peptide inhibitor (VK) of proapoptotic Bax .
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5.2.4 Direct ex vivo rescue of HBV-specific CD 8+ T cells from patients with 
CHB
The experiments on short-term enriched cell lines provided functional confirmation 
of the dysregulated apoptotic pathways identified by microarray profiling. They 
confirmed that HBV-specific CD8 + T cells from patients with CHB infection are 
highly susceptible to apoptosis following restimulation with cognate peptide in vitro. 
In order to determine whether these populations were also apoptosis-prone when 
circulating in patients with high viral load, we studied the effect of caspase-inhibition 
directly ex vivo.
PBMC from the same patients were stimulated with HBV peptide (core 18-27 or 
envelope 183-191) for six hours only in the presence of the inhibitor, and the 
responsive cells identified by intracellular IFN-y production. We found that higher 
frequencies of both envelope and core-specific CD8 + T cells could be detected when 
caspase activity was blocked directly ex vivo (Figure 5.10). The fact that responses 
became detectable after just six hours of culture indicted that the populations detected 
were a consequence of the inhibition of apoptosis rather than due proliferation.
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Figure 5.10
Direct ex vivo rescue of HBV-specific CD8+ T cells from patients with CHB.
Representative flow cytometry plots and cumulative data (below) indicating direct ex 
vivo frequencies of HBV-specific CD8+ T cells in patients with chronic infection as 
detected following stimulation with viral peptide, with and without treatment with the 
pan-caspase inhibitor zVAD-fmk.
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5 .2 .5  HBV-specific CD8+ T cells persisting in the face of high antigen load 
are selectively enriched for high expression of CD 127 and Mcl-l
Studies have shown that the CD8 + T cell populations that are killed through Bim- 
mediated mechanisms are those that express low levels of the IL-7 receptor a  chain 
(CD 127) (Pellegrini et ah, 2004; Wojciechowski et ah, 2006). This phenotype is 
typically seen in situations of persistent antigenic stimulation (Kaech et ah, 2003; 
Paiardini et ah, 2005; van Leeuwen et ah, 2005).
We therefore hypothesised that the bulk of HBV-specific CD8 + T cells in chronic 
infection (most likely to be CD 127'°'^) have already succumbed to Bim-mediated 
deletion; however the small populations that do persist in these patients may be those 
that have escaped the deleterious effects of Bim because they express relatively high 
levels of CD 127. The recent finding that HBV-specific CD8 + T cells that persisted in 
patients with chronic infection expressed a CD 127 '^^  ^ phenotype supported this 
proposition (Boni et ah, 2007). IL-7 receptor-mediated signalling is capable of 
inducing Mcl-l expression and this anti-apoptotic protein has the capacity to bind 
directly to Bim thereby neutralizing its pro-apoptotic activity (Opferman et ah, 2003).
In order to determine whether persisting HBV-specific CD8 + T cells had survived the 
effects of increased Bim though the upregulation of M cl-l, we measured intracellular 
levels of this latter protein. We found that Mcl-l levels were indeed strikingly 
elevated in the core and envelope-specific CD8 + T cells, with an MF I approximately 
double that observed in CD8 + T cells of the same specificity from patients who had 
resolved their HBV infection (figure 5.11 A&B). Mcl-l levels were also significantly 
higher (p=0.0001) in HBV-specific (IFN-y positive) than total CD8 + T cells (IFN-y 
negative) within the same patients, whereas levels in influenza-specific CD8 + T cells 
were similar to that in total CD8 + T cells (figure 5.11 C). We confirmed that HBV- 
specific CD8 + T cells in patients with chronic HBV infection were CD 127 '^^ ,^ in 
accordance to the published data (Boni et al., 2007). By co-staining these populations 
for CD 127 and M cl-l, we found that all the CD 127^ '®^  HBV-specific CD8 + T cells
228
also expressed high intracellular levels of Mel-1, consistent with their rescue through 
this mechanism (figure 5.11 D).
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Figure 5.11
Mcl-l and CD127 expression of HBV-specific CD8+ T cells.
(A) Intracellular staining for Mcl-l in core and envelope-specific CD8 + T cells from 
individuals with chronic and resolved infection (A) with cumulative data (B). (C) Sum­
mary of Mcl-l levels in HBV-specific (H), total (T) and influenza (I)-specific CD8+ T 
cells. (D) Intracellular stain for Mcl-l in CD127hi populations of HBV-specific and 
total CD8 + T cells.
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5,2.6 Bim expression in HBV-specific CD8-  ^T cell populations following 
cross-presentation o f HBV antigens
Adoptive transfer of CD8 + T cells from influenza hemagglutinin-specific TCR 
transgenic mice into mice expressing hemagglutinin has been shown to result in 
tolerance following cross-presentaton of antigen by pAPCs in the draining lymph 
nodes (Hernandez et ah, 2001); deletion of CD8 + T cells was preceeded by an 
upregulation of CD69 and CD44, partial downregulation of CD62L, the failure to 
express CD25, the inability to produce IFN-y, and a lack of cytolytic function. A 
subsequent study found that cross-presentation of soluble ovalbumin (OVA) in 
transgenic mice also resulted in the peripheral deletion of the OVA-specific CD8 + T 
cells (Kurts et ah, 1997), but importantly, these populations persisted when T cells 
were Bim-deficient (Davey et ah, 2002). These data indicated that cross-presentation 
of soluble antigen could drive the deletion of reactive CD8 + T cells through a 
mechanism involving Bim.
Given that chronic HBV infection is associated with the secretion of large quantities 
of viral antigens, we hypothesized that HBV-specific CD8 + T cells in chronic 
infection could also be prone to Bim-mediated tolerance following cross-presentation 
of these soluble HBV antigens.
In order to test this hypothesis in vitro, we employed the well-characterised HLA- 
A2+ MUTZ-3 monocytic cell line (kindly provided by B.Chain, U.C.L) that can be 
differentiated into professional antigen presenting cells (Larsson et ah, 2006; 
Masterson et ah, 2002; Santegoets et ah, 2006); exposure to IL-4 and GM-CSF 
induces differentiation into a dendritic cell-like populations that are able to present 
antigen to CD8 + T cells (Santegoets et ah, 2006). We aimed to use MUTZ-3-derived 
DCs (M-DC) to cross present HBV antigens to HBV-specific CD8 + T cells that had 
relatively low levels of Bim and then evaluate the effect that this interaction had on 
the expression of Bim in these antiviral CD8 + T cell populations.
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To achieve this, total PBMCs from three individuals that had resolved infection were 
enriched for HBV-specific CD8 + T cells by stimulating cells with immunodominant 
viral peptides and allowing them to proliferate over 10 days, as done previously. We 
have already demonstrated that these enriched virus-specific populations had 
relatively low levels of Bim compared to HBV-specific CD8 + T cells from 
individuals with chronic infection.
At day 10, the enriched cell lines were restimulated (for 5 hours) either with HBV 
peptides alone or M-DC that had been previously loaded with hepatitis B surface and 
core antigen. The frequency of HBV-specific CD8 + T cells (IFN-y+ by ICS) and the 
quantity of Bim in these populations were then determined. HBV-specific CD8 + T 
cells in enriched lines stimulated with peptide alone are primed either by endogenous 
APCs or by fraternal CD8 + T cells that express empty cell surface MHCI 
(unpublished observations by A.Bertoletti, Singapore Institute of Clinical Sciences). 
This M-DC-independent stimulation was used to assess the HBV-specific CD8 + T 
cel frequency following enrichment for each patient sample as well as to allow us to 
bench-mark the quantity of Bim in cells that were not stimulated through cross­
presentation.
5.2.6,1 Mutz-derived dendritic cells cross-present soluble HB V antigens to
HBV-specific CD8+ T cells
Resolved patients 1, 2 and 3 (Rl, R2, R3) had variable HBV-specific CD8 + T cell 
populations at day 10 (15.9, 1.54 and 1.27% of total CD8 + T respectively) (figure 
5.12), as detected by peptide restimulation. We found that HBsAg-loaded M-DC 
could induce HBV-specific T cells to produce IFN-y in all three patients (3.09, 1.17 
and 2.8% for R l, R2 and R3 respectively) (Figure 5.12). Although enriched lines 
stimulated with unloaded M-DCs resulted in some non-specific IFN-y production that 
was slightly above the unstimulated controls, this was well below the frequencies that 
were detected with the antigen loaded M-DC (Figure 5.12; R2). These data thus 
confirmed that in vitro generated pAPC were able to take up soluble antigen, digest,
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load and cross-present critical antigenic determinants via MHCI to HBV-specific 
CD8 + T cells.
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Figure 5.12
In vitro stimulation of CD8+ T cells with antigen-loaded Mutz-3-derived dendritic 
cells.
HBV-specific CD8+ T cell were enriched in PBMCs from three patients (Rl, R2 and 
R3) that resolved infection by stimulation with a pool of HBV peptides (cl 8-27, el 83- 
191, e335-343, e338-347, e348-357, p455-463, p502-510) followed by 10 days of 
culture. At day 10, appropriate samples were either unstimulated (a), restimulated with 
HBV peptides (b), restimulated with unloaded M-DCs (c), or restimulated with M-DCs 
loaded with HBs&cAg (d).
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5.2.6.2 Bim expression
In line with the previous data (figure 5.3; where the average of the median 
fluorescence intensity for Bim in HBV-specific CD8 + T cells from resolved 
individuals was 20.7; n=23), the level of Bim in peptide alone-stimulated HBV- 
specific CD8 + T cells in R l, R2 and R3 was also correspondingly low (MFl of 21.4,
28.4 and 24.9; mean of 24.9).
In samples Rl and R2, HBV-specific CD8 + T cells stimulated HBs&cAg-loaded M- 
DC (compared to peptide stimulated samples) exhibited slightly raised levels of Bim 
(MFl of 23 versus 21.4 and 34.9 versus 28.4 respectively), (figure 5.13, top and 
middle graphs). The exception however was R3 (figure 5.13, bottom graph). Here a 
slight decline in Bim was observed in the HBV-specific CD8 + T cell population 
following stimulation with HBs&cAg loaded M-DC compared to the peptide alone 
stimulation (Bim MF1=21.4 and 24.9 respectively).
These differences are not strikingly different, however, these preliminary studies 
require further optimization, particularly with regard to the duration of stimulation. It 
is likely that five hours, as applied in this study, may not be sufficient to induce a 
significant difference in the levels of Bim expression.
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Figure 5.13
Bim expression in HBV-specific CD8+ T cells following stimulation by APCs 
cross-presenting HBc&sAg.
HBV-specific CD8 + T cells were enriched in PBMCs from three patients that resolved 
infection by stimulation with a pool of HBV peptides (c l8-27, e l83-191, e335-343, 
e338-347, e348-357, p455-463, p502-510) followed by 10 days of culture. Enriched 
PBMCs were restimulated either with HBV peptides (black) or with M-DC (red) 
loaded with whole HBV protein (core and envelope). Intracellular levels of Bim 
(median fluorescence intensity) was evaluated in HBV-specific (IFN-7+) CD8 + T cells 
by flow cytometry.
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5,3 Discussion
In the previous chapter, cDNA microarray analysis revealed that the most 
consistently up-regulated gene in HBV-specific CD8 + T cells in chronic infection 
with strongest statistical significance was the Bcl-2 interacting mediator (Bim). Here, 
we validated these data at the transcriptional level by demonstrating similar results 
with real-time QPCR and subsequently extended this to the protein level by 
intracellular staining of HBV-specific CD8 + T cells from an extended patient cohort. 
The latter work confirmed that Bim was increased in the attenuated response 
associated with chronicity.
Murine models have demonstrated the requirement for Bim in the termination of the 
CD8 + T cell response following superantigenic stimulation (staphylococcal 
enterotoxin B) in the absence of FAS or TNF-R signalling; this deletion could be 
overcome by increasing Bcl-2 (Hildeman et al., 2002). Additionally, Bim was found 
to mediate the deletion of HSV-specific CD8 + T cells following viral clearance in 
both wild-type and Fas-deficient mice whereas these activated virus-specific 
responses were not terminated in mice that were Bim-deficient (Pellegrini et al., 
2003). Conversely, down-regulation of Bim was found to be critical for memory 
CD8 + T cell survival in the absence of antigen (Sabbagh et al., 2006).
The study by Grayson et al. is more pertinent to the context of chronic infection HBV 
infection (Grayson et al., 2006). In addition to demonstrating that Bim regulates the 
CD8 + T cell response during chronic LCMV infection in mice, they have also shown 
that this loss was particularly focussed on the immunodominant LCMV-specific 
CD8 + T cell response, which parallels chronic HBV infection where responses to an 
immunodominant core epitope become undetectable in patients with high viral loads 
(Webster et al., 2004).
Bim mediates the apoptosis of CD8 + T cells that have low levels of the lL-7 receptor 
alpha chain (CD 127) (Wojciechowski et al., 2006) and is also a major apoptotic 
factor in virus-specific CD8 + T cells that bear this phenotype (Pellegrini et al., 2004).
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In agreement with these data, we found that the HBV-specific CD8 + T cells that 
managed to survive in chronic HBV infection maintained expression of CD 127. The 
maintenance of CD8 + T cells expressing high levels of CD 127 has been described in 
chronic HBV (Boni et al., 2007) and HCV (Bengsch et al., 2007; Ferma et al., 2007; 
Radziewicz et al., 2007) infection but contrasts to chronic HIV, CMV and EBV 
infections (Paiardini et al., 2005; van Leeuwen et al., 2005) where low levels were 
observed.
We propose that the majority of HBV-specific CD8 + T cells expressing low levels of 
CD 127 have succumbed to Bim-mediated deletion but those populations that manage 
to persist have neutralized this proapoptotic-factor through mechanisms initiated by 
rescue signals delivered by lL-7 through its cognate receptor (Kaech et al., 2003). In 
particular, 1L-7/1L-7R signalling triggers an increase in the anti-apoptotic protein 
Mcl-l (Opferman et al., 2003) and this protein has been shown to play an essential 
role in mature lymphocyte survival by counteracting the pro-apoptotic effects of Bim 
(Opferman et al., 2003). In line with these findings we found that the persisting HBV- 
specific CD8 + T cells had raised levels of Mcl-1.
The obvious conclusion is that these small populations persist by because of their 
ability to counteract Bim-mediated deletion. Alternatively, recent data has shown that 
newly generated T cells are continuously recruited to the antiviral response in chronic 
LCMV infection (Vezys et al., 2006); it is therefore possible that the expression of 
CD 127 reflects a recently primed status of the HBV-specific CD8 + T cells. This 
implies that that the HBV-specific CD8 + T cell response in chronically infected 
individuals has a higher turnover than previously realised. It also suggests that the 
protection by Mcl-l is only temporary; continual recruitment would result in an 
increasing frequency of surviving cells. Alternatively, competitive scavenging for 
limited quantities of lL-7 would only allow some populations to persist.
By interfering with Bim-mediated apoptosis through the inactivation of caspases and 
pro-apoptotic Bax, we were able to rescue HBV-specific CD8 + T cells in culture. 
Apart from providing functional confirmation of the microarray data and supporting
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the need to further investigate other apoptosis-related short-listed genes, this 
highlighted a strategy that could potentially be used to recover these populations.
Disrupting PD-l/PD-Ll interactions has recently been found to reverse virus-specific 
CD8 + T cell dysfunction in patients with CHB infection (Boni et al., 2007) but only 
of certain specificities; envelope-specific responses could not be detected, suggesting 
that these were prone to an alternative tolerogenic mechanism that is very likely to be 
related to the excessive quantities of surface antigen produced by those patients. We 
have shown that blockade of Bim-mediated apoptosis allows the recovery of both 
core and envelope specificities. Furthermore, inhibition of this apoptosis pathway 
directly ex vivo also resulted in substantial rescue of HBV-specific CD8 + T cells, 
indicating that circulating responses are highly susceptible to apoptosis in patients 
with chronic infection.
These data do not argue against the involvement of negative co-stimulatory ligands 
and receptors such as PD-1. Instead, we propose that in chronic infection, it is likely 
that the tolerogenic signals have already been delivered to antigen-specific CD8 + T 
cells, and it would be more beneficial to interfere with the downstream events that 
lead to deletion of these populations. In this regard, we would only expect to be able 
to achieve a limited amount of reconstitution ex vivo as most antiviral populations 
would have been deleted.
The transient restoration of HBV-specific responses reconstituted during antiviral 
therapy (Boni et al., 2003) suggests that a short-term reduction in viral load is not 
sufficient to reverse their propensity to apoptosis. As activation of protein kinase C 
and calcineurin is necessary for Bim up-regulation following TCR ligation 
(Sandalova et ah, 2004), a strategy aimed at blocking Bim induction (with 
Cyclosporin A or FK506) could be more effective at protecting recent thymic 
emigrants capable of recognising the virus. However, these studies must also take 
into account the confounding generalized immunosupproessive activity of these 
agents.
239
Thus, in addition to preventing apoptosis in HBV-specific CD8 + T cells with 
upregulated Bim, specific re-programming of HBV-specific CD8 + T cell 
susceptibility to Bim-mediated apoptosis in patients with CHB infection (undergoing 
suitable antiviral therapy) holds greater potential for the reconstitution of effective 
HBV-specific responses.
The mechanism specifically driving the upregulation of Bim in HBV-specific CD8 + 
T cells in CHB remains to be identified. It may well be the level of antigenic drive 
and activation status of responding cells, since T cell receptor triggering has been 
shown to induce Bim in effector CD8 + T cells (Sandalova et al., 2006; Sandalova et 
al., 2004). This is consistent with the preferential deletion of immunodominant 
responses (Grayson et al., 2006) and is in keeping with our data, which focused on 
two frequently recognised HBV epitopes (core 18-27 and envelope 183-191) from 
antigens that are produced at high concentrations in this infection.
It will be important to investigate whether Bim levels are lower in the subdominant 
responses present in chronic infection, but these studies can only be executed once 
the hierarchy of HBV-specific CD8 + T cell responses restricted by diverse HLA 
alleles has been better defined. Preliminary data indicates that the level of Bim in a 
polymerase-specific response is lower than that in core and envelope-specific CD8 + 
T cells in CHB in line with the fact that polymerase is expressed at a much lower 
quantities compared to the surface and core proteins.
Another possibility could be the actual site of CD8 + T cell priming. Studies in 
transgenic mouse models have shown that antigen that is endogenously processed and 
presented by hepatocytes induces proliferation that is followed by anergy or deletion 
of the responding CD8 + T cells (Bertolino et al., 1998; Morimoto et al., 2007). 
Human HBV-specific CD8 + T cells that recognise antigen presented by HBV- 
infected human hepatocytes (Gehring et al., 2007) also become highly prone to 
apoptosis (unpublished observations; A. Bertoletti et al, Singapore Institute of 
Clinical Sciences); the involvement of Bim in this process remains to be investigated.
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An alternative factor could be related to the large amounts of soluble surface and 
HBeAg are produced and secreted by hepatocyes in CHB infection as these antigens 
could access the MHCI processing pathway for cross-presentation (Jin et ah, 1988). 
Liver sinusoidal endothelial cells or hepatic stellate cells (Winau et ah, 2007), are 
particularly well positioned to take up exogenous soluble antigen released from 
infected hepatocytes, and have been shown to induce cross-tolerance of Ovalbumin- 
specific CD8 + T cells in transgenic mice (Limmer et ah, 2000). Cross-presentation of 
antigens released from apoptotic cells has also been associated with induction of 
tolerance in the liver (Albert et al., 1998; Berg et al., 2006).
Our preliminary studies aimed at examining tolerance through cross-priming 
demonstrated that pAPCs could effectively present whole soluble HBV antigens to 
HBV-specific CD8 + T cells but we did not detect significant increases in the 
expression of Bim following activation by protein loaded M-DCs. This could be 
related to the duration of stimulation of our assay. Although two hours of contact are 
sufficient to initiate cell division, approximately 24 hours of contact is required for 
full programming (Kaech and Ahmed, 2001; Kaech et ah, 2002; van Stipdonk et ah, 
2001); the deletion of CD8 + T cells is not programmed by a brief interaction with 
tolerogenic APCs but has been shown to rely on persistent antigenic stimulation that 
could act by maintaining the tolerising signals for long enough to overcome survival 
signals delivered by certain cytokines (Redmond et ah, 2003). Our assay employed a 
five-hour stimulation that may not have been sufficient to detect significant changes 
in Bim expression; further studies should be aimed at addressing this factor.
However, in addition to the strength of signalling at the level of individual TCRs, 
growing evidence suggests that the maturation state of professional APCs is critical in 
determining whether the CD8 + that they prime are instructed to undergo a vigorous 
effector response or anergy and death. Multiple signals including triggers from the 
pathogen itself, proinflammatory cytokines or CD4+ T cell help, lead to an 
upregulation of costimulatory molecules (Banchereau and Steinman, 1998; Bennett et 
ah, 1998; Ridge et ah, 1998; Schoenberger et ah, 1998; Steinman et ah, 1997), also 
known as licensing (Marsland et ah, 2005; Smith et ah, 2004), that is required for
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optimal CD8 + T cell priming (Larsson et al., 2000; Salio et al., 2001) (Bachmann et 
al., 1999b), in fact, the efficacy of vaccines is significantly improved when 
administered with some form of adjuvant (Bendelac and Medzhitov, 2002; Cooper et 
al., 2005; Cooper et al., 2004); this is most likely due to the initiation of a local 
inflammatory reaction that drives maturation of pAPCs that take-up the foreign 
antigen that is key to the priming of an effective T cell response.
Although a small proportion of T cells may survive priming by unlicensed resting 
DCs in draining lymph nodes (van Mierlo et al., 2002), the absence of costimulation 
leads to the premature death of most T cells (Hawiger et al., 2001 ; Kaech and Ahmed, 
2001; Kaech et al., 2002; Sauter et al., 2000; van Stipdonk et al., 2001).
Thus, the maturation state of the M-DCs appears to be of particular importance. LPS 
treatment can drive maturation of M-DCs as evidenced by increases co-stimulatory 
molecules (CD80, CD8 6 , CD40) and the activation marker HLA-DR (personal 
communication; B.Chain, U.C.L.). Although the M-DCs utilized in this study were 
immature, it is possible that traces of LPS in the whole HBV antigen preparations 
were of sufficient quantity to trigger some degree of maturation that could have 
influenced Bim expression.
Studies have shown that anti-inflammatoiy glucocorticoids, Dexamethasone in 
particular, can be used to maintain immature DCs with tolerogenic potential despite 
stimulation with conventional maturation stimuli (Matyszak et al., 2000; Moser et al., 
1995; Piemonti et al., 1999; Rea et al., 2000; Roelen et al., 2003; Woltman et al., 
2000; Xia et al., 2005). This enables us to manipulate the maturation status of the 
APCs in future studies in order to assess its importance to the process of cross­
tolerance.
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In conclusion, the profound HBV-specific CD8 + T cell hyporesponsiveness that is 
observed in CHB infection could be due to mechanisms related to the high level of 
antigen load in these patients. In this study, a global, unbiased approach allowed us to 
dissect these mechanisms and highlighted a dysregulated apoptotic pathway. 
Preliminary studies suggest that cross-presentation of HBV antigens and subsequent 
Bim-mediated deletion could contribute to the failure of CD8 + T cell responses in 
chronic HBV infection. Interfering with this tolerogenic mechanism may provide a 
new strategy to sustain the HBV-specific responses that are indispensable for 
effective viral control.
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6 Future directions
Our data indicate that the immunodominant CD8 + T cell response associated with 
resolution of infection is prone to deletion in chronic infection. However, these 
studies were focused on a limited number of epitopes and it is critical that future 
studies aim to generate more comprehensive profiles of HBV-specific CD8 + T 
immunodominance hierarchies and their association with immune failure.
Overlapping peptides that span all viral proteins could be used in conjunction with 
flow cytometry and elispot assays to obtain a more representative definition of the 
overall immune response to HBV (Boni et al., 2007; Chang et al., 2005). These 
should match the sequence of the infecting virus but as this is currently unrealistic, 
efforts should at least be made to utilize a peptide panel that corresponds to the viral 
genotype involved. These studies should ideally be conducted directly ex vivo but 
responses are rarely detectable when studied in this way (Boni et al., 2007; Chang et 
al., 2005) therefore the use of short-term in vitro enrichment must continue in order to 
detect low-level frequencies.
Once key responses have been identified, there are various strategies that may be 
applied to enhance these frequencies for further study:
1) selective enrichment based on effector function such as IFN-y could be used to 
increase populations of virus-specific CD8 + T cells normally present at very low 
levels as has been described (Barnes et al., 2004).
2) endogenous (T or B) regulatory cells are able to exert generalised (non-contact 
dependent) and specific (contact-dependent) immunosuppressive activity 
(Accapezzato et al., 2004; Boussiotis et al., 2000b; Hyodo et al., 2004; Plebanski et 
al., 1999; Pohl-Koppe et al., 1999). Depleting these populations could help increase 
the HBV-specific CD8 + T cell frequency. Recent data suggest that virus-specific 
populations may themselves produce and secrete immuosuppressive mediators such 
as IL-10 (Abel et al., 2006; Elrefaei et al., 2007). Activity could be blocked with anti-
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IL-10 antibodies (Maris et aL, 2007), or alternatively, antagonistic anti-IL-10 receptor 
antibodies could be used to interfere with immune suppression (Brooks et al., 2006b) 
(Ejmaes et al., 2006).
3) Data from our microarray analyses indicate that TGF-j3 is also up-regulated in 
HBV-specific CD8 + T cells associated with chronic infection. Several studies have 
implicated this cytokine in immune suppression (Alatrakchi et al., 2007; Garba et al., 
2002; Kekow et al., 1990; Lotz et al., 1990) and anti-TGF-|3 strategies similar to 
those proposed for the neutralization of IL-10 activity could be investigated to see if 
they improve the detection of HBV-specific antiviral CD8 + T cell populations.
Returning to the findings of the cDNA microarray analyses, we found that the core 
and envelope specificities that were most prevalent in resolved infection had elevated 
levels of proapoptotic factors, particularly Bim, during persistent HBV infection, 
consistent with studies that demonstrate the selective deletion of T cells specific for 
antigen present at a high level (Wherry et al., 2003) (Grayson et al., 2006). We 
propose that this could be due to tolerance mechanisms involving cross-presentation 
of soluble HBeAg and HBsAg as reported recently (Davey et al., 2002). Studies of 
Bim expression in HBV polymerase- and X-specific CD8 + T cell could help provide 
a better understanding of the relationship between cross-presentation, tolerance and 
exhaustion, given that the polymerase and X protein are not secreted are present in 
comparatively reduced quantities.
Ongoing studies are aimed at establishing an in vitro model to investigate the 
mechanism of cross-tolerance of HBV-specific CD8 + T cells. As memory CD8 + T 
cells are susceptible to peripheral deletion following secondary encounter with 
antigen (Kreuwel et al., 2002), functional HBV-specific CD8 + T from resolved 
individuals could help further understand the specific mechanism of tolerance 
involved.
One important consideration in these studies is that commercially produced HBsAg 
and HBcAg is produced in bacterial systems and will be prone to lipopolysacchride
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contamination that will undoubtedly interfere with the assay employed. Given that the 
maturation status of the antigen presenting cells may be the key factor in the process 
of tolerance, and that LPS mediates maturation, this issue needs to be resolved. This 
will involve characterisation of the maturation status of the antigen presenting cells 
prior to and following loading with the HBcAg and HBsAg. We also aim to test the 
use of the dexamethasone in overcoming this problem; this steroid has been 
successfully used to maintain immaturity of pAPCs (Xia et al., 2005).
The data arising from this work indicate that interfering with Bim-mediated deletion 
of HBV-specific CD8 + T cells may facilitate successful containment of the pathogen 
in individuals with chronic infection. This can be readily translated to the clinical 
setting because calcineurin or protein kinase C inhibitors (tacrolimus/cyclosporin or 
tamoxifen respectively) that can inhibit Bim upregulation (Sandalova et al., 2004) are 
already in clinical use. Treatment of HBV infected individuals was in fact associated 
with a slight increase of the HBV-specific CD8 + T cell response during but not after 
steroid (prednisolone) therapy (Gotto et al., 2006).
Our data also indicates that inhibition of Bax, the death mediator further downstream 
of Bim, can also rescue antiviral specificities. Given that the proapoptotic cascade 
involves multiple death mediators, there are in fact multiple specific factors, in 
addition to Bim, that could potentially be targeted and this may be particularly 
important for the rescue of cells that have already upregulated Bim.
The overall strategy should therefore aim to combine antivirals with some form of 
immune rescue that we suggest could be achieved by blocking Bim. Although steroid 
therapy is normally administered for immunosuppressive purposes, the influence of 
these agents on antigen-specific CD8 + T cells may depend on their state of activation 
or differentiation (Ashwell et al., 2000; Riccardi et al., 2002). Nonetheless, initial 
studies could aim employ short courses of steroids. Additionally, previous studies 
have demonstrated that immune reconstitution following antiviral therapy was only 
transient, however, those studies were conducted following short-term therapy with 
lamivudine, and a more prolonged course of treatment of perhaps three years with
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more potent antivirals may be required to confer a more sustained improvement in the 
CD8 + T cell response. Furthermore, the combination of antiviral drugs therapy with 
specific apoptotic inhibitors may even facilitate the reprogramming of anergised 
antiviral T cell populations as has been proposed recently (Brooks et ah, 2006a).
Finally, one factor that has been overlooked in HBV studies has been the importance 
of the route of infection. It is important to consider whether the individuals studied 
were infected vertically or horizontally as this would have strong implications on the 
extent of tolerance induced in these individuals. Perinatal transmission would lead to 
the development of an immune system that considers HBV antigens as self-protein, 
and therefore, the majority of HBV-reactive CD8 + T cells would be deleted in the 
thymus.
In these individuals, it might be necessary to reengineer autologous CD8 + T cells to 
specifically recognize key HBV determinants. We are currently collaborating with 
Hans Stauss (U.C.L) on a project aimed at transducing CD8 + T cells with a TCR 
specific for the immunodominant HLA-A2-restricted core 18-27 determinant. 
Focusing the introduction of this receptor specifically into memory CD8 + T cell 
populations may overcome co stimulatory requirements and therefore generate more 
effective antiviral populations.
The limitation of this approach would be that the transduced TCR would only be 
effective in patients with the appropriate HLA-restriction. However, the studies with 
overlapping peptides proposed at the start of this section will contribute to the 
development of a database that associates specific HLA-types with commonly 
targeted viral determinants. These data will contribute to the customization of TCR- 
transduction technology to suit alternative HLA-types.
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7 Publications arising during the course o f this thesis
Bim-mediated deletion of antigen-specific CD8 + T cells in patients unable to control 
hepatitis B virus.
Lopes, AR., Kellam. P., Das, A., Dunn, C., Kwan, A., Turner, J., Gilson, R.J., 
Bertoletti, A., Maini, MK. Submitted (July 2007)
A selective reversible defect in the global CD8 + T cell population in chronic hepatitis 
B virus infection.
Das, A., Hoare, M., Lopes, AR., Dunn, C., Kennedy, FT., Graeme, A., Plunkett, P., 
Akbar, A., Bertoletti, A., Maini, MK. Submitted (September 2007)
Cytokines induced during chronic hepatitis B virus infection promote a pathway for 
NK cell-mediated liver damage.
Dunn. C., Brunetto. M., Reynolds, G., Christophides, T., Kennedy, PT., Lampertico, 
P., Das, A., Lopes, AR., Borrow, P., Williams, K., Humphreys, E., Afford, S.,
Adams, DH., Bertoletti, A, Maini, MK. Journal of Experimental Medicine (2007) 
204(3): 667-80
Distinct, cross-reactive epitope specificities of CD8  T cell responses are induced by 
natural hepatitis B surface antigen variants of different hepatitis B virus genotypes. 
Riedl, P., Bertoletti, A., Lopes, R., Lemonnier, P., Reimann, J., Schirmbeck, R. 
Journal of Immunology (2006) 176(7): 4003-11.
HIV-1 epitope-specific CD8 + T cell responses strongly associated with delayed 
disease progression cross-recognize epitope variants efficiently.
Turnbull, EL., Lopes, AR., Jones, NA., Comforth, D., Newton, P., Aldam, D., 
Pellegrino, P., Turner, J., Williams, L, Wilson, CM., Goepfert, PA., Maini, MK., 
Borrow P. Journal of Immunology (2006) 176(10): 6130-46.
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Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific 
T cell responses in patients who have resolved HBV infection.
Lascar, RM. & Lopes, AR., Gilson, RJ., Dunn, C., Johnstone, R., Copas, A., Reignat, 
S., Webster, G., Bertoletti, A., Maini, MK. Journal of Infectious Diseases (2005) 
191(7): 1169-79.
Reconstitution of hepatitis B virus (HB V)-specific T cell responses with treatment of 
human immunodeficiency virus/HBV coinfection.
Lascar, RM., Gilson, RJ., Lopes, AR., Bertoletti, A., Maini, MK. Journal of 
Infectious Diseases (2003) 188(12): 1815-9.
Greater CD8 + TCR heterogeneity and functional flexibility in HIV-2 compared to 
HIV-1 infection.
Lopes, AR., Jaye, A., Dorrell, L., Sabally, S., Alabi, A., Jones, NA., Flower, DR., De 
Groot, A., Newton, P., Lascar, RM., Williams, L, Whittle, H., Bertoletti, A., Borrow, 
P., Maini, MK. Journal of Immunology (2003) 171(1): 307-16.
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